CCO Oncology Podcast: Recent Episodes
Clinical Care Options
Updates on new data and best practices in the care of patients with cancer across a wide variety of solid tumors and hematologic malignancies from Clinical Care Options. Gain practical clinical insights and strategies and earn CME/CE credit for selected episodes.
In this episode, listen to Ana Oaknin, MD, PhD and Alexandra Leary, MD, PhD, share their clinical insights and takeaways on key updates and new data presented for ovarian, endometrial, and cervical cancer at the ESMO 2024 annual congress including:
- Phase III PRIMA/ENGOT-OV26/GOG-3012 Final OS Results: Niraparib as First-Line Maintenance in Advanced Ovarian Cancer
- ATHENA COMBO/GOG-3020/ENGOT-ov45: Rucaparib With or Without Nivolumab Maintenance in Newly Diagnosed Ovarian Cancer
- Phase II PICCOLO Trial of Mirvetuximab Soravtansine in Recurrent Platinum-Sensitive Ovarian Cancer With High-FRα Expression
- Phase III KEYNOTE-B21/GOG-3053 Study of Adjuvant Chemotherapy With or Without Radiotherapy With or Without Pembrolizumab in Patients With Newly Diagnosed Endometrial Cancer or Carcinosarcoma After Curative Surgery With no Residual Disease
- Phase III KEYNOTE-A18 Overall Survival Results: Pembrolizumab Plus Concurrent Chemoradiation in High-Risk Locally Advanced Cervical Cancer
Program faculty:
Ana Oaknin, MD, PhD
Head of Gynaecologic Cancer Programme
Department of Medical Oncology
Vall d’ Hebron University Hospital
Vall d’Hebron Institute of Oncology
Barcelona, Spain
Alexandra Leary, MD, PhD
Co-Director, Department of Medical Oncology
Medical Oncologist, Gynecology
Team Leader, Gynecologic Translational Research Lab,
Institut Gustave Roussy
Paris, France
Resources:
To download the slides associated with this podcast discussion, please visit the program page.
In this episode, listen to Matthew S. Davids, MD, MMSc, and Lindsey Roeker, MD, discuss BTK inhibitor resistance and how it shapes treatment choices for patients with CLL, including:
- Contemporary treatment paradigms for patients with CLL
- Safety and efficacy of current regimens
- Molecular testing, including when and how to test for BTK inhibitor resistance
- Considering BTK inhibitor resistance when sequencing therapy
Program faculty:
Matthew S. Davids, MD, MMSc
Associate Professor of Medicine
Harvard Medical School
Leader, Lymphoma Program
Dana-Farber/Harvard Cancer Center
Director of Clinical Research
Division of Lymphoma
Dana-Farber Cancer Institute
Boston, Massachusetts
Lindsey Roeker, MD
Assistant Attending
CLL Program Director
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York
Resources:
To review a CME-certified text activity and download slides associated with this podcast discussion, please visit the program page.
In this episode, listen to Alice T. Shaw, MD, PhD, and Jessica J. Lin, MD, share their thoughts on the available and emerging clinical data for second-line and beyond treatments in patients with recurrent ROS1-altered advanced NSCLC including:
- Assessing ROS1-TKI resistance mutations with tumor and liquid biopsies in patients with ROS1-altered advanced NSCLC
- Previous TKI-treated cohort from the TRIDENT-1 study: efficacy of repotrectinib in patients with recurrent ROS1-altered NSCLC and measurable baseline brain metastases
- Phase II TRUST-1 trial of taletrectinib: activity in patients with known ROS1 G2032R resistance mutation ROS1-altered advanced NSCLC
- The global phase I/II ARROS-1 study of zidesamtinib (NVL-520): safety summary in patients with ROS1-altered advanced NSCLC
Program faculty:
Jessica J. Lin, MD
Attending Physician
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Alice T. Shaw, MD, PhD
Chief, Strategic Partnerships
Attending Physician, Thoracic Oncology
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts
Resources:
To download the slides associated with this podcast discussion, please visit the program page.
In this episode, listen to Alice T. Shaw, MD, PhD, and Jessica J. Lin, MD, share their thoughts on the available clinical data in support of frontline treatments for ROS1-altered NSCLC including:
- Efficacy and safety data for crizotinib, entrectinib, and repotrectinib in patients with ROS1-altered advanced NSCLC
- Long-term safety observations for crizotinib and entrectinib
- CNS activity of entrectinib and repotrectinib in patients with brain metastases
- Repotrectinib activity in ROS1-TKI resistance mutations
Program faculty:
Jessica J. Lin, MD
Attending Physician
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Alice T. Shaw, MD, PhD
Chief, Strategic Partnerships
Attending Physician, Thoracic Oncology
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts
Resources:
To download the slides associated with this podcast discussion, please visit the program page.
In this episode, listen to Alice T. Shaw, MD, PhD, and Jessica J. Lin, MD, share their thoughts on the current understanding of ROS1 rearrangements in non-small-cell lung cancer tumor biology and its implications for molecular testing and treatment selection including:
- ROS1-gene fusions in advanced lung cancer
- ROS1 testing recommendations with DNA NGS, RNA NGS, FISH break apart assay, and IHC
- Comparative specificity of ROS1 and ALK targeting tyrosine kinase inhibitors
- Advantages of RNA- vs DNA-based next-generation sequencing
Program faculty:
Jessica J. Lin, MD
Attending Physician
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Alice T. Shaw, MD, PhD
Chief, Strategic Partnerships
Attending Physician, Thoracic Oncology
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts
Resources:
To download the slides associated with this podcast discussion, please visit the program page
In this episode, listen to Floor J. Backes, MD, and Angeles Alvarez Secord, MD, MHSc, share their clinical insights and takeaways on new data presented for endometrial, ovarian, and cervical cancers presented at the 2024 annual meetings of the Society of Gynecologic Oncology and American Society of Clinical Oncology including:
- RUBY Part 1 Subgroup Analyses by MRR Status: Addition of dostarlimab to platinum-based therapy followed by dostarlimab maintenance in advanced endometrial cancer
- RUBY Part 2: Survival outcomes with addition of dostarlimab to platinum-based therapy followed by dostarlimab plus niraparib maintenance in advanced endometrial cancer
- Survival Analyses From Phase III NRG GY018: Carboplatin plus paclitaxel with or without pembrolizumab as frontline treatment for patients with advanced endometrial cancer
- DUO-E: First-line therapy with carboplatin plus paclitaxel plus bevacizumab and durvalumab followed by maintenance with bevacizumab, durvalumab, and olaparib in newly diagnosed endometrial cancer
- Long-term Follow-up From SIENDO: PFS in TP53 wild-type and preliminary survival by molecular subgroups in patients with endometrial cancer and complete or partial response after ≥12 weeks of first line taxane/carboplatin
- Subgroup Analyses From the Randomized Phase III MIRASOL: Mirvetuximab soravtansine vs investigator’s choice of chemotherapy in FR𝝰-high platinum-resistant ovarian cancer
- Subgroup Analyses of Raludotatug Deruxtecan (R-DXd): An anti-CDH6 antibody–drug conjugate in previously treated ovarian cancer
- Phase III CARACO Trial: Omission of lymphadenectomy in advanced ovarian cancer treated with interval cytoreductive surgery after neoadjuvant chemotherapy
- innovaTV 301/ENGOT-cx12/GOG-3057: Tisotumab vedotin vs investigator’s choice of chemotherapy in patients with advanced cervical cancer
- Randomized, Double-blind, Placebo-controlled Phase III Trial: Addition of pembrolizumab to concurrent chemoradiation in high-risk locally advanced cervical cancer
Program faculty:
Floor J. Backes, MD
Professor
Director of Clinical Research
Division of Gynecologic Oncology
Associate Fellowship Director
Department of Obstetrics and Gynecology
The Ohio State University College of Medicine
The James Cancer Hospital and Solove Research Institute
Columbus, Ohio
Angeles Alvarez Secord, MD, MHSc
Professor of Obstetrics & Gynecology
Division of Gynecologic Oncology
Director, Gynecologic Oncology Clinical Trials
Associate Director, Clinical Research, Gynecologic Oncology Program
Duke Cancer Institute
Duke University Medical Center
Durham, North Carolina
Resources:
To download the slides associated with this podcast discussion, please visit the program page.
In this episode, Dr Virginia Kaklamani moderates a discussion with Dr Aditya Bardia and Dr Sarah Sammons answering audience questions on the latest data on the use of oral SERDs therapy, including how to incorporate this new class of therapy into treatment plans for patients with HR+/HER2- breast cancer.
Presenters:
Virginia Kaklamani, MD, DSc
Professor of Medicine
Ruth McLean Bowman Bowers Chair in Breast Cancer Research and Treatment
A.B. Alexander Distinguished Chair in Oncology Leader
Breast Oncology Program
UT Health San Antonio
MD Anderson Cancer Center
San Antonio, Texas
Aditya Bardia, MD, MPH, FASCO
Professor of Medicine
Geffen School of Medicine at UCLA
Director, Breast Oncology Program
Assistant Chief (Translational Research)
Division of Medical Oncology
Director of Translational Research Integration
UCLA Health Jonsson Comprehensive Cancer Center
Los Angeles, California
Sarah Sammons, MD
Assistant Professor of Medicine
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts
Link to full program:
https://bit.ly/46hLGcM
In this podcast episode, Farrukh Awan, MD, Jeremy S. Abramson, MD, MMSc, and Shuo Ma, MD, PhD, discuss real-world patient cases and how to align current clinical practice with the NCCN guidelines for CLL/SLL, including:
- Prognostic variables when deciding between regimens
- Role of MRD in CLL
- Results from the phase II CAPTIVATE trial
- Choosing among the available covalent BTK inhibitors
- Preferred partner anti-CD20 antibody in CLL/SLL
- Role of the noncovalent BTK inhibitor, pirtobrutinib, in CLL/SLL
- Use of CAR T-cell therapy in CLL/SLL
Presenters:
Farrukh Awan, MD
Professor of Internal Medicine
Director of Lymphoid Malignancies Program
Harold C. Simmons Comprehensive Cancer Center
University of Texas Southwestern Medical Center
Dallas, Texas
Jeremy S. Abramson, MD, MMSc
Director, Center for Lymphoma
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Shuo Ma, MD, PhD
Professor of Medicine
Division of Hematology-Oncology
Department of Medicine
Robert H. Lurie Comprehensive Cancer Center
Northwestern University
Feinberg School of Medicine
Chicago, Illinois
Content based on an online CME program supported by educational grants from BeiGene; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Lilly, and an independent medical education grant from AbbVie.
Link to full program:
https://bit.ly/3LzA2As
In this episode, listen to Dr Brady L. Stein share his clinical insights and takeaways on new data for myeloproliferative neoplasms (MPNs) presented at the 2024 ASCO Annual Meeting and the EHA 2024 Congress including:
- Long-term survival adjusted for treatment crossover in patients with myelofibrosis (MF) treated with momelotinib vs danazol in the MOMENTUM trial
- Efficacy of pacritinib in patients with MF who have both thrombocytopenia and anemia
- Updated safety and efficacy data from the phase III MANIFEST-2 study of pelabresib in combination with ruxolitinib for JAK inhibitor–naive MF
- Impact of spleen volume on post-allogenic hematopoietic transplant outcomes in patients with MF: utility of 3D volumetrics in splenomegaly
- Progression to MF in patients with essential thrombocythemia: an analysis from the prospective MOST study
- JAK2V617F molecular response correlates with event-free survival in a patient population with early polycythemia vera
- Phase III TRANSFORM-1 study: efficacy and safety of navitoclax combined with ruxolitinib vs ruxolitinib plus placebo in patients with untreated MF
- Patient characteristics, treatment patterns, and health outcomes in a real-world population of patients with MF treated with fedratinib
Program faculty:
Brady L. Stein, MD, MHS
Professor of Medicine
Department of Hematology/Oncology
Northwestern University Feinberg School of Medicine
Chicago, Illinois
Resources:
To download the slides associated with this podcast discussion, please visit the program page.
In this podcast episode, Julio C. Chavez, MD, MS, and Alan Skarbnik, MD, discuss the emerging role of CELMoDs in NHL care, including:
- Rationale for targeting CELMoDs in NHL
- Mechanism of action of CELMoDs
- Key studies and available efficacy and safety data with investigational CELMoDs in NHL
- Key ongoing clinical trials of CELMoDs in NHL
- Strategies to boost NHL clinical trial diversity among underserved communities
Presenters:
Julio C. Chavez, MD, MS
Associate Member
Department of Malignant Hematology
ICE-T Clinical Research Medical Director for Hematologic Malignancies
H. Lee Moffitt Cancer Center and Research Institute
Associate Professor
University of South Florida
Tampa, Florida
Alan Skarbnik, MD
Director, Lymphoma and CLL Program
Director, Immune Effector Cell Therapeutics Program
Novant Health Cancer Institute
Charlotte, North Carolina
Content based on an online CME program supported by educational grants from Bristol-Myers Squibb.
Link to full program:
https://bit.ly/45YXoZI
In this episode, Dr Joyce O’Shaughnessy moderates a discussion with Dr Sara Hurvitz and Dr Erica Mayer answering audience questions on the latest data on incorporating CDK4/6 inhibitors into treatment plans for patients with HR+/HER2- breast cancer. Topics in this podcast include:
- Evidence from the monarchE and NATALEE trials of adjuvant abemaciclib and ribociclib, respectively in HR+/HER2- high-risk early breast cancer
- Factors used to assess risk of recurrence in early breast cancer, including the role of Ki-67 expression
- Determining the need for adjuvant chemotherapy and selection of chemotherapy agents
- Selection of patients who may benefit from the addition of adjuvant CDK4/6 inhibitor therapy with endocrine therapy
- Potential use of preoperative CDK4/6 inhibitors
- Sequencing therapy for patients with high-risk early breast cancer and a germline BRCA mutation
- Overview of first-line therapy for advanced HR+/HER2 breast cancer
- Expert opinion on selection of first-line therapy and factors to consider
- Selection of second-line therapy based on mutational analysis and recent data from the post-MONARCH trial
Presenters:
Joyce O’Shaughnessy, MD
Celebrating Women Chair in
Breast Cancer Research
Baylor University Medical Center
Chair, Breast Disease Committee
Sarah Cannon Research Institute
Texas Oncology
Dallas, Texas
Sara A. Hurvitz, MD, FACP
Professor of Medicine
Head, Division of Hematology and Oncology
Department of Medicine, UW Medicine
Senior Vice President
Clinical Research Division
Fred Hutchinson Cancer Center
Seattle, Washington
Erica L. Mayer, MD, MPH
Director of Breast Cancer Clinical Research
Institute Physician
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Link to full program:
https://bit.ly/3XZKp8f
In this episode, listen to Professor Eunice S. Wang, MD, share her clinical insights and takeaways on new data for acute myeloid leukemia (AML) presented at the 2024 ASCO annual meeting and the EHA 2024 Congress including:
- Data from the prospective, single-center phase Ib/II study of FLAG-IDA plus venetoclax in newly diagnosed or relapsed/refractory AML
- Phase I/II study of oral decitabine/cedazuridine with venetoclax and gilteritinib in patients with newly diagnosed and relapsed/refractory FLT3-mutant AML
- A retrospective comparison of abbreviated course 7+7 vs standard HMA plus venetoclax doublet in older/unfit patients with newly diagnosed AML
- Multisite randomized trial of a collaborative palliative and oncology care model for patients with AML and myelodysplastic syndromes (MDS) receiving nonintensive therapy
- Final 5-year results from the phase II pivotal cohort of olutasidenib for IDH1-mutated AML
- Post hoc analyses of outcomes in patients with AML and MDS-related changes who received oral azacitidine maintenance therapy in the phase III QUAZAR AML-001 study
- First-in-human phase I/II of the menin-MLL inhibitor DSP-5336 in patients with R/R acute leukemia: updated results from the dose escalation phase
- A phase Ib study of the menin-KMT2A inhibitor bleximenib in combination with venetoclax and azacitidine in R/R AML with alterations in KMT2A or NPM1
Program faculty:
Eunice S. Wang, MD
Chief, Leukemia and Benign Hematology Service
Professor of Oncology
Roswell Park Comprehensive Cancer Center
Buffalo, New York
Courtney DiNardo, MD, MSCE
Professor of Medicine
Department of Leukemia
MD Anderson Cancer Center
Houston, Texas
Resources:
To download the slides associated with this podcast discussion, please visit the program page:
https://bit.ly/4bvJGij
In this episode, listen to Professor Courtney DiNardo, MD, MSCE, share her clinical highlights and clinical takeaways on new data for myelodysplastic syndromes (MDS) presented at the 2024 ASCO annual meeting and the EHA 2024 Congress including:
- COMMANDS trial of luspatercept in transfusion-dependent, erythropoietin stimulating agent–naive, very low–, low- or intermediate-risk MDS
- Real-world dose-escalation and outcomes among patients with lower-risk MDS receiving luspatercept in clinical practice
- Phase II ASTREON trial―preliminary safety/efficacy of oral azacitidine in low-/intermediate, intermediate-risk, MDS
- Phase III IMerge: overall survival and transfusion independence with imetelstat in patients with low-risk or intermediate-1–risk MDS
- Phase III ENHANCE study of magrolimab plus azacitidine vs azacitidine plus placebo for higher-risk MDS
- Oral decitabine/cedazuridine plus venetoclax vs oral decitabine/cedazuridine alone in high-risk MDS: a propensity score analysis
Program faculty:
Courtney DiNardo, MD, MSCE
Professor of Medicine
Department of Leukemia
MD Anderson Cancer Center
Houston, Texas
Brady L. Stein, MD, MHS
Professor of Medicine
Department of Hematology/Oncology
Northwestern University Feinberg School of Medicine
Chicago, Illinois
Eunice S. Wang, MD
Chief, Leukemia and Benign Hematology Service
Professor of Oncology
Roswell Park Comprehensive Cancer Center
Buffalo, New York
Resources:
To download the slides associated with this podcast discussion, please visit the program page.
In this episode, Manali Bhave, MD; Annalise Labatut, PharmD, BCOP; and nurse practitioner Jamie L. Carroll, CNP, APRN, MSN, begin by discussing the landmark EMERALD study that led to FDA approval of elacestrant, the first oral selective estrogen receptor degrader (SERD) for treatment of hormone receptor–positive/HER2-negative metastatic breast cancer. Dr. Bhave also briefly reviews ongoing clinical trials of other oral SERDs for estrogen receptor–positive/HER2-negative metastatic breast cancer.
Next, the panel discusses the possible adverse effects with elacestrant, potential drug–drug interactions, and their personal experiences with managing adverse effects in their patients.
Finally, the discussion turns to methods for promoting treatment adherence and persistence and briefly touches on insurance coverage and affordability, including ways that patients and providers can work together to ensure access to approved oral SERDs.
Presenters:
Manali Bhave, MD
Phase I Medical Director
Assistant Professor
Department of Hematology & Medical Oncology
Winship Cancer Institute
Emory University
Atlanta, Georgia
Annalise Labatut, PharmD, BCOP
Oncology Clinical Pharmacy Specialist – Breast Oncology
Emory Healthcare/Winship Cancer Institute
Atlanta, Georgia
Jamie L. Carroll, CNP, APRN, MSN
Assistant Professor of Medical Oncology
Mayo Clinic
Rochester, Minnesota
Link to the full program:
https://bit.ly/3UT5Be8
Claim CME Credit:
https://bit.ly/4dBuxhx
In this episode, Danielle M. Brander, MD; Deborah Stephens, DO; and Brian Hill, MD, PhD, discuss key aspects of the NCCN CLL guidelines and share strategies for applying these recommendations in your clinical practice to optimize treatment and outcomes. The greater discussion addresses:
- Optimal selection of therapy for treatment-naive CLL, including second-generation covalent BTK inhibitors
- Considerations in therapy selection for previously treated CLL
- Novel strategies for treating CLL
Presenters:
Danielle M. Brander, MD
Assistant Professor of Medicine
Division of Hematologic Malignancies and Cellular Therapy
Duke Cancer Institute
Durham, North Carolina
Brian Hill, MD, PhD
Director, Lymphoid Malignancies Program
Staff Physician, Department of Hematology and Medical Oncology
Taussig Cancer Institute
Cleveland Clinic
Cleveland, Ohio
Deborah Stephens, DO
Associate Professor
Director of the CLL Program
Lineberger Comprehensive Cancer Center
University of North Carolina
Chapel Hill, North Carolina
Content based on a live and online CME program supported by educational grants from AstraZeneca; BeiGene, Ltd.; and Lilly.
Link to full program including downloadable slides:
https://bit.ly/49YxtSq
In this episode, Colin C. Pritchard, MD, PhD, a pathologist, and Heather H. Cheng, MD, PhD, a medical oncologist, discuss optimal biomarker testing to guide treatment decisions in advanced prostate cancer, with topics including:
- Rationale for targeting PARP in prostate cancer with ARI combinations
- Study design nuances and findings from key randomized phase III clinical trials evaluating combination therapy with a PARP inhibitor and ARI, including PROpel, MAGNITUDE, and TALAPRO-2
- FDA approvals of combination therapy with a PARP inhibitor and ARI, including a comparison of populations based on mutations
- Optimal biomarker testing for gene mutations in homologous recombination and mismatch repair pathways
- Tips for optimal coordination between pathology and medical oncology
Presenters:
Heather H. Cheng, MD, PhD
Associate Professor
Department of Medicine
Division of Hematology and Oncology
Attending Physician
Department of Genitourinary Medical Oncology
Fred Hutchinson Cancer Center
Seattle, Washington
Colin C. Pritchard, MD, PhD
Co-Director
Genetics and Solid Tumors Laboratory
University of Washington Medical Center
Professor
Department of Laboratory Medicine and Pathology
University of Washington
Seattle, Washington
Content based on an online CME program supported by an independent educational grant from Pfizer, Inc.
Link to full program:
https://bit.ly/3PFagxb
In this podcast episode, Sara M. Tolaney, MD, MPH, and Melinda Telli, MD, delve into the critical aspects of the current therapeutic landscape for patients with unresectable or metastatic HER2-low, hormone receptor–positive, and triple-negative breast cancer, including:
- Challenges with the pathologic testing for HER2-low expression
- Optimal treatment of patients with HER2-low advanced breast cancer
- Role of TROP-2–targeted therapies
- Management of ADC-associated adverse events to optimize treatment outcomes
- ADCs on the horizon for patients with advanced breast cancer
Presenters:
Sara M. Tolaney, MD, MPH
Chief, Division of Breast Oncology
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Melinda Telli, MD
Professor of Medicine
Stanford University School of Medicine
Director, Breast Cancer Program
Stanford Cancer Institute
Palo Alto, California
Content based on an online CME program supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.
Link to full program:
https://bit.ly/49WxRBM
The third and final episode in a 3-part series covers the safety profile of and considerations for managing adverse events associated with HER3-targeted antibody–drug conjugates, including patritumab deruxtecan (HER3-DXd) and others, in the setting of lung cancer.
Presenters in this series include:
Rebecca S. Heist, MD, MPH
Associate Professor of Medicine
Harvard Medical School
Medical Oncology
Massachusetts General Hospital
Boston, Massachusetts
Helena Yu, MD
Associate Attending
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York
Supported by an educational grant from Daiichi Sankyo, Inc.
Link to full program, including a downloadable highlights slideset:
https://bit.ly/48ecElW
This second episode in a 3-part series on HER3-targeted agents in NSCLC covers current clinical trials with HER3-targeted therapy, including:
- Recent data on patritumab deruxtecan (HER3-DXd) in the HERTHENA-Lung01 trial
- The EGFRxHER3 bispecific antibodies BL-B01D1 and izalontamab
- The HER2xHER3 bispecific antibody zenocutuzumab
- The HER3-targeted antibody–drug conjugate SHR-A2009
Presenters in this series include:
Rebecca S. Heist, MD, MPH
Associate Professor of Medicine
Harvard Medical School
Medical Oncology
Massachusetts General Hospital
Boston, Massachusetts
Helena Yu, MD
Associate Attending
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York
Supported by an educational grant from Daiichi Sankyo, Inc.
Link to full program, including a downloadable highlights slideset:
https://bit.ly/48ecElW
This first episode in a 3-part series tackles the role of HER3 in cancer, specifically in NSCLC, and how HER3 can be effectively targeted with ADCs.
Presenters in this series include:
Rebecca S. Heist, MD, MPH
Associate Professor of Medicine
Harvard Medical School
Medical Oncology
Massachusetts General Hospital
Boston, Massachusetts
Helena Yu, MD
Associate Attending
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York
Supported by an educational grant from Daiichi Sankyo, Inc.
Link to full program, including a downloadable highlights slideset:
https://bit.ly/48ecElW
In this episode, Brian Slomovitz, MD, MS, FACOG, and Keiichi Fujiwara, MD, PhD, share their thoughts and opinions on seminal data presented at the 2023 IGCS annual meeting for endometrial, ovarian, and cervical cancers, including:
- Phase III NRG GY018 trial of carboplatin and paclitaxel with or without pembrolizumab followed by pembrolizumab or placebo maintenance for 2 years in patients with measurable stage III/IVA, stage IVB, or recurrent endometrial cancer.
- Phase III ENGOT-EN6/GOG-3031/RUBY trial of carboplatin and paclitaxel with or without dostarlimab followed by dostarlimab or placebo maintenance for 3 years in patients with primary advanced or recurrent endometrial cancer.
- Results from the double-blind, randomized, placebo-controlled phase III AtTEnd trial of atezolizumab plus carboplatin/paclitaxel in advanced or recurrent endometrial cancer.
- Randomized, multicenter, double-blind, placebo-controlled phase III DUO-E study of carboplatin and paclitaxel vs durvalumab plus carboplatin and paclitaxel followed by durvalumab maintenance with or without olaparib as frontline treatment of newly diagnosed, advanced, endometrial cancer.
- An international, randomized, multicenter phase III trial evaluating short-course chemotherapy followed by chemoradiation vs chemoradiation alone in patients with newly diagnosed stage IB1N+, IB2, II, IIIB, IVA squamous, adeno, adenosquamous cervical cancer (INTERLACE).
- Randomized, double-blind, placebo-controlled phase III KEYNOTE-A18 trial of pembrolizumab plus concurrent chemoradiotherapy vs placebo plus chemoradiation in patients with high-risk locally advanced cervical cancer.
- Phase III ICON8B study comparing carboplatin, paclitaxel, and bevacizumab every 3 weeks vs dose-dense weekly paclitaxel plus bevacizumab every 3 weeks in newly diagnosed high-risk epithelial ovarian cancer, either stage III (with residual disease or requiring new adjuvant chemotherapy) or stage IV.
Presenters:
Brian Slomovitz, MD, MS, FACOG
Director
Gynecologic Oncology
Mount Sinai Medical Center
Professor
Obsterics and Gynecology
Florida International University
Member, Board of Directors
GOG Foundation
Uterine Cancer Lead
GOG Partners
Miami, Florida
Keiichi Fujiwara, MD, PhD
Professor of Gynecologic Oncology
Saitama Medical University International Medical Center
Hidaka, Japan
Professor of OBGYN
International University of Health and Welfare
Narita, Japan
This educational activity is supported by educational grants from AstraZeneca, Genmab, GlaxoSmithKline, Merck Sharp & Dohme Corp, Novocure, and Seagen.
Link to full program, including a downloadable highlights slideset and ClinicalThought commentaries:
https://bit.ly/424E3Uq
In this episode, Jacqueline S. Garcia, MD, discusses novel agents and strategies in clinical trial development for treating patients with myelofibrosis, including:
- Navitoclax (BCL-XL/BCL-2 inhibitor)
- Pelabresib (BET inhibitor)
- Imetelstat (telomerase inhibitor)
- Luspatercept (erythroid maturation agent)
- Additional strategies
Presenter:
Jacqueline S. Garcia, MD
Assistant Professor of Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts
Link to the full program here. https://bit.ly/47z8WCV
In this episode, Ana Marin-Niebla, MD, PhD, and Stephan Stilgenbauer, MD, discuss key trial data on the use of BTK inhibitors in CLL and MCL throughout the past year, how these studies have impacted their practice, and what data they are looking forward to in the near future. The discussion includes analyses of:
- SHINE: First-Line Ibrutinib + Bendamustine/Rituximab Followed by Rituximab Maintenance in Older Patients With MCL
- TRIANGLE: Ibrutinib + Chemoimmunotherapy With or Without ASCT vs Chemoimmunotherapy Followed by ASCT in Younger Patients with Previously Untreated MCL
- ZUMA-2: Brexucabtagene Autoleucel in R/R MCL
- BRUIN: Pirtobrutinib for Previously Treated MCL
- GLOW: Fixed-Duration Ibrutinib + Venetoclax vs Chlorambucil + Obinutuzumab in Previously Untreated CLL
- FLAIR: Ibrutinib + Venetoclax vs FCR in Previously Untreated CLL
- ELEVATE-RR: Acalabrutinib vs Ibrutinib in Previously Treated CLL
- ALPINE: Zanubrutinib vs Ibrutinib in Previously Treated CLL
- BRUIN: Pirtobrutinib for Previously Treated CLL
Presenters:
Ana Marin-Niebla, MD, PhD
Hematology Consultant, Lymphoma Unit
Vall d’Hebron Institute of Oncology, Hematology Department
Hospital Universitario Vall d’Hebron
Barcelona, Spain
Stephan Stilgenbauer, MD
Medical Director Comprehensive Cancer Center Ulm
Head, Early Clinical Trials Unit
Head, Division of CLL Dept. of Internal Medicine III
University Medical Center
Ulm University
Ulm, Germany
Link to full program:
https://bit.ly/3MNaUri
In this episode, Isabelle Ray-Coquard, MD, PhD, and Ana Oaknin, MD, PhD, provide expert insights on new clinical trial data presented at the 2023 ESMO annual congress for endometrial, ovarian, and cervical cancers, including:
- Results from the double-blind, randomized, placebo-controlled phase III AtTEnd trial of atezolizumab plus carboplatin/paclitaxel in advanced or recurrent endometrial cancer
- Randomized, multicenter, double-blind, placebo-controlled phase III DUO-E study of durvalumab plus carboplatin and paclitaxel followed by durvalumab maintenance with or without olaparib as frontline treatment of newly diagnosed, advanced, endometrial cancer
- First results from a phase II biomarker-directed platform study with assigned treatments for patients with measurable persistent or recurrent platinum-resistant epithelial ovarian cancer based on tumor-specific molecular alterations (ENGOT-GYN/GOG-3051/BOUQUET)
- Randomized, double-blind, placebo-controlled phase III KEYNOTE-A18 trial of pembrolizumab plus concurrent chemoradiotherapy in patients with high-risk locally advanced cervical cancer
- An international, randomized, multicenter phase III trial evaluating short-course chemotherapy followed by chemoradiation vs chemoradiation alone in patients with newly diagnosed stage IB1N+, IB2, II, IIIB, IVA squamous, adeno, adenosquamous cervical cancer (INTERLACE)
- Primary results from the global, randomized phase III BEATcc trial of atezolizumab plus platinum-based chemotherapy + bevacizumab as frontline treatment in patients with persistent, recurrent, or metastatic cervical cancer
- Interim analysis results from the global, randomized, open-label phase III innovaTV 301 study of tisotumab vedotin vs investigator’s choice of chemotherapy in second-line or third-line recurrent/metastatic cervical cancer
Presenters:
Ana Oaknin, MD, PhD
Head of Gynaecologic Cancer Programme
Department of Medical Oncology
Vall d’ Hebron University Hospital
Vall d’Hebron Institute of Oncology
Barcelona, Spain
Isabelle Ray-Coquard, MD, PhD
President of the Gineco Group
Centre Leon Bérard
Laboratories RESHAPE
Université Claude Bernard Lyon Est
Lyon, France
This educational activity is supported by educational grants from AstraZeneca, Genmab, GlaxoSmithKline, Merck Sharp & Dohme Corp, Novocure, and Seagen.
Link to full program, including a downloadable highlights slideset and ClinicalThought commentaries:
https://bit.ly/424E3Uq
In this episode, Aakash Desai, MD; Narjust Florez, MD; and Paolo Tarantino, MD, discuss the biologic rationale and clinical development of agents targeting HER3 for the treatment of breast and lung cancers. The potential niche for HER3-targeted agents in these treatment landscapes is considered, with consideration of acquired resistance to previous targeted therapies and parallels to other approved antibody–drug conjugates. Their conversation covers clinical trial data from:
- Phase I/II study of patritumab deruxtecan in HR-positive/HER2-negative or triple-negative metastatic breast cancer, published by Krop and colleagues in the Journal of Clinical Oncology
- BRE-354: A phase II study of patritumab deruxtecan in several subtypes of previously treated advanced/metastatic breast cancer, presented at ASCO 2023
- ICARUS-Breast01: A phase II study of patritumab deruxtecan in patients with HR-positive/HER2-negative or HER2-low advanced breast cancer, presented at the ESMO Breast Cancer Congress 2023
- SOLTI-TOT-HER3: A window-of-opportunity study of neoadjuvant patritumab deruxtecan for treatment-naive HER2-negative early stage breast cancer, presented at the ESMO Breast Cancer Congress 2023
- HERTHENA-Lung01: A phase II study of patritumab deruxtecan in in patients with EGFR-mutated NSCLC after treatment with osimertinib and platinum-based chemotherapy, presented at the World Conference on Lung Cancer 2023
- HERTHENA-Lung02: An ongoing phase III study of patritumab deruxtecan vs platinum-based chemotherapy after osimertinib for the treatment of EGFR-mutated NSCLC
- eNRGy: A phase I/II study of the bispecific HER2 x HER3 antibody zenocutuzumab in multiple solid tumor types with NRG1 gene fusion, presented at ASCO 2022
- DESTINY-Breast04: A phase III study of trastuzumab deruxtecan for the treatment of patients with HER2-low metastatic breast cancer, published by Modi and colleagues in the New England Journal of Medicine
- DAISY: A phase II trial of trastuzumab deruxtecan for the treatment of breast cancer with variable levels of HER2 expression including HER2-low and HER2-zero, published by Mosele and colleagues in Nature Medicine
Presenters:
Aakash Desai, MD
Affiliation awaiting contract
Narjust Florez, MD
Associate Director of The Cancer Care Equity Program
Thoracic Medical Oncologist, Dana-Farber Cancer Institute
Assistant Professor of Medicine, Harvard Medical School
Boston, Massachusetts
Paolo Tarantino, MD
Advanced Research Fellow
Breast Oncology Center
Dana-Farber Cancer Institute
Boston, Massachusetts
Content based on an online CME program supported by an independent educational grant from Daiichi Sankyo, Inc.
Link to full program: https://bit.ly/45UYsw3
In this episode, Dr Leslie Boyd and Adrienne Moore, a patient advocate and endometrial cancer survivor, discuss how healthcare professionals can partner with Black patients to improve the diagnosis and management of endometrial cancer (EC). Topics include:
- Data on racial disparities in EC survival
- Importance of listening to Black patients to better diagnose EC
- Financial and practical considerations regarding care
- How to help empower Black patients in shared decision-making with their care team
Presenters:
Leslie R. Boyd, MD
Associate Professor
Department of Obstetrics and Gynecology at NYU Grossman School of Medicine
Director of Division of Gynecologic Oncology
Vice Chair of Gynecology
Department of Obstetrics and Gynecology
Laura and Isaac Perlmutter Cancer Center
New York University Langone Health
New York, New York
Adrienne Moore, RT
President and Board Member
Endometrial Cancer Action Network for African-Americans
Director of Peer Support, SISTER Study
Research Coordinator, Gynecologic Oncology
Department of Obstetrics and Gynecology
University of Washington School of Medicine
Seattle, Washington
In this episode, Domenica Lorusso, MD, PhD, and Alexandra Leary, MD, PhD, provide expert insights on key updates and new clinical trial data presented at the ESGO 2023 Congress for cervical, endometrial, and ovarian cancers, including:
- Long-Term Follow Up From Phase III SIENDO Study of Selinexor vs Pbo Maintenance in Patients With TP53wt Advanced/Recurrent Endometrial Cancer
- Global, Open-Label, Phase I/IIa of HER2-Targeting ADC (DB-1303) in Recurrent/Metastatic Endometrial Cancer
- Phase III From KEYNOTE-826: Bevacizumab Subgroup Analysis Based on Protocol Specified Final Overall Survival Results
- Phase III ICON8B: Weekly DD-CT + Bev vs Q3W CT + Bev as First Line in High-Risk Epithelial Ovarian Cancer
- HRD Testing on Cell-Free Tumor DNA From Peritoneal Fluid of Patients With Newly-Diagnosed Epithelial Ovarian Cancer
Presenters:
Alexandra Leary, MD, PhD
Co Director
Medical Oncologist and Team Leader
Gynecology Translational Research Lab
Department of Medicine
Gustave Roussy Cancer Center
Paris, France
Domenica Lorusso, MD, PhD
Associate Professor
Gynecologic Oncology Department
Clinical Research Unit
Fondazione Policlinico Gemelli IRCCS
Rome, Italy
This educational activity is supported by educational grants from AstraZeneca, GlaxoSmithKline, Merck Sharp & Dohme Corp, Novocure, Genmab, and Seagen.
Link to full program, including a downloadable highlights slideset and ClinicalThought commentaries:
https://bit.ly/424E3Uq
In this episode, Catherine C. Coombs, MD, MS, and Toby Eyre, MBChB, MD, discuss key trials presented at SOHO 2023 evaluating the use of BTK inhibitors in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The discussion includes analyses of:
- Matching-adjusted indirect comparison of 3 randomized phase III trials of ibrutinib for relapsed/refractory CLL
- Meta-analysis of cardiovascular adverse events with second-generation BTK inhibitors in CLL
- BRUIN: updated results of pirtobrutinib in covalent BTK inhibitor–pretreated MCL
- ViPOR: venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide for relapsed/refractory and treatment-naive MCL
Presenters:
Catherine C. Coombs, MD, MS
Associate Clinical Professor
Division of Hematology/Oncology, Department of Medicine
UCI Health
Orange, California
Toby Eyre, MBChB, MD
Honorary Senior Lecturer
Hematology and Cancer
University of Oxford
Consultant Hematologist
Department of Hematology
Hematology and Cancer Centre, Oxford University Hospitals NHS Foundation Trust
Oxford, United Kingdom
In this episode, Catherine C. Coombs, MD, and Toby Eyre, MBChB, MD, discuss key trials presented at ICML 2023 evaluating the use of BTK inhibitors in mantle cell lymphoma (MCL). The discussion includes analyses of:
- Phase II trial of acalabrutinib with rituximab for older patients with untreated MCL
- BRUIN: updated results of pirtobrutinib in covalent BTK inhibitor–pretreated MCL
- IMCL-2015 GELTAMO: 5-year update ibrutinib for untreated indolent MCL
Presenters:
Catherine C. Coombs, MD, MS
Associate Clinical Professor
Division of Hematology/Oncology, Department of Medicine
UCI Health
Orange, California
Toby Eyre, MBChB, MD
Honorary Senior Lecturer
Hematology and Cancer
University of Oxford
Consultant Hematologist
Department of Hematology
Hematology and Cancer Centre, Oxford University Hospitals NHS Foundation Trust
Oxford, United Kingdom
In this episode, Catherine C. Coombs, MD, MS, and Toby Eyre, MBChB, MD, discuss key trials presented at EHA 2023 evaluating the use of BTK inhibitors in chronic lymphocytic leukemia (CLL). The discussion includes analyses of:
- CLL12: final results of the phase III trial of ibrutinib vs placebo in asymptomatic, treatment-naive CLL
- SEQUOIA: extended follow-up of zanubrutinib vs BR in treatment-naive CLL
- CAPTIVATE: 4-year follow-up from the fixed duration cohort of ibrutinib plus venetoclax in CLL/small lymphocytic lymphoma
- Phase II trial of acalabrutinib plus obinutuzumab in treatment-naive CLL
- BRUIN: genomic evaluation of resistance to pirtobrutinib in BTK inhibitor‒pretreated CLL
Presenters:
Catherine C. Coombs, MD, MS
Associate Clinical Professor
Division of Hematology/Oncology, Department of Medicine
UCI Health
Orange, California
Toby Eyre, MBChB, MD
Honorary Senior Lecturer
Hematology and Cancer
University of Oxford
Consultant Hematologist
Department of Hematology
Hematology and Cancer Centre, Oxford University Hospitals NHS Foundation Trust
Oxford, United Kingdom
In this episode, Kathleen Moore, MD, MS, and Nicoletta Colombo, MD, PhD, provide expert insights on key updates and new clinical trial data presented at the 2023 ASCO Annual Meeting for cervical, endometrial, and ovarian cancers, including:
- ENGOT-EN6-NSGO/GOG-3031/RUBY: phase III study of dostarlimab plus chemotherapy followed by dostarlimab maintenance in primary advanced or recurrent endometrial cancer outcomes by BICR
- CCTG CX.5-SHAPE: phase III trial of radical hysterectomy and pelvic node dissection compared with simple hysterectomy and pelvic node dissection in low-risk, early-stage cervical cancer
- Final OS results from KEYNOTE-826: phase III study of CT with or without pembrolizumab as first-line treatment for patients with persistent, recurrent, or metastatic cervical cancer
- DUO-O: a randomized, placebo-controlled phase III study of durvalumab plus carboplatin, paclitaxel, and bevacizumab and then maintenance bevacizumab, durvalumab, and olaparib in patients with newly diagnosed advanced ovarian cancer and no BRCA1/2 gene alteration
- MIRASOL: an initial report from a phase III study of mirvetuximab soravtansine vs investigator’s choice of CT in platinum-resistant ovarian cancer with high expression of FRα
- Patient-reported outcomes from the phase III ENGOT-EN6/RUBY trial of dostarlimab plus standard-of-care CT in primary advanced or recurrent endometrial cancer
Presenters:
Kathleen Moore, MD, MS
Associate Director, Clinical Research
Department of Gynecologic Oncology
Stephenson Cancer Center, University of Oklahoma
Oklahoma City, Oklahoma
Nicoletta Colombo, MD, PhD
Associate Professor of Obstetrics and Gynecology
European Institute of Oncology
University of Milan-Bicocca
Milan, Italy
Content supported by educational grants from AstraZeneca, GlaxoSmithKline, Merck Sharp & Dohme Corp., Novocure Inc., and Seagen Inc.
Link to full program, including a downloadable highlights slideset and ClinicalThought commentaries:
bit.ly/43Q5CBI
In this episode, David Scott Miller, MD, FACOG, FACS, and Linda Duska, MD, MPH, provide expert insights on practice-changing data and other new findings presented at SGO 2023 in endometrial, cervical, and ovarian cancers, including:
- NRG GY018: randomized phase III study evaluating standard of care of carboplatin plus paclitaxel with or without pembrolizumab as frontline treatment for patients with endometrial cancer
- ENGOT-EN6/GOG-3031/RUBY: randomized, placebo-controlled phase III study of dostarlimab plus standard-of-care chemotherapy in primary advanced or recurrent endometrial cancer
- Phase I NRG-GY017 study of priming-dose atezolizumab before or concurrently with chemoradiotherapy in locally advanced high-risk cervical cancer
- Randomized phase II study of chemoradiation plus pembrolizumab immunotherapy in locally advanced cervical cancer
- GOG 3026: phase II trial of letrozole plus ribociclib in women with recurrent low-grade serous ovarian cancer
Presenters:
David Scott Miller, MD, FACOG, FACS
Amy and Vernon E. Faulconer Distinguished Chair in Medical Science
Director and Dallas Foundation Chair in Gynecologic Oncology
Professor of Obstetrics & Gynecology
Fred F. Florence Bioinformation Center
University of Texas Southwestern Medical Center
Medical Director of Gynecologic Oncology Chair, Cancer Committee
Parkland Health & Hospital System
Dallas, Texas
Linda Duska, MD, MPH
Gynecologic Oncologist
Department of OB GYN/Gynecologic Oncology
University of Virginia School of Medicine
Charlottesville, Virginia
Content supported by educational grants from AstraZeneca, GlaxoSmithKline, Merck Sharp & Dohme Corp, Novocure Inc., and Seagen Inc.
Link to full program: bit.ly/424E3Uq
In this episode, Suzanne Lentzsch, MD, Ph.D., and Joseph Mikhael, MD, MEd, FRCPC, FACP, discuss the role of BCMA-targeted therapies in the management of patients with multiple myeloma, including their experiences and challenges with implementing recent data. This overview will include a discussion of:
- Considerations with administration, including access challenges
- Sequencing Therapies
- Future developments with BCMA-targeted therapies
Presenters:
Suzanne Lentzsch, MD, PhD
Professor of Medicine
Division of Hematology/Oncology
Director, Multiple Myeloma and Amyloidosis Program
Columbia University Medical Center
New York, New York
Joseph Mikhael, MD, MEd, FRCPC, FACP
Professor
Applied Cancer Research and Drug Discovery
Translational Genomics Research Institute
Phoenix, Arizona
Chief Medical Officer
International Myeloma Foundation
HonorHealth Research Institute
Scottsdale, Arizona
Provided by Clinical Care Options, LLC in partnership with Smart Patients.
Content supported by educational grants from AbbVie; Bristol-Myers Squibb; GlaxoSmithKline; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Karyopharm Therapeutics; and Regeneron Pharmaceuticals, Inc.
Link to full program: bit.ly/41YEOO6
In this episode, John Mascarenhas, MD, and Ruben A. Mesa, MD, FACP, discuss current best practices and emerging approaches for treating patients with myelofibrosis, including:
- Overall approach to treatment
- Use of JAK inhibitors for treating myelofibrosis
- Treating patients with low platelets
- Defining JAK inhibitor failure
- Unmet needs in treatment and emerging therapeutic options, including momelotinib, luspatercept, ruxolitinib add-on therapy, and other phase III approaches
Presenters:
John Mascarenhas, MD
Professor of Medicine
Icahn School of Medicine at Mount Sinai
Director, Adult Leukemia Program
Leader, Myeloproliferative Disorders Clinical Research Program
Division of Hematology/Oncology
Tisch Cancer Institute
New York, New York
Ruben A. Mesa, MD, FACP
Executive Director, Atrium Health Wake Forest Baptist Comprehensive Cancer Center
Enterprise Senior Vice President, Atrium Health
President, Enterprise Cancer Service Line
Vice Dean for Cancer Programs, Wake Forest University School of Medicine
Professor of Medicine, Wake Forest University School of Medicine
Winston-Salem, North Carolina
In this episode, Banu Arun, MD; Allison Butts, PharmD, BCOP; and Marissa Marti-Smith, MSN, APRN, AGNP-C, AOCNP, discuss the role of BRCA testing and adjuvant olaparib in early breast cancer, including their experiences and challenges with implementing recent data. This overview will include discussion of:
- Data supporting the use of adjuvant PARP inhibition in early breast cancer and impact on BRCA testing and clinical practice
- The multidisciplinary role in ensuring that BRCA testing is completed for eligible patients
- Barriers to implementing BRCA testing and adjuvant olaparib in clinical practice and methods to overcome them
- Administration of adjuvant olaparib with other available adjuvant systemic therapies
- Tolerability of single-agent PARP inhibitors
Presenters:
Banu Arun, MD
Professor, Breast Medical Oncology
Director, Clinical Cancer Genetics
University of Texas MD Anderson Cancer Center
Houston, Texas
Allison Butts, PharmD, BCOP
Pharmacist Manager, Oncology
Director, PGY2 Oncology Residency Program
UK HealthCare
Assistant Adjunct Professor
UK College of Pharmacy
Lexington, Kentucky
Marissa Marti-Smith, MSN, APRN, AGNP-C, AOCNP
Nurse Practitioner
Breast Oncology
Texas Oncology Baylor Sammons Cancer Center
Dallas, Texas
Content supported by educational grants from AstraZeneca and Merck Sharp & Dohme Corp.
Link to full program:
https://bit.ly/42VeUMM
In this podcast episode, Samuel Klempner, MD, and Gregory Botta, MD, PhD, provide expert commentary on the rationale and development of novel agents under investigation for targeting claudin 18.2 in gastric and gastroesophageal cancers, with topics including:
- Expression patterns and function of the claudin family of proteins in normal gastric tissues
- Biologic rationale for utility of claudin 18.2 as an actionable therapeutic target in oncology
- Prognostic implications of claudin 18.2 overexpression in gastric and gastroesophageal cancers
- Laboratory methodology involved in claudin 18.2 scoring as a potential predictive biomarker for patient selection
- Future directions for clinical development of agents targeting claudin 18.2, including monoclonal antibodies, bispecific antibodies, antibody‒drug conjugates, and CAR T-cell constructs
Presenters:
Samuel Klempner, MD
Associate Professor
Department of Medicine
Division of Hematology-Oncology
Mass General Cancer Center
Harvard Medical School
Boston, Massachusetts
Gregory Botta, MD, PhD
Clinical Professor of Medicine
Department of Medicine
Division of Hematology & Oncology
University of California San Diego
La Jolla, California
Content for this program was supported by educational grants from Astellas and Bristol Myers Squibb.
Link to the full program, including a CME-certified text module, downloadable slideset, and ClinicalThought (coming soon!):
bit.ly/3lQxPrq
In this podcast episode, Prithviraj Bose, MD, and Andrew Kuykendall, MD, discuss their contemporary approaches to the treatment of patients with essential thrombocythemia.
The topics covered include:
- When to use cytoreduction therapies and which therapies to use in low-risk patients
- Type 1 and type 2 CALR mutations and addressing patient concerns with data from sequencing reports
- Experts’ thoughts on therapy options in higher-risk patients
Presenters:
Prithviraj Bose, MD
Associate Professor
Division of Cancer Medicine
Department of Leukemia
The University of Texas
MD Anderson Cancer Center
Houston, Texas
Andrew Kuykendall, MD
Assistant Professor
Department of Oncologic Sciences
University of South Florida
Assistant Member
Malignant Hematology
H. Lee Moffitt Cancer Center
Tampa, Florida
Content for this program was supported by educational grants from GSK, Incyte Corporation, and PharmaEssentia Corp.
Link to the full program, including downloadable slides and an on-demand webcast from the live event:
bit.ly/3XF3cSF
In this episode, Daniel J. DeAngelo, MD, PhD; Kjeld Schmiegelow, MD, DMSci; and Emily Curran, MD, answer key questions asked by the audience during a live satellite symposium at the 2022 American Society of Hematology Annual Meeting on optimizing pediatric or pediatric-inspired regimens containing asparaginase for the treatment of young and older adults with acute lymphoblastic leukemia.
Topics discussed include:
- Practical considerations for management of allergy-like reactions and hypersensitivity to asparaginase
- Indirect methods for measuring asparaginase activity
- Strategies to mitigate adverse events with asparaginase treatment, including hepatotoxicity, pancreatitis, and thrombosis
- Considerations for use of asparaginase in special populations (eg, high BMI, older age)
Presenters:
Program Director
Daniel J. DeAngelo, MD, PhD
Professor of Medicine
Department of Medicine
Harvard Medical School
Chief of the Division of Leukemia
Department of Medical Oncology
Division of Hematologic Malignancies
Dana‐Farber Cancer Institute
Boston, Massachusetts
Emily Curran, MD
Assistant Professor
Division of Hematology/Oncology
University of Cincinnati Cancer Institute
Cincinnati, Ohio
Kjeld Schmiegelow, MD, DMSci
Professor
Department of Pediatric Oncology
Righospitalet University Hospital
Copenhagen, Denmark
Content based on an online CME program supported by an independent educational grant from Jazz Pharmaceuticals.
Link to full program:
http://bit.ly/3YXkLyj
In this podcast, Rami Komrokji, MD; María Díez Campelo, MD, PhD; and Amer Zeidan, MBBS, MHS answer questions from an audience of healthcare professionals on topics related to personalized management of myelodysplastic syndromes including:
- Practical use of the Molecular International Prognostic Scoring System
- Mutational targets and other treatments in ongoing clinical trials
- Prophylaxis with venetoclax therapy
- Best practices for bone marrow transplant, including induction and salvage regimens
- Treatment options for hypoplastic myelodysplastic syndromes
Presenters:
Rami Komrokji, MD
Professor
Department of Oncologic Sciences
University of South Florida
Vice Chair
Malignant Hematology Department
Moffitt Cancer Center
Tampa, Florida
María Díez Campelo, MD, PhD
Associate Professor
Department of Medicine
School of Medicine
University of Salamanca
Hematologist
Department of Hematology
University Hospital of Salamanca
Salamanca, Spain
Amer Zeidan, MBBS, MHS
Associate Professor, Internal Medicine
Hematology
Leader, Leukemia and Myeloid Disease Aligned Research Team (DART)
Director, Hematology Early Therapeutics Research
Yale Cancer Center and Smilow Cancer Hospital
Yale University School of Medicine
New Haven, Connecticut
Link to full program, including downloadable slidesets, expert commentaries, and on-demand webcast:
http://bit.ly/3YXgKK3
In this podcast episode, Steven M. Horwitz, MD; Pamela B. Allen, MD, MSc; and Kerry Savage, MD, MSc, answer questions from an audience of healthcare professionals on topics related to the management of T-cell lymphomas, including:
- Use of brentuximab vedotin in ≤1% CD-30‒expressing lymphomas
- Strategies with JAK inhibition and epigenetic agents
- Allogeneic transplantation in cutaneous T-cell lymphoma
Presenters:
Steven M. Horwitz MD
Member, Memorial Sloan Kettering Cancer Center
Attending Physician, Memorial Hospital
Professor of Medicine, Weill Cornell Medical College
New York, New York
Pamela B. Allen, MD, MSc
Assistant Professor
Department of Hematology/Oncology
Emory University, Winship Cancer Institute
The Emory Clinic
Atlanta, Georgia
Kerry Savage MD, MSc
Professor of Medicine
University of British Columbia
Medical Oncologist
Division of Medical Oncology
BC Cancer
Vancouver, British Columbia, Canada
Content for this program was supported by educational grants from Daiichi Sankyo; Kyowa Kirin, Inc.; and Seagen Inc.
Link to the full program, including downloadable slides, expert commentary, and an on-demand webcast:
bit.ly/3ItqEOd
In this podcast episode from a live CCO Cancer Conversations webinar, Mark Pegram, MD, and Sara Tolaney, MD, MPH, provide expert perspectives on optimal treatment strategies for patients with triple-negative breast cancer (TNBC), with topics including:
- Current data and strategies for using PD-1/PD-L1 inhibitors in early-stage TNBC
- Clinical implications of PD-L1 status on therapeutic planning for patients with metastatic TNBC
- Current data and treatment strategies and the future of antibody–drug conjugates in the management of relapsed/refractory advanced TNBC
- Treatment implications of the presence of BRCA1/2 mutations and homologous recombination deficiency genes in advanced TNBC
- Role of PARP inhibitors in the treatment of TNBC
Presenters:
Mark Pegram, MD
Professor
Medical Oncology
Stanford University
Palo Alto, California
Sara Tolaney, MD, MPH
Associate Professor of Medicine
Division of Breast Oncology
Harvard Medical School
Chief, Division of Breast Oncology
Breast Oncology Program
Dana-Farber Cancer Institute
Boston, Massachusetts
Content based on an online CME/CE/CPE program supported by educational grants from Gilead Sciences, Inc.
Link to full program:
http://bit.ly/3iQzDz5
In this podcast episode, Raajit Rampal, MD, PhD, and Brady L. Stein, MD, MHS, discuss their contemporary approaches to the treatment of patients with polycythemia vera. The topics covered include:
- Patient presentation and goals of frontline therapy
- Considerations for second-line therapy in the setting of treatment intolerance
- Experts’ thoughts on the potential of early intervention to alter disease progression
Presenters:
Raajit Rampal, MD, PhD
Associate Member
Associate Attending Physician
Leukemia Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York
Brady L. Stein, MD, MHS
Professor of Medicine
Department of Hematology/Oncology
Northwestern University Feinberg School of Medicine
Chicago, Illinois
Content for this program was supported by educational grants from GSK, Incyte Corporation, and PharmaEssentia Corp.
Link to the full program, including downloadable slides and an on-demand webcast from the live event:
https://bit.ly/3X3x6jX
In this episode, David Kaplan, MD, MSc, and Tamar Taddei, MD, discuss which patients should be screened for hepatocellular carcinoma, current surveillance recommendations, barriers to implementation, emerging biomarkers in development, and unmet needs in hepatocellular carcinoma surveillance.
Presenters:
David E. Kaplan, MD, MSc
Associate Professor
Perelman School of Medicine
Chief, Hepatology Section
Division of Gastroenterology and Hepatology
University of Pennsylvania
Director of Hepatology
Corporal Michael J. Crescenz VA Medical Center
Philadelphia, Pennsylvania
Tamar Taddei, MD
Professor
Section of Digestive Diseases
Department of Internal Medicine
Yale School of Medicine
Chief, GI Section
VA Connecticut Healthcare System
West Haven, Connecticut
In this episode, Zoe Lanham, a woman with high-risk hormone receptor–positive/HER2-negative early breast cancer, discusses the importance of effective communication between patients and their healthcare team, drawing on her personal experience.
Presenter:
Zoe Lanham
Patient
Link to full program:
https://bit.ly/3Fukjzk
In this episode, Prof Isabelle Ray Coquard, MD, PhD, and Ignace Vergote, MD, PhD, share their thoughts on key studies of interested presented at the 2022 ESGO annual meeting in Berlin, Germany, including:
• Phase III CALLA trial of durvalumab combined with and following chemoradiotherapy in locally advanced cervical cancer
• Geneva HRD test: validation of samples from PAOLA-1 dataset using Geneva laboratory–developed test
• Validation of NOGGO-GIS HRD assay using samples from the PAOLA-1 trial
• Survival results from phase III ARIEL3: maintenance rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancer
Presenters:
Isabelle Ray-Coquard, MD, PhD
Professor of Department of Medical Oncology
Clinical Science Institute of the Léon Bérard Center
Lyon, France
Ignace Vergote, MD, PhD
Professor Em. of Department of Obstetrics and Gynecologic Oncology
University Hospitals Leuven
Leuven, Belgium
Content supported by educational grants from AstraZeneca, GlaxoSmithKline, Karyopharm Therapeutics, and Merck Sharp & Dohme Corp.
Link to full program, including a downloadable highlights slideset, and ClinicalThought commentaries:
https://bit.ly/3SSSqpN
In this episode, activist and breast cancer survivor Yee Won Chong shares his experience as a transmasculine person navigating the healthcare system with Norma Steiner, MD, a gynecologic oncologist, who in turn offers her perspective on caring for patients across the gender spectrum. Topics include:
- 4 aspects of transgender care: emotional, social, medical, legal
- Getting language right and how to gracefully recover from fumbles
- Sensitively approaching ongoing cancer care in transmasculine and transfeminine individuals
- Handling billing and charting challenges when caring for transgender patients
- Ideas for institutional change to improve healthcare for transgender individuals
Presenters:
Yee Won Chong
Co-filmmaker, Trans Dudes with Lady Cancer
Senior Fellow, Racial Equity
Western States Center
Equity, Diversity, and Inclusion Strategist and Consultant
Portland, Oregon
Norma Steiner, MD
Gynecological Oncologist
Northwest Permanente
Portland, Oregon
Link to full program:
http://bit.ly/3Ugz0LR
In this episode, Farrukh T. Awan, MD, and Nicole Lamanna, MD, answer questions from an audience of healthcare professionals on topics related to the use of BTK inhibitors for the management of chronic lymphocytic leukemia (CLL). The topics covered include:
- Whether it is justifiable to use chlorambucil plus obinutuzumab as a control arm in a registrational trial today
- Relevance of overall response rate vs progression-free survival for BTK inhibitor therapy
- Approval of ibrutinib/venetoclax combination therapy for patients with CLL
- Key differences between zanubrutinib and acalabrutinib in the treatment of patients with CLL
- How to transition/overlap next therapy in patients with CLL with progression while receiving a BTK inhibitor
Faculty:
Farrukh T. Awan, MD
Associate Professor of Internal Medicine
Director of Lymphoid Malignancies Program
Harold C. Simmons Comprehensive Cancer Center
University of Texas Southwestern Medical Center
Dallas, Texas
Nicole Lamanna, MD
Associate Professor
Leukemia Service
Director of CLL Program
Hematologic Malignancies Section
Department of Medicine
New York-Presbyterian/Columbia University Medical Center
New York, New York
Link to the complete program, including downloadable slidesets and an on-demand webcast:
https://bit.ly/3EjvSKm
In this episode, Christopher R. Flowers, MD, MS, and Kami Maddocks, MD, discuss their choices of recent important trials presented at the Society of Hematologic Oncology 2022 Annual Meeting evaluating the use of BTK inhibitors in chronic lymphocytic leukemia and mantle cell lymphoma. The discussion includes analyses of:
- GLOW: phase III randomized trial of ibrutinib plus venetoclax vs chlorambucil plus obinutuzumab for older or unfit patients with previously untreated chronic lymphocytic leukemia
- BRUIN: phase I/II study of pirtobrutinib for previously treated mantle cell lymphoma (including previous BTK inhibitor)
Presenters:
Christopher R. Flowers, MD, MS
Department Chair, Department of Lymphoma/Myeloma
Division of Cancer Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas
Kami Maddocks, MD
Professor of Clinical Internal Medicine
Division of Internal Medicine
Department of Hematology
The Ohio State University
Lymphoma Program Director
The Ohio State University James Cancer Hospital
Columbus, Ohio
In this podcast episode from Clinical Care Options, Paul G. Richardson, MD; Natalie S. Callander, MD; and Noopur Raje, MD, answer questions from a live webinar on therapeutic options currently available for patients with relapsed/refractory multiple myeloma. The topics covered include:
- How to sequence currently available therapies after relapse
- Challenges with using BCMA-targeted agents in clinical practice
- Experts’ thoughts on the potential approval of bispecific agents
Presenters include:
Paul G. Richardson, MD
RJ Corman Professor of Medicine
Harvard Medical School
Clinical Program Leader
Director of Clinical Research
Jerome Lipper Multiple Myeloma Center
Dana Farber Cancer Institute
Boston, Massachusetts
Natalie S. Callander, MD
Professor of Medicine
School of Medicine and Public Health
University of Wisconsin
Director
Myeloma Clinical Program
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin
Noopur Raje, MD
Director
Center for Multiple Myeloma
Massachusetts General Hospital Cancer Center
Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Content for this program was supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Karyopharm Therapeutics Inc.; and Regeneron Pharmaceuticals, Inc.
Link to the full program, including downloadable slides and an on-demand webcast from the live event:
https://bit.ly/3Fc7eMK
In this episode,Susana Banerjee, MBBS, MA, PhD, and Mansoor Raza Mirza, MD, share their thoughts on key studies of interested presented at the IGCS 2022 Annual Global Meeting for ovarian and cervical cancers including:
- Post-hoc analyses from SOLO-3: olaparib vs physician’s choice chemotherapy in germline BRCA mutant platinum-sensitive recurrent ovarian cancer
- Phase III CALLA trial: durvalumab combined with and following chemoradiation for locally-advanced cervical cancer
- Phase III ARIEL3: final OS for maintenance rucaparib vs placebo following response to platinum-based chemotherapy for recurrent high-grade serous ovarian cancer
- Retrospective NeCTuR study: outcomes with topotecan, paclitaxel, and bevacizumab (TPB) vs non-TPB regimens for recurrent high-grade neuroendocrine carcinoma of the cervix
Presenters:
Susana Banerjee, MBBS, MA, PhD, FRCP
Consultant Medical Oncologist and Research Lead
Gynaecology Unit
Royal Marsden NHS Foundation Trust
London, United Kingdom
Mansoor Raza Mirza, MD
Chief Oncologist
Department of Oncology
Rigshopitalet – Copenhagen University Hospital
Copenhagen, Denmark
Content supported by educational grants from AstraZeneca, GlaxoSmithKline, Karyopharm Therapeutics, and Merck Sharp & Dohme Corp.
Link to full program, including a downloadable highlights slideset, and ClinicalThought commentaries:
https://bit.ly/38xuRBv
In this episode, Domenica Lorusso, MD, PhD, and Alexandra Leary, MD, PhD, provide their expert insights on key updates presented for ovarian cancer trials including:
- Phase III GOG-3004/SOLO-1: OS results after 7 years of follow-up for patients with newly diagnosed advanced ovarian cancer receiving maintenance olaparib vs placebo
- Phase III ENGOT-ov25/PAOLA-1: final OS results from the trial of maintenance therapy with olaparib with bevacizumab vs bevacizumab alone in women with newly diagnosed advanced ovarian cancer
- Phase III ATHENA-MONO: outcomes by disease subgroups receiving rucaparib vs placebo maintenance after platinum-based chemotherapy in patients with newly diagnosed advanced ovarian cancer
- Phase III ARIEL4: OS outcomes following treatment with rucaparib vs chemotherapy in patients with relapsed advanced ovarian cancer and a deleterious BRCA1/2 mutation
Presenters:
Domenica Lorusso, MD, PhD
Associate Professor
Gynecologic Oncology Department
Clinical Research Unit
Fondazione Policlinico Gemelli IRCCS
Rome, Italy
Alexandra Leary, MD, PhD
Medical Oncologist and Team Leader
Gynecology Translational Research Lab
Department of Medicine
Gustave Roussy Cancer Center
Paris, France
Content supported by educational grants from AstraZeneca, GlaxoSmithKline, Karyopharm Therapeutics, and Merck Sharp & Dohme Corp.
Link to full program, including a downloadable highlights slideset, and ClinicalThought commentaries:
https://bit.ly/3SSSqpN
In this episode, Ryan D. Gentzler, MD, MS, and Jonathan Riess, MD, MS, answer audience questions on managing EGFR-mutated non-small-cell lung cancer (NSCLC) from a live meeting series. The episode includes expert insights on:
• Identifying patients who may benefit the most from adjuvant osimertinib
• Testing for EGFR mutations in early-stage NSCLC
• Critical importance of getting molecular test results before starting immunotherapy
• Monitoring cardiac toxicity in patients receiving osimertinib
• Key ongoing trials in EGFR-mutated NSCLC for patients with newly diagnosed disease and following progression on osimertinib
Presenters:
Ryan D. Gentzler, MD, MS
Associate Professor
Division of Hematology/Oncology
Department of Medicine
University of Virginia
Thoracic Medical Oncologist
University of Virginia Comprehensive Cancer Center
Charlottesville, Virginia
Jonathan Riess, MD, MS
Associate Professor
Department of Internal Medicine/Hematology-Oncology
University of California, Davis
Medical Director, Thoracic Oncology
University of California, Davis Comprehensive Cancer Center
Sacramento, California
Link to full program:
https://bit.ly/3DZGzSO
In this episode, Julie M. Vose, MD, MBA, and Matthew S. Davids, MD, MMSc, discuss their choices of recent important trials presented at the Pan Pacific Lymphoma Conference 2022 evaluating the use of BTK inhibitors in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The discussion includes analyses of:
- BRUIN (CLL/small lymphocytic lymphoma [SLL]): phase I/II study of pirtobrutinib for previously treated CLL (including previous BTK inhibitor)
- SEQUOIA: phase III study evaluating cohort 1 of zanubrutinib vs bendamustine/rituximab in untreated CLL/SLL without del(17p)
- MAJIC: phase III trial in progress of acalabrutinib + venetoclax vs venetoclax + obinutuzumab in previously untreated CLL
- BRUIN (MCL): phase I/II study of pirtobrutinib for previously treated MCL (including previous BTK inhibitor)
- BRUIN MCL-321: phase III trial in progress of pirtobrutinib vs investigator’s choice acalabrutinib, ibrutinib, or zanubrutinib in previously treated, BTK inhibitor–naive MCL
- BRIDGE: series case report from phase II study evaluating zanubrutinib-based induction and maintenance in young patients with MCL
Presenters:
Julie M. Vose, MD, MBA
Chief, Division of Oncology and Hematology
Neumann M. and Mildred E. Harris Professor
Department of Internal Medicine
University of Nebraska Medical Center
Omaha, Nebraska
Matthew S. Davids, MD, MMSc
Associate Professor of Medicine
Harvard Medical School
Director of Clinical Research
Division of Lymphoma
Dana-Farber Cancer Institute
Boston, Massachusetts
Link to full program:
https://bit.ly/3OQ6634
In this podcast episode from Clinical Care Options (CCO), Heinz-Josef Klumpen, MD, PhD, and Chris Verslype, MD, PhD, discuss challenges in selecting and sequencing therapy for patients with advanced hepatocellular carcinoma. Topics include:
- Factors to consider before selecting frontline immunotherapy
- Role of TKIs in the frontline
- Impact of Child-Pugh status on the efficacy of immunotherapy/VEGF inhibitor combination therapy
- Real-world evidence on frontline immunotherapy/VEGF combination therapy
- Factors to consider when selecting second-line therapy including the role of TKIs and planning for multiple lines of therapy
Presenters:
Heinz-Josef Klumpen, MD, PhD
Staff Specialist, Medical Oncologist
Department of Medical Oncology
Amsterdam UMC
Amsterdam, The Netherlands
Chris Verslype, MD, PhD
Professor
Clinical Digestive Oncology
KULeuven
Head of Clinic
Hepatology
Digestive Oncology
U.Z. Leuven
Leuven, Belgium
In this episode, Erika P. Hamilton, MD, and Komal Jhaveri, MD, discuss their approaches to and key studies for current management of patients with HER2-positive breast cancer. The discussion includes:
- Optimizing systemic therapy for patients with HER2-positive early breast cancer based on disease characteristics and risk
- Sequencing available therapies for patients with HER2-positive metastatic disease, including new data on first- and second-line therapy and how to manage patients with central nervous system metastases
- Managing common adverse events associated with HER2-targeted therapy
Presenters:
Erika P. Hamilton, MD
Director, Breast and Gynecologic Cancer Research Program
Drug Development Unit
Sarah Cannon Research Institute
Investigator
Tennessee Oncology
Nashville, Tennessee
Komal Jhaveri, MD
Assistant Professor of Medicine
Weill Cornell Medical College
Associate Attending Physician
Breast Medicine Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York
See full program:
https://bit.ly/3oBdd45
In this episode, Othman Al-Sawaf, MD, and Lydia Scarfò, MD, discuss key trials presented at EHA 2022 evaluating the use of BTK inhibitors in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The discussion includes analyses of:
- GAIA/CLL13: phase III trial of time-limited venetoclax + obinutuzumab ± ibrutinib vs chemoimmunotherapy as first-line therapy for CLL
- FLAIR: randomized, adaptive-design phase III trial with data reported from ibrutinib + venetoclax and ibrutinib arm; includes measurable residual disease–defined therapy duration
- BRUIN: phase I/II study of pirtobrutinib for previously treated CLL (including previous BTK inhibitor)
- SHINE: phase III study of ibrutinib with bendamustine + rituximab and rituximab maintenance in older patients with MCL
Presenters:
Othman Al-Sawaf, MD
Faculty of Medicine
University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne
Düsseldorf, Germany
Visiting Scientist
The Francis Crick Institute
UCL Cancer Institute, University College London
London, United Kingdom
Lydia Scarfò, MD
Laboratory of B-Cell Neoplasia, Division of Experimental Oncology
Strategic Research Program on CLL
Università Vita Salute San Raffaele and IRCCS Ospedale San Raffaele
Milano, Italy
Link to full program:
https://bit.ly/3OQ6634
In this episode, Brad S. Kahl, MD, and Anthony Mato, MD, MSCE, discuss their choices of 3 recent important trials presented at ASCO 2022 evaluating the use of BTK inhibitors in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The discussion will include analyses of:
- The SHINE trial evaluating the addition of ibrutinib to bendamustine/rituximab followed by rituximab maintenance in the first-line setting for older patients with MCL
- 3-year follow-up analysis from the CAPTIVATE fixed-duration cohort of first-line ibrutinib plus venetoclax for CLL/small lymphocytic lymphoma
- Phase I/II study of zilovertamab, an anti-ROR1 antibody, plus ibrutinib in MCL or CLL
Presenters:
Brad S. Kahl, MD
Professor of Medicine
Department of Medical Oncology
Washington University School of Medicine
St Louis, Missouri
Anthony Mato, MD, MSCE
Associate Professor
Division of Leukemia
Memorial Sloan Kettering Cancer Center
New York, New York
See full program:
https://bit.ly/3OQ6634
In this episode, Jubilee Brown, MD, and Elisabeth Diver, MD, provide expert insights on new data presented at ASCO 2022 for ovarian, endometrial, and cervical cancers regarding:
Subgroup analyses from KEYNOTE-826 evaluating pembrolizumab in combination with chemotherapy with or without bevacizumab in persistent, recurrent, or metastatic cervical cancer
- Preliminary subgroup analyses from phase III ENGOT-EN5/GOG-3055 SIENDO trial of selinexor vs placebo maintenance in recurrent endometrial cancer
- Updated analyses from phase I GARNET trial of dostarlimab in dMMR/MSI-H and pMMR/MSS advanced/recurrent endometrial cancer (cohorts A1 and A2)
- EndoBARR trial of atezolizumab, bevacizumab, and rucaparib in previously treated recurrent and progressive endometrial cancer
- Phase III ATHENA-MONO trial of first-line rucaparib vs placebo maintenance after platinum-based chemotherapy in patients with advanced ovarian cancer
Presenters:
Jubilee Brown, MD
Professor and Division Director
Gynecologic Oncology
Levine Cancer Institute, Atrium Health
Charlotte, North Carolina
Elisabeth Diver, MD
Clinical Assistant Professor
Division of Gynecologic Oncology
Department of Obstetrics and Gynecology
Stanford University
Stanford Cancer Institute
Stanford University Hospital and Clinics
Stanford, California
Content supported by educational grants from AstraZeneca, GlaxoSmithKline, Karyopharm Therapeutics, and Merck Sharp & Dohme Corp.
Link to full program, including a downloadable highlights slideset, and ClinicalThought commentaries:
https://bit.ly/3ufB8Js
In this episode, David Scott Miller, MD, FACOG, FACS, and Angeles Alvarez Secord, MD, MHSc, provide expert insights on key data presented at SGO 2022 for ovarian, endometrial, and cervical cancers regarding:
- Results from the prospective phase III PRIME study of an individualized dose for niraparib vs placebo maintenance in newly diagnosed advanced ovarian cancer
- Final OS analysis from phase III SOLO-3 evaluating olaparib vs physician’s choice of single-agent nonplatinum chemotherapy in gBRCAm platinum-sensitive relapsed ovarian cancer
- Results from the phase III SORAYA trial of mirvetuximab soravtansine, an FRα-targeting ADC with a potent tubulin-targeting maytansinoid (DM4) delivered to tumor cells, in patients with platinum-resistant ovarian cancer who had recurrence within 6 months after last platinum dose and had 1-3 prior treatments
- Results from the randomized, double-blind, placebo-controlled phase III trial of selinexor vs placebo as maintenance in patients with stage IV endometrial cancer who had a PR/CR on ≥12 weeks of first-line taxane/carboplatin
- The results from a cost-effectiveness analysis for the addition of pembrolizumab to chemotherapy with or without bevacizumab in patients with persistent, recurrent, or metastatic cervical cancer
Presenters:
David Scott Miller, MD, FACOG, FACS
Amy and Vernon E. Faulconer Distinguished Chair in Medical Science
Director and Dallas Foundation Chair in Gynecologic Oncology
Professor of Obstetrics & Gynecology
University of Texas Southwestern Medical Center
Medical Director of Gynecologic Oncology
Chair, Cancer Committee
Parkland Health & Hospital System
Dallas, Texas
Angeles Alvarez Secord, MD, MHSc
Professor
Division of Gynecologic Oncology
Department of OB/GYN
Duke Cancer Institute
Duke University Health System
Durham, North Carolina
Content supported by educational grants from AstraZeneca, GlaxoSmithKline, Karyopharm Therapeutics, and Merck Sharp & Dohme Corp.
Link to full program, including a downloadable highlights slideset, and ClinicalThought commentaries:
https://bit.ly/38xuRBv
In this episode for all healthcare professionals and any patient-facing clinical staff, Nelson F. Sanchez, MD, shares key insights on the need for equitable, compassionate healthcare for transgender individuals, along with practical guidance based on his clinical experience caring for these patients. Topics include:
- Communication and physical exam skills
- Specific clinical care needs of transgender individuals related to transition
- Creating an inclusive and welcoming environment for transgender patients and healthcare workers
- Increasing access to clinical trials for transgender individuals
- Support for transgender-identified healthcare professionals
Presenter:
Nelson F. Sanchez, MD
Associate Professor of Medicine
Department of Medicine
Weill Cornell Medicine
Associate Attending
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York
In this episode, Pharmacist Olivia Buckoski shares her experience undergoing medical and social transition and offers advice from the perspective of both a transgender person and healthcare professional on caring for transgender individuals. Topics include:
- Importance of educating entire care team about needs of transgender individuals, starting with the waiting room
- Specific advice for the exam room
- Pharmacy and adherence considerations with hormone therapy
- Examples of uninformed care
In this episode, Jyoti D. Patel, MD, and Ani Balmanoukian, MD, discuss several studies investigating agents targeting TIGIT, an emerging immune checkpoint target with promising results in PD-L1-positive NSCLC. The episode includes a review of phase II data on the use of tiragolumab plus atezolizumab in NSCLC, the use of PD-L1 as a marker of response, the potential role of anti-TIGIT therapies in solid tumors, and ongoing trials in lung cancer including SKYSCRAPER-01, SKYSCRAPER-02, SKYSCRAPER-03, and SKYSCRAPER-05.
Presenters:
Jyoti D. Patel, MD
Professor of Medicine
Division of Hematology and Oncology
Medical Director for Thoracic Oncology
Assistant Director for Clinical Research
Associate Vice Chair of Clinical Research
Department of Medicine
Robert H. Lurie Comprehensive Cancer Center
Northwestern University
Chicago, Illinois
Ani Balmanoukian, MD
Director of Thoracic Oncology
Medical Oncology
The Angeles Clinic and Research Institute,
a Cedars-Sinai Affiliate
Los Angeles, California
Link to the complete program, including an online text module with downloadable slidesets, ClinicalThought commentaries, and an additional podcast on this topic:
https://bit.ly/38qVCH7
In this episode, Jyoti D. Patel, MD, and Diwakar Davar, MD, discuss several studies investigating agents targeting TIGIT, an emerging immune checkpoint target with promising early-phase clinical trial results. The episode includes a comprehensive explanation of TIGIT, how the TIGIT pathway functions, and the potential role of TIGIT inhibition for the treatment of cancer, including analyses from ongoing clinical trials such as CITYSCAPE, PACIFIC-8, ARC-7, and SKYSCRAPER-01.
Presenters:
Jyoti D. Patel, MD
Professor of Medicine
Division of Hematology and Oncology
Medical Director for Thoracic Oncology
Assistant Director for Clinical Research
Associate Vice Chair of Clinical Research
Department of Medicine
Robert H. Lurie Comprehensive Cancer Center
Northwestern University
Chicago, Illinois
Diwakar Davar, MD
Assistant Professor, Melanoma and Phase I Therapeutics
Division of Hematology/Oncology
Department of Medicine
University of Pittsburgh Hillman Cancer Center
Pittsburgh, Pennsylvania
Link to the complete program, including an online text module with downloadable slidesets, ClinicalThought commentaries, and an additional podcast on this topic:
https://bit.ly/3r9BLmB
In this episode, Nilofer S. Azad, MD, and Kanwal Raghav, MD, discuss current and emerging uses of regorafenib and TAS-102 in later-line treatment of patients with mCRC, with topics including:
- Current use of regorafenib and TAS-102 monotherapy
- Combination therapy with regorafenib and PD-1 inhibitors
- Adding bevacizumab to TAS-102
Presenters:
Nilofer S. Azad, MD
Professor, Oncology
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University
Baltimore, Maryland
Kanwal Raghav, MD
Associate Professor, GI Medical Oncology
University of Texas MD Anderson Cancer Center
Houston, Texas
Content based on an online CME program supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.
Follow along with the slideset:
https://bit.ly/3NLejWe
Link to full program:
https://bit.ly/33yrIyh
In this episode, Jeff P. Sharman, MD; Matthew S. Davids, MD, MMSc; and Anthony Mato, MD, MSCE, answer questions from a live CCO webinar on current best practices and emerging strategies in BTK inhibitor therapy for patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), with questions including:
- For patients with CLL, when should acalabrutinib-, ibrutinib-, or venetoclax-based regimens be considered?
- What is the optimal therapy for a patient with del(17p) CLL?
- When should an anti-CD20 antibody be added to BTK inhibitor therapy for patients with CLL?
- What are best practices in the use of BTK inhibitors for patients with MCL?
- How can BTK inhibitor resistance occur?
- How might investigational noncovalent BTK inhibitors be used should they be approved?
- What are key adverse events with BTK inhibitors?
Presenters:
Jeff P. Sharman, MD (chair)
Medical Director
Hematology Research
US Oncology
Willamette Valley Cancer Institute
Eugene, Oregon
Matthew S. Davids, MD, MMSc
Associate Professor of Medicine
Harvard Medical School
Director of Clinical Research
Division of Lymphoma
Dana-Farber Cancer Institute
Boston, Massachusetts
Anthony Mato, MD, MSCE
Associate Professor
Division of Leukemia
Memorial Sloan Kettering Cancer Center
New York, New York
Content based on an online CME program supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit https://bit.ly/3wXOsV5.
Link to full program:
https://bit.ly/3NEpsYQ
In this episode, Lipika Goyal, MD, leads an engaging discussion with Christine Chio, PharmD, BCOP, and Caroline Kuhlman, NP, on current treatment of patients with cholangiocarcinoma. Topics include:
- Initial diagnosis
- Biomarker testing to guide treatment with immunotherapies and targeted agents
- Adverse event management
- Strategies for counseling patients
Presenters:
Christine Chio, PharmD, BCOP
Clinical Ambulatory GI Oncology Pharmacist
Department of Pharmacy
Massachusetts General Hospital
Boston, Massachusetts
Lipika Goyal, MD
Assistant Professor of Medicine
Division of Hematology/Oncology
Department of Medicine
Harvard Medical School
Attending Physician
Massachusetts General Hospital Cancer Center
Boston, Massachusetts
Caroline Kuhlman, NP
Department of Gastrointestinal Oncology
Massachusetts General Hospital Cancer Center
Boston, Massachusetts
Link to the full program on the CCO website:
https://bit.ly/3JGDBCk
In this podcast episode, Amy DeZern, MD, MHS, Daniel Pollyea, MD, MS, and Amer Zeidan, MBBS, discuss challenging cases in MDS, including
- Treatment for MDS after ESA failure
- Strategies for patients with intermediate- or high-risk MDS
- Luspatercept therapy in MDS
- MDS case challenges
Link to full program, including downloadable slidesets:
https://bit.ly/3tYwcYu
Presenters:
Amy E. DeZern, MD, MHS
Associate Professor
Oncology and Medicine
The Johns Hopkins University School of Medicine
Baltimore, Maryland
Daniel Pollyea, MD, MS
Associate Professor of Medicine
Clinical Director of Leukemia Services
Division of Hematology
University of Colorado School of Medicine
Aurora, Colorado
Amer Zeidan, MBBS
Associate Professor, Internal Medicine
Hematology
Yale University
New Haven, Connecticut
In this episode, Dr Prithviraj Bose, Pharmacist Caitlin R. Rausch, and Nurse Practitioner Ilene A. Galinsky discuss incorporating KIT-targeted therapies into management of patients with advanced systemic mastocytosis. Topics include:
- Diagnosis and prognosis of advanced systemic mastocytosis
- Clinical trial data on efficacy of avapritinib and midostaurin
- Monitoring for and managing key toxicities with avapritinib, including cognitive dysfunction
Presenters:
Prithviraj Bose, MD
Associate Professor
Division of Cancer Medicine
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas
Caitlin R. Rausch, PharmD
Clinical Pharmacy Specialist, Leukemia
Division of Pharmacy
University of Texas MD Anderson Cancer Center
Houston, Texas
Ilene A. Galinsky, NP
Senior Research Program Adult Leukemia Nurse Practitioner
Department of Leukemia
Dana-Farber Cancer Institute/Brigham and Women's Hospital
Boston, Massachusetts
In this episode, Julie M. Vose, MD, MBA; Brad S. Kahl, MD; and John P. Leonard, MD, discuss treatment approaches for patients with B-cell lymphomas, including information on:
- Follicular lymphoma
- Marginal zone lymphoma
- Mantle cell lymphoma
- Diffuse large B-cell lymphoma
- Posttransplant lymphoproliferative disorder
Presenters:
Julie M. Vose, MD, MBA
Chief, Division of Oncology and Hematology
Neumann M. and Mildred E. Harris Professor
Department of Internal Medicine
University of Nebraska Medical Center
Omaha, Nebraska
Brad S. Kahl, MD
Professor of Medicine
Department of Medical Oncology
Washington University School of Medicine
St Louis, Missouri
John P. Leonard, MD
Richard T. Silver Distinguished Professor of Hematology and Medical Oncology
Professor of Medicine
Weill Cornell Medicine
New York Presbyterian Hospital
New York, New York
Link to the complete program, including downloadable slidesets, expert commentaries, an on-demand webcast, and treatment resource guides:
https://bit.ly/3tb47wU
In this podcast episode from Clinical Care Options (CCO), Josep M. Llovet, MD, PhD, and Markus Peck-Radosavljevic, MD, MBA, discuss second line treatment of patients with advanced hepatocellular carcinoma. Topics include:
- Available agents for the management of advanced hepatocellular carcinoma in the second line
- The current role of tyrosine kinase inhibitors in second-line treatment of advanced hepatocellular carcinoma
- Ongoing clinical trials in the second-line setting
Presenters:
Josep M. Llovet, MD, PhD, FAASLD
Professor of Medicine
Director, Mount Sinai Liver Cancer Program
Division of Liver Diseases
Mount Sinai School of Medicine
New York, New York
Professor of Research
Liver Unit, IDIBAPS
Hospital Clinic Barcelona
Barcelona, Spain
Univ. Prof. Markus Peck-Radosavljevic, MD, MBA
Professor of Medicine
Medical University of Vienna
Vienna, Austria
Department Chair, Innere Medizin und Gastroenterologie
Klinikum Klagenfurt am Wörthersee
Klagenfurt am Wörthersee, Austria
Link to full program, including accompanying downloadable slidesets:
https://bit.ly/2ZL9bxq
In this episode, Eileen M. O’Reilly, MD, and Naureen Starling, MD, FRCP, discuss emerging therapeutic strategies involving PARP inhibitor therapy in the treatment of pancreatic cancer. Topics include:
- Current treatment landscape and testing in the United States vs the United Kingdom
- Testing for molecular subgroups beyond BRCAm
- Using PARP inhibitors in earlier stages of the disease
- Learning from other cancers, such as prostate, breast, and ovarian
Presenters:
Eileen M. O’Reilly, MD
Winthrop Rockefeller Chair in Medical Oncology
Section Head, Hepatopancreaticobiliary/Neuroendocrine Cancers
Gastrointestinal Oncology Service
Associate Director
David M. Rubenstein Center for Pancreatic Cancer
Attending Physician, Member
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Medical College
New York, New York, USA
Naureen Starling, MD, FRCP
Associate Director of Clinical Research
Department of GI Cancers
Consultant Medical Oncologist, GI Cancers
The Royal Marsden Hospital
London, United Kingdom
Content based on an online CME program supported by an educational grant from AstraZeneca.
Link to full program:
https://bit.ly/3s6AnSz
In this episode,Brian G.M. Durie, MD; Thomas G. Martin, MD; Philippe Moreau, MD; S. Vincent Rajkumar, MD; and Jesús F. San-Miguel, MD, PhD, discuss treatment approaches for multiple myeloma using example patient cases.
- Smoldering myeloma
- Induction therapy for autologous stem cell transplant–eligible patients
- First-line approaches for autologous stem cell transplant–ineligible patients
- Treatment after first relapse
- Selecting therapy for heavily pretreated myeloma
Presenters:
Brian G.M. Durie, MD
Medical Director, AMyC
Co-Chair Myeloma Committee, SWOG
Chairman, International Myeloma Foundation
Specialist in Multiple Myeloma and Related Disorders
Cedars-Sinai Outpatient Cancer Center
Los Angeles, California
Thomas G. Martin, MD
Clinical Professor of Medicine
Associate Director, Myeloma Program
University of California, San Francisco Medical Center
San Francisco, California
Philippe Moreau, MD
Professor of Clinical Hematology
Head, Hematology Department
University Hospital Hôtel-Dieu
Nantes, France
S. Vincent Rajkumar, MD
Edward W. and Betty Knight Scripps Professor of Medicine
Mayo Clinic
Rochester, Minnesota
Jesús F. San-Miguel, MD, PhD
Director of Clinical and Translational Medicine
Universidad de Navarra
Pamplona, Spain
Link to the complete program, including downloadable slidesets, an expert commentary, an on-demand webcast, and treatment resource guide.
https://bit.ly/3JJbWk9
In this episode, Keith R. McCrae, MD; Nichola Cooper, MD; and Rachael Grace, MD, MMSc,provide expert insights on immune thrombocytopenia management, along with addressing frequently asked questions from a live CCO symposium. Topics include:
- New and emerging therapeutic options
- Special patient populations, including children
- The management of immune thrombocytopenia
- COVID-19 vaccinations and immune thrombocytopenia
Presenters:
Keith R. McCrae, MD
Professor of Molecular Medicine
Department of Hematology and Oncology
Taussig Cancer Institute
Cleveland Clinic
Cleveland, Ohio, USA
Nichola Cooper, MD
Honorary Consultant Hematologist
Hammersmith Hospital
Imperial College
London, United Kingdom
Rachael Grace, MD, MMSc
Associate Professor of Pediatrics
Harvard Medical School
Dana-Farber/Boston Children’s Cancer and Blood Disorders Center
Boston, Massachusetts, USA
Content based on an online CME program supported by an educational grant from Amgen; Dova Pharmaceuticals, Inc.; and Sanofi Genzyme.
Advances in Immune Thrombocytopenia:
https://bit.ly/3gzykzy
In this episode, Ara Metjian, MD; Paul Coppo, MD, PhD; and Marshal Mazepa, MD, answer questions from an audience of healthcare professionals on topics related to the management of acquired thrombotic thrombocytopenic purpura (aTTP), including:
- Rationale of the CAPLAVIE regimen of caplacizumab with corticosteroids and rituximab in aTTP in the acute phase
- Data for caplacizumab in pediatric patients with aTTP
- Initiating rituximab after completion of plasma exchange
- International Society on Thrombosis and Haemostasis guideline recommendations against using aspirin
- Triggers of aTTP episodes aside from infection
- Effect of COVID-19 vaccines and COVID-19 infections on aTTP onset or relapse
Presenters:
Ara Metjian, MD
Associate Professor
Division of Hematology
Department of Medicine
University of Colorado, Anschutz Medical Campus
Aurora, Colorado
Paul Coppo, MD, PhD
Professor of Hematology
Hematology Department, AP-HP
Sorbonne University
Paris, France
Marshall Mazepa, MD
Assistant Professor of Medicine
Division of Hematology, Oncology, and Transplantation
University of Minnesota
Minneapolis, Minnesota
Link to the complete program, including downloadable slidesets, an expert commentary, an on-demand webcast, and healthcare professional resource guide:
https://bit.ly/3J1fcad
In this episode, Steven M. Horwitz, MD; Francine Foss, MD; and Barbara Pro, MD, answer questions from an audience of healthcare professionals on topics related to the management of patients with T-cell lymphomas including:
- Threshold of CD30 positivity useful to inform brentuximab vedotin use in patients with CTCL and PTCL
- Managing relapsed mycosis fungoides after allogeneic SCT
- Experience with ALK inhibition in ALCL with central nervous system metastases
- Managing refractory pruritus in CTCL
- Role of PI3K inhibitors in frontline and relapsed/refractory PTCL
- When to consider SCT in CTCL cycling through monotherapies
Presenters:
Steven M. Horwitz, MD
Member
Memorial Sloan Kettering Cancer Center
Attending Physician
Memorial Hospital
Professor of Medicine
Weill Cornell Medical College
New York, New York
Francine Foss, MD
Professor of Medical Oncology
Yale Cancer Center
Yale University School of Medicine
New Haven, Connecticut
Barbara Pro, MD
Professor of Medicine
Division of Hematology/Oncology
Northwestern University
Chicago, Illinois
Link to the complete program, including downloadable slidesets, an expert commentary, and on-demand webcast, and healthcare professional resource guide:
https://bit.ly/3AKJE5s
In this podcast episode, Conor Ernst Steuer, MD, a medical oncologist; Frank Schneider, MD, a pathologist; and Elise Hitron, MSN, FNP-C, a phase I clinical trials nurse practitioner, engage in a multidisciplinary discussion of the latest management strategies for EGFR-mutated NSCLC. Topics include:
- Testing for targetable biomarkers
- Talking with patients about biomarker testing
- Frontline therapy for EGFR-positive NSCLC
- Resistance to front-line osimertinib
- Treatment of EGFR TKI–resistant disease, including the emerging antibody–drug conjugate patritumab deruxtecan
- HER3 protein testing
- Pathology considerations
- Nursing considerations
- Interdisciplinary communication
Presenters:
Conor Ernst Steuer, MD
Assistant Professor
Department of Medical Oncology
Winship Cancer Institute
Emory University
Atlanta, Georgia
Frank Schneider, MD
Associate Professor of Pathology
Department of Pathology and Laboratory Medicine
Director, Cancer Tissue and Pathology Shared Resource
Winship Cancer Institute
Emory University
Atlanta, Georgia
Elise Hitron, MSN, FNP-C
Adjunct Instructor
School of Nursing
Phase I Clinical Trials Nurse Practitioner
Winship Cancer Institute
Emory University
Atlanta, Georgia
Supported by an educational grant from Daiichi Sankyo, Inc.
Link to full program, including a series of short interactive virtual presentations with downloadable slidesets on EGFR-mutated advanced NSCLC, including the evolving role of HER3 in the setting of EGFR TKI resistance:
https://bit.ly/3G32Jkm
| In this podcast episode, 3 experts answers questions on the management of hemophilia A from a live webinar. Topics include: * Which patients should have pharmacokinetic-guided therapy? * Toxicities with PEGylated extended half-life products * Factor VIII and bone health * Factor VIII peaks, thrombotic risk, and cardiovascular disease * Choosing between extended half-life products and emicizumab for active patients * Role of fitusiran in the treatment paradigm if approved
Presenters:Miguel A. Escobar, MDProfessor of Medicine and PediatricsDepartment of HematologyUniversity of Texas Health Science CenterMcGovern Medical SchoolDirectorGulf States Hemophilia and Thrombophilia CenterHouston, TexasMark Reding, MDProfessor of MedicineDivision of Hematology, Oncology, and TransplantationDirectorCenter for Bleeding and Clotting DisordersUniversity of MinnesotaMinneapolis, MinnesotaGuy A. Young, MDProfessor of PediatricsDirector, Hemostasis and Thrombosis CenterChildren’s Hospital Los AngelesUniversity of Southern California Keck School of MedicineLos Angeles, California |
Link to full program, including downloadable slidesets, expert commentary, and on-demand webcast:
https://bit.ly/3zZwP6G
In this podcast episode, Sarah M. Tinsley, PhD, APRN, AOCN, discusses targeted therapy with FLT3 and IDH1/2 inhibitors in AML, with a focus on the nursing perspective. Topics include:
- Approved and emerging treatment options for FLT3-mutated AML
- Management of adverse events associated with FLT3 inhibitors
- Therapies for IDH1- and IDH2-mutated AML
- Identifying and managing differentiation syndrome associated with IDH1/2 inhibitors
Presenters:
Sarah M. Tinsley, PhD, APRN, AOCN
Nurse Practitioner
Courtesy Assistant Professor
Department of Malignant Hematology
Moffitt Cancer Center
University of South Florida
Tampa, Florida
In this podcast episode, Sarah M. Tinsley, PhD, APRN, AOCN, discusses management strategies for secondary AML and novel therapies currently in clinical trials for AML. Topics include:
- Liposomal cytarabine plus daunorubicin for secondary AML
- An overview of emerging immune-based strategies for AML
- Evidence on immune-based therapies, including agents targeting CD47, TIM3, and bispecific antibodies
Presenter:
Sarah M. Tinsley, PhD, APRN, AOCN
Nurse Practitioner
Courtesy Assistant Professor
Department of Malignant Hematology
Moffitt Cancer Center
University of South Florida
Tampa, Florida
In this podcast episode, Ashley Leak Bryant, PhD, RN, OCN, FAAN, discusses therapeutic options for younger, fit patients with AML and no targetable mutations. Topics include:
- Induction chemotherapy and consolidation therapy
- Use of gemtuzumab ozogamicin
- Management of sinusoidal obstruction syndrome
- Nursing considerations for younger, fit patients with AML
Presenter:
Ashley Leak Bryant, PhD, RN, OCN, FAAN
Associate Professor
School of Nursing
UNC Lineberger Comprehensive Cancer Center
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
In this podcast episode, Ashley Leak Bryant, PhD, RN, OCN, FAAN, discusses acute myeloid leukemia and management approaches for patients unfit for intensive chemotherapy, with a focus on the nursing perspective. Topics include:
- An overview of AML
- Identifying patients unfit for intensive therapy
- Treatment options for unfit patients including venetoclax combinations
- Adverse event profiles of treatment options
- Nursing considerations for managing patients with AML unfit for intensive therapy
Presenters:
Ashley Leak Bryant, PhD, RN, OCN, FAAN
Associate Professor
School of Nursing
UNC Lineberger Comprehensive Cancer Center
The University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
In this podcast episode,Sarah Tinsley, PhD, APRN, AOCN, discusses management strategies for higher-risk and relapsed/refractory (R/R) myelodysplastic syndromes (MDS) with a focus on the nursing perspective. Topics include:
- Current and ongoing clinical trials in the higher-risk and R/R MDS setting
- Therapies surrounding transplant
- Nursing considerations for managing a patient with higher risk and/or R/R MDS
Presenters:
Sarah Tinsley, PhD, APRN, AOCN
Nurse Practitioner
Courtesy Assistant Professor
Department of Malignant Hematology
Moffitt Cancer Center
University of South Florida
Tampa, Florida
In this podcast episode, Ashley Leak Bryant, PhD, RN, OCN, FAAN, discusses management strategies for lower-risk myelodysplastic syndrome (MDS) with a focus on the nursing perspective. Topics include
- Risk scoring and treatment algorithms
- Current and ongoing clinical trials in the lower-risk MDS setting
- Adverse event profiles of current treatment options
- Nursing considerations for managing a patient with lower-risk MDS
Presenters:
Ashley Leak Bryant, PhD, RN, OCN, FAAN
Associate Professor
School of Nursing
UNC Lineberger Comprehensive Cancer Center
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
In this episode, Chiara Cremolini, MD, PhD, and Teresa Macarulla, MD, PhD, discuss the clinical data that inform how they select regorafenib and TAS-102 as later-line treatment for patients with mCRC, with topics including:
- Transitioning from second- to third-line therapy
- Factors in selecting among available therapies
- Key predictors of improved outcomes with regorafenib vs TAS-102
Presenters:
Chiara Cremolini, MD, PhD
Medical Oncologist
Unit of Medical Oncology 2
Azienda Ospedaliero-Universitaria Pisana
Professor
Department of Translational Research and New Technologies in Medicine and Surgery
University of Pisa
Pisa, Italy
Teresa Macarulla, MD, PhD
Medical Oncologist
Head, Gastrointestinal and Endocrine Tumors Unit
Division of Medical Oncology
Vall d´Hebrón Institute of Oncology
Barcelona, Spain
Content based on an online CME program supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.
Follow along with the slideset:
https://bit.ly/3FjekMo
Link to full program:
https://bit.ly/33yrIyh
In this podcast episode from Clinical Care Options (CCO), Josep M. Llovet, MD, PhD, and Markus Peck-Radosavljevic, MD, MBA, discuss first-line treatment of patients with advanced hepatocellular carcinoma. Topics include:
- Atezolizumab plus bevacizumab as the current standard of care
- Contraindications to atezolizumab plus bevacizumab
- The current role of tyrosine kinase inhibitors in first-line treatment of advanced hepatocellular carcinoma
- Ongoing clinical trials in the first-line setting
Presenters:
Josep M. Llovet, MD, PhD, FAASLD
Professor of Medicine
Director, Mount Sinai Liver Cancer Program
Division of Liver Diseases
Mount Sinai School of Medicine
New York, NY
Professor of Research
Liver Unit, IDIBAPS
Hospital Clinic Barcelona
Barcelona, Spain
Univ. Prof. Markus Peck-Radosavljevic, MD, MBA
Professor of Medicine, Medical University of Vienna
Vienna, Austria
Department Chair, Innere Medizin and Gastroenterologie
Klinikum Klagenfurt am Wörthersee
Klagenfurt am Wörthersee, Austria
Link to full program, including accompanying downloadable slidesets:
https://bit.ly/2ZL9bxq
In this episode, Nicole Concin, MD, PhD, highlights key data for endometrial and ovarian cancers presented at the ESGO 2021 annual meeting, including:
- Pooled data from 7 phase III clinical trials evaluating surgical outcomes as prognostic factors for patients with high-grade serous, low-grade serous, mucinous, and clear cell ovarian cancer
- Update from the phase I GARNET study in patients with advanced/recurrent mismatch repair deficient/microsatellite instability‒high or proficient/stable endometrial cancer
- Results from the TOTEM trial evaluating the impact of minimalist vs intensive follow-up on health-related quality of life and cost for patients with endometrial cancer
Presenters:
Nicole Concin, MD, PhD
Professor
Department of Gynaecology and Obstetrics
Medical University Innsbruck
Innsbruck, Austria
Consultant in Gynaecological Oncology
Department of Gynaecology and Gynaecologocial Oncology
KEM Evang. Kliniken Essen-Mitte
Essen, Germany
Content supported by an educational grant from GlaxoSmithKline.
Link to full program, including a downloadable highlights slideset and ClinicalThought commentaries:
https://bit.ly/30PjPnl
In this podcast episode, Julie Brahmer, MD, MSc, and Jarushka Naidoo, MB BCH BAO, MHS, answer audience questions from a live CCO webinar on evolving immunotherapy strategies for NSCLC, with topics including:
- Patient and/or disease-related factors considered when choosing first-line immunotherapy-based regimens
- Second-line therapeutic options after disease progression on an immunotherapy-based regimen
- Immunotherapy in patients with advanced NSCLC and brain metastases
- Distinguishing between immunotherapy-induced and radiation-induced pneumonitis, with expert perspective on rebiopsy
- Future directions in immunotherapy for NSCLC, including the role of the gut microbiome in response
Presenters:
Julie Brahmer, MD, MSc
Professor of Oncology
Director, Thoracic Oncology
Co-Director, Upper Aerodigestive Cancer Program
Bloomberg-Kimmel Institute for Cancer Immunology
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins Medicine
Baltimore, Maryland
Jarushka Naidoo, MB BCH BAO, MHS
Consultant Medical Oncologist
Beaumont Hospital/RCSI University of Health Sciences
Dublin, Ireland
Adjunct Assistant Professor of Oncology
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University
Baltimore, Maryland
Content based on an online CME program supported by educational grants from Bristol-Myers Squibb; Genentech, a member of the Roche Group; Helsinn Healthcare SA; and Merck Sharp & Dohme Corp.
Follow along with the PDF:
https://bit.ly/31aRRmd
Link to full program:
https://bit.ly/3CLC0Hd
In this podcast episode, George D. Demetri, MD, and Alexander Drilon, MD, discuss emerging data on the efficacy, safety, and clinical role of second-generation TRK inhibitors that can overcome acquired resistance to first-generation agents in NTRK fusion–positive solid tumors. Topics include:
- Mechanisms of acquired resistance to TRK inhibitor therapy
- Clinical trial data on the second-generation inhibitors selitrectinib and repotrectinib
- Safety profiles of first- vs second-generation TRK inhibitors
Presenters:
George D. Demetri, MD
Professor of Medicine
Harvard Medical School
Harvard University
Co-Director, Ludwig Center at Harvard
Senior Vice President for Experimental Therapeutics
Director, Sarcoma Center
Dana-Farber Cancer Institute
Boston, Massachusetts
Alexander Drilon, MD
Chief, Early Drug Development
Attending, Thoracic
Memorial Sloan Kettering Cancer Center
New York, New York
Link to full program, including downloadable slides:
https://bit.ly/2YFIPfr
In this podcast episode, Jean-Yves Blay, MD, PhD, and Robin L. Jones, BSc, MBBS, MRCP, MD(Res), discuss the most important clinical trial data on leveraging TKIs as monotherapy and in combination with chemotherapy or immune checkpoint inhibitors for treatment of soft tissue sarcoma and osteosarcoma.
Presenters:
Jean-Yves Blay, MD, PhD
Professor of Medical Oncology
Department of Medicine
Centre Leon Berard
Lyon, France
Robin L. Jones, BSc, MBBS, MRCP, MD(Res)
Professor
Sarcoma Unit
Royal Marsden Hospital and Institute of Cancer Research
London, United Kingdom
Link to full program, including accompanying downloadable slidesets:
https://bit.ly/2ZL9bxq
In this episode, Philip Agop Philip, MD, PhD, FRCP, and Elena Gabriela Chiorean, MD, discuss the importance of testing for biomarkers along with thecurrent paradigm of PARP inhibitor therapy in the treatment of pancreatic cancer. Topics include:
- Importance of germline and somatic testing
- Adverse events associated with PARP inhibitors
- Maintenance therapy in pancreatic cancer
Presenters:
Philip Agop Philip, MD, PhD, FRCP
Professor
School of Medicine
Wayne State University
Leader, Gastrointestinal Multidisciplinary Team
Department of Oncology
Karmanos Cancer Institute
Detroit, Michigan
Elena Gabriela Chiorean, MD
Professor of Medicine
Division of Medical Oncology
Department of Medicine
University of Washington
Member
Fred Hutchinson Cancer Research
Seattle, Washington
Content based on an online CME program supported by an educational grant from AstraZeneca.
Link to full program:
https://bit.ly/3jEehCc
Link to associated downloadable PDF:
https://bit.ly/3nSfTcR
In this episode, Kanwal Raghav, MD, and Rachel Riechelmann, MD, PhD, discuss key data supporting contemporary dosing strategies with the later-line treatment options regorafenib and TAS-102 for patients with mCRC, with topics including:
- Individualizing therapy
- Clinical data and experience informing optimal dosing
- Key adverse events
Presenters:
Kanwal Raghav, MD, MBBS
Associate Professor, Gastrointestinal Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas
Rachel Riechelmann, MD, PhD
Head, Clinical Oncology Department
Medical Oncologist
AC Camargo Cancer Center
Sao Paulo, Brazil
Content based on an online CME program supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.
Link to full program:
https://bit.ly/3aVXplL
In this episode, George D. Demetri, MD, and Alexander Drilon, MD, discuss key clinical data leading to FDA approvals and current indications for first-generation TRK inhibitors in NTRK fusion–positive solid tumors and ROS1-positive NSCLC. Topics include:
- Basket trials leading to FDA approvals of larotrectinib and entrectinib
- Current pan-tumor indications for first-generation TRK inhibitors in NTRK fusion–positive solid tumors as well as ROS1-positive NSCLC
- Sequencing treatment with TRK inhibition in patients with solid tumors
- Clinically relevant similarities and differences between larotrectinib and entrectinib
Presenters:
George D. Demetri, MD
Professor of Medicine
Harvard Medical School
Harvard University
Co-Director, Ludwig Center at Harvard
Senior Vice President for Experimental Therapeutics
Director, Sarcoma Center
Dana-Farber Cancer Institute
Boston, Massachusetts
Alexander Drilon, MD
Chief, Early Drug Development
Attending, Thoracic
Memorial Sloan Kettering Cancer Center
New York, New York
Link to full program, including downloadable slidesets:
https://bit.ly/2YFIPfr
In this episode, Nicoletta Colombo, MD; Philipp Harter, MD, PhD; and Alexandra Leary, MD, PhD, discuss patient cases from a live webinar on the current paradigm and long-term benefits of PARPi therapy in the treatment of ovarian cancer. Topics include:
- Maintenance therapy in ovarian cancer
- SOLO1, PRIMA, PAOLO-1 clinical data
- Role of bevacizumab in treatment of ovarian cancer
Presenters:
Nicoletta Colombo, MD
Professor of Obstetrics and Gynecology
University of Milan-Bicocca
European Institute of Oncology
Milan, Italy
Philipp Harter, MD, PhD
Deputy Director
Department of Gynecology and Gynecologic Oncology
Evang. Kliniken Essen-Mitte
Essen, Germany
Alexandra Leary, MD, PhD
Medical Oncologist and Team Leader
Gynecology Translational Research Lab
Department of Medicine
Gustave Roussy Cancer Center
Paris, France
Content based on an online CME program supported by an educational grant from AstraZeneca.
New Perspectives in Ovarian Cancer: Current Paradigm and Long-term Benefits of PARPi Therapy
https://bit.ly/3aF8Lui
In this episode, listen to Guy A. Young, MD, as he counsels a teenage patient with severe hemophilia A and the patient’s mother on various available treatment options and strategies for optimizing hemophilia A prophylaxis and adherence. Topics include:
- Overcoming challenges to adherence
- Choice of standard vs extended half-life factor VIII vs emicizumab
- Safety and efficacy data with emicizumab
Presenter:
Guy A. Young, MD
Professor of Pediatrics
Director, Hemostasis and Thrombosis Center
Children’s Hospital Los Angeles
University of Southern California Keck School of Medicine
Los Angeles, California
Link to full program:
https://bit.ly/3FxrVk2
In this episode, George D. Demetri, MD, and Alexander Drilon, MD, discuss the biologic rationale behind testing for NTRK fusions in patients with various solid tumors, along with clinical strategies for testing. Topics include:
- Differences between NTRK fusions vs gene mutations
- Frequency of NTRK fusions by age and tumor type
- When to test patients for NTRK fusions and interpreting reports
- Methods of testing: multiplex gene testing, next-generation sequencing of DNA vs RNA, immunohistochemistry, and liquid biopsy
Presenters:
George D. Demetri, MD
Professor of Medicine
Harvard Medical School
Harvard University
Co-Director, Ludwig Center at Harvard
Senior Vice President for Experimental Therapeutics
Director, Sarcoma Center
Dana-Farber Cancer Institute
Boston, Massachusetts
Alexander Drilon, MD
Chief, Early Drug Development
Attending, Thoracic
Memorial Sloan Kettering Cancer Center
New York, New York
Link to full program:
https://bit.ly/2YFIPfr
Link to slideset based on this podcast:
https://bit.ly/3amgU6w
In this episode, Daniel W. Lin, MD; Alicia K. Morgans, MD, MPH; and David F. Penson, MD, answer audience questions from a live CCO webinar focused on current best practices and emerging strategies in androgen deprivation therapy, with questions including:
- How to select between GnRH agonists and antagonists for initial androgen deprivation therapy?
- How should androgen receptor inhibitors be incorporated into treatment paradigms for nonmetastatic castration-resistant prostate cancer and metastatic hormone-sensitive prostate cancer?
- How should patients with prostate cancer and bone density issues be managed?
- How should nonmetastatic and metastatic prostate cancer be classified in light of novel imaging modalities, and how does this affect treatment?
Presenters:
Daniel W. Lin, MD
Professor and Chief of Urologic Oncology
Department of Urology
University of Washington
Seattle, Washington
Alicia K. Morgans, MD, MPH
Genitourinary Medical Oncologist
Dana-Farber Cancer Institute
Boston, Massachusetts
David F. Penson, MD
Professor and Chair
Department of Urology
Vanderbilt University School of Medicine
Nashville, Tennessee
Content based on an online CME program supported by educational grants from Astellas, Bayer HealthCare Pharmaceuticals Inc., Myovant Sciences Ltd, and Pfizer, Inc.
Link to full program:
https://bit.ly/3iFCis5
In this episode, Prof. Isabelle Ray-Coquard, MD, PhD, and Bernard Doger de Spéville, MD, PhD, provide expert insights on key new data from ESMO 2021 presented for endometrial and ovarian cancers including:
- Data from the phase III OReO/ENGOT Ov-38 trial of olaparib rechallenge in patients with recurrent ovarian cancer previously treated with a PARP inhibitor
- A subgroup analysis of KEYNOTE-775, comparing lenvatinib vs pembrolizumab vs TPC, with outcomes by tumor histology and prior lines of therapy
- A preplanned analysis from phase III NRG-GY004 of outcomes by HRD status for olaparib with or without cediranib vs platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer
- Quality-adjusted time without symptom or toxicity from the phase III PRIMA trial of maintenance niraparib vs placebo in newly diagnosed advanced ovarian cancer
Presenters:
Prof. Isabelle Ray-Coquard, MD, PhD
Professor of Department of Medical Oncology
Clinical Science Institute of the Léon Bérard Center
Lyon, France
Bernard Doger de Spéville, MD, PhD
Medical Oncologist
START-Madrid, Early Phase Clinical Trials Unit
Hospital Fundación Jiménez Díaz
Madrid, Spain
Content supported by an educational grant from GlaxoSmithKline.
Link to full program, including a downloadable highlights slideset and ClinicalThought commentaries:
https://bit.ly/3dAttwi
In this podcast episode, Jeffrey S. Weber, MD, PhD; Allison Betof Warner, MD, PhD; and Hussein Tawbi, MD, PhD, discuss recent key data on adjuvant and neoadjuvant therapy and review the latest evidence on therapies for metastatic disease.
Link to full program:
https://bit.ly/3ogPjMo
Follow along with the downloadable slideset:
https://bit.ly/2XYNIzt
Presenters:
Jeffrey S. Weber, MD, PhD
Deputy Director
Laura and Isaac Perlmutter Cancer Center
NYU Langone Health
Professor of Medicine
NYU Grossman School of Medicine
New York, New York
Allison Betof Warner, MD, PhD
Assistant Member
Assistant Attending Physician
Melanoma Service
Division of Solid Tumor Oncology
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York
Hussein Tawbi, MD, PhD
Professor
Department of Melanoma Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas
In this episode, Domenica Lorusso, MD, PhD, and Alexandra Leary, MD, PhD, provide expert insights on practice changing data from IGCS 2021 presented for endometrial, ovarian, and cervical cancers regarding:
- A subgroup analysis from phase III KEYNOTE-775 evaluating lenvatinib plus pembrolizumab efficacy in patients with advanced endometrial cancer and dMMR status
- A subgroup analysis from the phase I GARNET trial─cohorts A1 and A2─in patients with advanced endometrial cancer who had received either 1 or ≥2 prior lines of therapy
- Data from the TOTEM trial reporting survival outcomes for patients undergoing intensive vs minimalist follow-up in following treatment for endometrial cancer
- An exploratory analysis from the phase III ARIEL3 trial evaluating characteristics of patients with ovarian cancer with exceptional benefit from rucaparib
- A post hoc analysis from the phase III NORA trial assessing efficacy of starting PARP inhibitor maintenance following either ≤4 vs >4 cycles of platinum-based chemotherapy
- Highly anticipated results from the phase III EMPOWER-CERVICAL 1 trial of cemiplimab vs investigator’s choice chemotherapy in women with cervical cancer
Presenters:
Domenica Lorusso, MD, PhD
Associate Professor
Gynecologic Oncology Department
Clinical Research Unit
Fondazione Policlinico Gemelli IRCCS
Rome, Italy
Alexandra Leary, MD, PhD
Medical Oncologist and Team Leader
Gynecology Translational Research Lab
Department of Medicine
Gustave Roussy Cancer Center
Paris, France
Content supported by an educational grant from GlaxoSmithKline.
Link to full program, including a downloadable highlights slideset and ClinicalThought commentaries:
https://bit.ly/3dAttwi
In this episode, Paul G. Richardson, MD; Nina Shah, MD; and Peter M. Voorhees, MD, answer questions from a live webinar providing their thoughts on how to select the optimal therapy for patients with relapse/refractory multiple myeloma. Topics include:
- Treatment after first relapsed
- Optimal use of CAR T-cell therapy
- When to use selinexor and belantamab mafodotin
- COVID-19 vaccinations for patients with myeloma
Presenters:
Paul G. Richardson, MD
R. J. Corman Professor of Medicine
Harvard Medical School
Clinical Program Leader
Director of Clinical Research
Jerome Lipper Multiple Myeloma Center
Dana-Farber Cancer Institute
Boston, Massachusetts
Nina Shah, MD
Professor of Clinical Medicine
Division of Hematology-Oncology
Department of Medicine
University of California San Francisco
San Francisco, California
Peter M. Voorhees, MD
Director, Medical Operations and Outreach Services
Department of Hematology/Oncology
Levine Cancer Institute, Atrium Health
Charlotte, North Carolina
Content based on an online CME program supported by educational grants from Bristol-Myers Squibb, GlaxoSmithKline, Karyopharm, Oncopeptides, and Sanofi Genzyme.
Link to full program:
https://bit.ly/2UIhXcL
In this episode, Dr. Joyce O’Shaughnessy, MD, leads an engaging discussion with Matthew P. Goetz, MD, and Sara Hurvitz, MD, FACP, on leveraging CDK4/6 inhibitors for the treatment of patients with metastatic HR-positive/HER2-negative breast cancer. Topics include:
- How the experts currently use CDK4/6 inhibitors in clinical practice
- Clinical implications of key studies on CDK4/6 inhibitors from ASCO 2021
- Strategies for counseling patients receiving CDK4/6 inhibitors
Presenters:
Joyce O’Shaughnessy, MD
Celebrating Women Chair in Breast Cancer Research
Director, Breast Cancer Research Program
Baylor University Medical Center
Texas Oncology
US Oncology Network
Dallas, Texas
Matthew P. Goetz, MD
Erivan K. Haub Family Professor of Cancer Research Honoring Richard F. Emslander, M.D.
Professor of Oncology and Pharmacology
Director, Mayo Clinic Breast Cancer SPORE
Co-Leader, Women's Cancer Program, Mayo Clinic Cancer Center
Co-Chair, Mayo Breast Disease Group
Department of Medical Oncology
Mayo Clinic
Rochester, Minnesota
Sara Hurvitz, MD, FACP
Professor of Medicine
Director, Breast Oncology Program
Division of Hematology-Oncology
Department of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California
Link to the full program:
bit.ly/3kaJKeC
In this episode, John L. Marshall, MD, discusses current molecular testing considerations in the treatment of patients with gastrointestinal tumors, including:
- Current testing approaches, including IHC and PD-L1 assays and next-generation sequencing
- Tumor agnostic testing: MSI, TMB, and NTRK fusion testing
- Colon cancer: RAS, BRAF, and HER2
- Gastric cancer: PD-L1, HER2, and more
- Pancreatic cancer: BRCA
- Biliary cancers: FGFR and IDH1
- Liquid biopsies
- When to test
Presenter:
John L. Marshall, MD
Chief, Division of Hematology/Oncology
Department of Medicine
Georgetown University Hospital
Washington, DC
Content based on an online CME program supported by educational grants from Bayer and Merck, Sharp & Dohme.
Link to full program:
https://bit.ly/3j4hV8J
In this episode, Javier Cortes, MD, PhD; Stephen R. D. Johnston, MA, FRCP, PhD; and Sara Tolaney, MD, MPH, answer questions from an audience of healthcare professionals on topics related to leveraging CDK4/6 inhibitors for HR-positive/HER2-negative early breast cancer, including:
- Clinical role of Ki-67 testing
- Core biopsies for identifying potential benefit with neoadjuvant endocrine therapy
- Combining CDK4/6 inhibition with tamoxifen
Presenters:
Javier Cortes, MD, PhD
Head, Breast Cancer Program
IOB Institute of Oncology
Madrid and Barcelona, Spain
Stephen R. D. Johnston, MA, FRCP, PhD
Professor of Breast Cancer Medicine
Breast Unit
Department of Medicine
Royal Marsden Hospital
London, United Kingdom
Sara Tolaney, MD, MPH
Assistant Professor of Medicine
Harvard Medical School
Associate Director
Susan F Smith Center for Women’s Cancer
Director of Clinical Trials, Breast Oncology
Director of Breast Immunotherapy
Clinical Research
Senior Physician
Breast Oncology Program
Dana-Farber Cancer Institute
Boston, Massachusetts, USA
Content based on an online CME program supported by an educational grant from Lilly.
Link to full program, including downloadable slides and associated Podcast Pearls PDF:
https://bit.ly/37tfvtj
In this episode, Karim Fizazi, MD, PhD, and Alicia K. Morgans, MD, MPH, discuss the clinical implications of the latest data on androgen receptor–targeting agents in the treatment of patients with nonmetastatic castration-resistant prostate cancer (CRPC). Topics include:
- Updated safety and patient preference data from the ARAMIS and ODENZA trials
- Choice of apalutamide, darolutamide, and enzalutamide
- Counseling patients on adverse events
- Managing patients with asymptomatic nonmetastatic CRPC
Presenters:
Karim Fizazi, MD, PhD
Full Professor
Cancer Medicine
Gustave Roussy
Villejuif, France
Alicia K. Morgans, MD, MPH
Associate Professor
Division of Oncology
Department of Medicine
Northwestern University
Chicago, Illinois
Link to full program, including downloadable slides:
https://bit.ly/36IEnNE
In this podcast episode, Amy Goodrich, CRNP, discusses nursing perspectives on managing serious adverse events associated with BTK inhibitor therapy. Topics in this podcast include:
- Atrial fibrillation
- Cardiac toxicity
- Musculoskeletal AEs
- Managing risk of infections
Presenter:
Amy Goodrich, RN, MSN, CRNP-AC
Research Associate/Nurse Practitioner
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University
Baltimore, Maryland
CE/AAPA credit available by visiting the online program:
https://bit.ly/3zMXFOp
Link to full program, including downloadable slidesets:
https://bit.ly/3iwN9Ub
In this podcast episode, Sandra E. Kurtin, PhD, ANP-C, AOCN, discusses nursing perspectives on avoiding adverse reactions to BTK inhibitor therapy. Topics in this second of 2 podcast episodes on avoiding AEs include:
- Patient adherence to oral medications
- Lifestyle changes
- Monitoring, recording, and reporting of AEs
- The role of the nurse
- The role of the patient
- AE management
Presenter:
Sandra E. Kurtin, PhD, ANP-C, AOCN
Director, Advanced Practice and Clinical Integration
The University of Arizona Cancer Center
Assistant Professor, Clinical Medicine
Adjunct Clinical Professor, Nursing
The University of Arizona
Tucson, Arizona
CE/AAPA credit available by visiting the online program:
https://bit.ly/3zMXFOp
Link to full program, including downloadable slidesets:
https://bit.ly/3iwN9Ub
In this podcast episode,Sandra E. Kurtin, PhD, ANP-C, AOCN, discusses nursing perspectives on avoiding adverse reactions to BTK inhibitor therapy. Topics in this first of 2 podcasts on avoiding AEs include:
- Pharmacokinetics
- Drug metabolism
- Drug–drug interactions
- Drug–food interactions
- The role of CYP enzymes
- Foods to avoid
- Medication review
Presenter:
Sandra E. Kurtin, PhD, ANP-C, AOCN
Director, Advanced Practice and Clinical Integration
The University of Arizona Cancer Center
Assistant Professor, Clinical Medicine
Adjunct Clinical Professor, Nursing
The University of Arizona
Tucson, Arizona
CE/AAPA credit available by visiting the online program:
https://bit.ly/3zMXFOp
Link to full program, including downloadable slidesets:
https://bit.ly/3iwN9Ub
In this podcast episode, Amy Goodrich, CRNP, discusses nursing perspectives on managing adverse events associated with BTK inhibitor therapy. Topics in this podcast include:
- BTK inhibitor selectivity
- BTK inhibitor adverse event profiles
- Ibrutinib intolerance
- Management of common adverse events
Presenter:
Amy Goodrich, RN, MSN, CRNP-AC
Research Associate/Nurse Practitioner
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University
Baltimore, Maryland
CE/AAPA credit available by visiting the online program:
https://bit.ly/3zMXFOp
Link to full program, including downloadable slidesets:
https://bit.ly/3iwN9Ub
In this podcast episode, Beth Faiman, PhD, MSN, APRN-BC, AOCN, provides a nursing-focused overview on available BTK inhibitors in the treatment of CLL and lymphomas. Topics in this podcast include:
- Rationale for inhibiting BTK
- MOA of BTK inhibitors
- Approved BTK inhibitors
- Recent clinical trial findings
Link to full program, including downloadable slidesets:
https://bit.ly/3iwN9Ub
Presenter:
Beth Faiman, PhD, MSN, APRN-BC, AOCN
Nurse Practitioner
Cleveland Clinic Taussig Cancer Institute
Cleveland, Ohio
In this episode, Chris Parker, MD, and Bertrand Tombal, MD, PhD, discuss the clinical implications of the latest data on radiopharmaceuticals in the treatment of patients with metastatic castration-resistant prostate cancer (CRPC). Topics include:
- Data from the PEACE-3 trial on the effect of bone-protective agents on fracture risk with enzalutamide plus radium-223
- Efficacy and toxicity of PSMA lutetium plus standard of care in the VISION trial
- Ongoing trials evaluating radionuclides in combination with other agents in metastatic CRPC
Presenters:
Chris Parker, MD
Professor of Prostate Oncology
Institute of Cancer Research
Clinical Oncologist
Department of Uro-oncology
Royal Marsden Hospital
Sutton, Surrey, United Kingdom
Bertrand Tombal, MD, PhD
Professor of Urology
Institut de Recherche Clinique (IRC)
Cliniques universitaires Saint-Luc
Chairman
Department of Surgery
Cliniques universitaires Saint-Luc
Brussels, Belgium
Link to full program, including downloadable slides:
https://bit.ly/36IEnNE
In this podcast episode, Donna Catamero, ANP-BC, OCN, CCRC, highlights practical considerations for integrating anti-BCMA–targeted therapy into clinical practice for patients with multiple myeloma after multiple relapses. Don’t forget to listen to part 1 of this series with a discussion on other novel treatment options by Tiffany Richards, PhD, ANP-BC, AOCNP, Nurse Practitioner at the University of Texas MD Anderson Cancer Center.
Presenter:
Donna Catamero, ANP-BC, OCN, CCRC
Associate Director, Myeloma Translational Research
The Mount Sinai Health System
New York, New York
CE/AAPA credit available by visiting the online program:
https://bit.ly/3zMXFOp
Link to full program, including downloadable slidesets:
https://bit.ly/3iwN9Ub
In this episode, Caron A. Jacobson, MD; Jae H. Park, MD; and Noopur Raje, MD, answer audience questions from a live CCO webinar focused on current best practices and emerging strategies in CAR T-cell therapy, with questions including:
- At what time in the treatment journey should CAR T-cell therapy be considered?
- How to select among 3 approved products for relapsed/refractory large B-cell lymphoma?
- How is CAR T-cell therapy best used for multiple myeloma?
- What qualities of bridging therapy are most preferred?
- When do patients receiving CAR T-cell therapy need COVID-19 or other vaccinations?
- How are steroids optimally used in managing CAR T-cell therapy–related toxicities?
Presenters:
Caron A. Jacobson, MD
Assistant Professor
Division of Medical Oncology
Department of Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts
Jae H. Park, MD
Associate Member
Leukemia Service and Cellular Therapeutics Center
Memorial Sloan Kettering Cancer Center
New York, New York
Noopur Raje, MD
Director
Center for Multiple Myeloma
Massachusetts General Hospital Cancer Center
Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Content based on an online CME program supported by an educational grant from Bristol-Myers Squibb.
Link to full program:
https://bit.ly/3BfbEOf
In this podcast episode, Tiffany Richards, PhD, ANP-BC, AOCNP, highlights practical considerations for integrating novel treatments— selinexor, venetoclax, and melphalan flufenamide—into clinical practice for patients with multiple myeloma after multiple relapses. Check back to hear part 2 of this series with a discussion on BCMA-targeted therapy by Donna Catamero, ANP-BC, OCN, CCRC, Associate Director of Myeloma Translational Research at the Mount Sinai Health System.
Presenter:
Tiffany Richards, PhD, ANP-BC, AOCNP
Nurse Practitioner
Department of Lymphoma/Myeloma
The University of Texas MD Anderson Cancer Center
Houston, Texas
CE/AAPA credit available by visiting the online program: https://bit.ly/3ee9Ivs
Link to full program, including downloadable slidesets: https://bit.ly/3ee9Ivs
In this podcast episode, Beth Faiman, PhD, MSN, APRN-BC, AOCN, discusses clinical considerations for diagnosis and optimal treatment selection for initial management of patients with multiple myeloma. Topics in this podcast include:
- IMWG criteria for diagnosing smoldering and active myeloma
- Risk stratification of smoldering myeloma with 2/20/20 criteria and active myeloma with R-ISS staging
- Individualizing initial treatment for ASCT-ineligible myeloma
- Selecting optimal initial treatment for ASCT-eligible myeloma
Presenter:
Beth Faiman, PhD, MSN, APRN-BC, AOCN
Nurse Practitioner
Cleveland Clinic Taussig Cancer Institute
Cleveland, Ohio
CE/AAPA credit available by visiting the online program: https://bit.ly/3ee9Ivs
Link to full program, including downloadable slidesets: https://bit.ly/3ee9Ivs
In this podcast episode,Charise Gleason, MSN, NP-BC, AOCNP, discusses clinical considerations for patients with multiple myeloma after relapse on initial therapy. Topics in this podcast include:
- Strategies for monitoring for disease progression
- Disease, therapy, and patient considerations for treatment selection at first relapse
- Nursing implications and supportive care considerations for patients receiving therapy for relapsed disease
Presenter:
Charise Gleason, MSN, NP-BC, AOCNP
Advanced Practice Provider Chief
Winship Cancer Institute
Adjunct Faculty
Nell Hodgson Woodruff School of Nursing
Emory University
Atlanta, Georgia
CE/AAPA credit available by visiting the online program: https://bit.ly/3ee9Ivs
Link to full program, including downloadable slidesets:
https://bit.ly/3ee9Ivs
In this episode, Linda R. Duska, MD, MPH; Robert L. Coleman, MD, FACOG, FACS; and Leslie Randall, MD, MAS, answer questions from an audience of healthcare professionals on topics related to the management of patients with endometrial and ovarian cancer including:
- Adding bevacizumab to chemotherapy in frontline endometrial cancer
- Lenvatinib and pembrolizumab in MSI-H/dMMR endometrial cancer
- PARP inhibitor maintenance in ovarian cancer
- Bevacizumab with or without PARP inhibitors in ovarian cancer
Presenters:
Linda R. Duska, MD, MPH
Lawrence W. Penniston MD Family Professor in Women’s Oncology Research
Division of Gynecologic Oncology
Department of Obstetrics and Gynecology
University of Virginia School of Medicine
Charlottesville, Virginia
Robert L. Coleman, MD, FACOG, FACS
Gynecologic Oncologist and Chief Scientific Officer
US Oncology, US Oncology Research
The Woodlands, Texas
Leslie Randall, MD, MAS
Diane Harris Wright Professor and Director
Division of Gynecologic Oncology
Department of Obstetrics and Gynecology
Massey Cancer Center
Virginia Commonwealth University
Richmond, Virginia
Link to full program, including downloadable slidesets, expert commentaries, and on-demand webcast:
https://bit.ly/3e6pZCM
In this episode, Scott R. Plotkin, MD, PhD, and Brian D. Weiss, MD, answer questions from a healthcare professional audience on topics related to NF1 and plexiform neurofibromas including:
- Whole exome sequencing for diagnosis
- When to treat asymptomatic tumors
- Genetic testing of family members
- Choosing a MEK inhibitor
- Supportive care for acneiform rash
- Other RAS pathway inhibitors
Presenters:
Scott R. Plotkin, MD, PhD
Executive Director
Pappas Center for Neuro-Oncology
Professor of Neurology
Harvard Medical School
Boston, Massachusetts
Brian D. Weiss, MD
Clinical Professor of Pediatrics
Cancer and Blood Diseases Institute Division of Oncology
Medical Director
Solid Tumor Program
Cincinnati Children’s Hospital Medical Center
Cincinnati, Ohio
Link to full program, including downloadable slidesets, expert commentaries, and on-demand webcast:
https://bit.ly/3AXckHQ
In this episode, Wassim Abida, MD, PhD; Joaquin Mateo, MD, PhD; and Charles J. Ryan, MD, answer questions from an audience of healthcare professionals on topics related to prostate cancer and PARP inhibition including:
- Germline and somatic mutation testing
- PARP inhibition in earlier stage disease
- PARP inhibitors plus AR-targeted therapy after progression on AR-targeted therapy
- PARP inhibition in taxane-sensitive patients
Presenters:
Wassim Abida, MD, PhD
Assistant Member
Assistant Attending Physician
Genitourinary Oncology Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York
Joaquin Mateo, MD, PhD
Group Leader
Prostate Cancer Translational Research
Vall d'Hebron Institute of Oncology
Attending Physician
Medical Oncology
Vall d'Hebron University Hospital
Barcelona, Spain
Charles J. Ryan, MD
Professor of Medicine
B.J. Kennedy Chair in Clinical Medical Oncology
Director, Division of Hematology, Oncology and Transplantation
Department of Medicine
University of Minnesota
Oncologist
Division of Hematology, Oncology and Transplantation
University of Minnesota Health Clinics and Surgery Center
Minneapolis, Minnesota
Link to full program, including downloadable slidesets, expert commentaries, and on-demand webcast:
https://bit.ly/3h1T5oR
In this episode, David Kaplan, MD, MSc, and Thomas Karasic, MD, review approved immunotherapy options for advanced HCC and answer key questions surrounding use of immune checkpoint inhibitors, with topics including:
- Current systemic therapy standards of care for patients with advanced HCC
- Use of single-agent immune checkpoint inhibitor therapy in the first-line setting
- Assessing bleeding risk
- Using immunotherapy in patients with active HBV or HCV infections
Presenters:
David Kaplan, MD, MSc
Associate Professor
Perelman School of Medicine
University of Pennsylvania
Director of Hepatology
Corporal Michael J. Crescenz VA Medical Center
Philadelphia, Pennsylvania
Thomas Karasic, MD
Assistant Professor of Medicine
Department of Hematology-Oncology
University of Pennsylvania
Philadelphia, Pennsylvania
Content based on an online CME program supported by an educational grant from Genentech, a member of the Roche Group.
Link to full program:
https://bit.ly/39V6s72
In this episode, David Scott Miller, MD, FACOG, FACS, and Melissa M. Hardesty, MD, MPH, provide expert perspectives on new data from ASCO 2021 presented for endometrial, ovarian, and cervical cancers regarding:
- Results from a pilot study of pembrolizumab monotherapy in patients with Lynch-like vs sporadic MLH1-methylated endometrial cancer
- Updated analyses from the phase I GARNET trial, including data for patients with dMMR solid tumors (endometrial cancer and nonendometrial cancer cohorts)
- Final analyses from a study of mirvetuximab soravtansine plus bevacizumab in platinum-agnostic recurrent ovarian cancer
- Results from the randomized phase III BOOST trial evaluating optimal treatment duration of bevacizumab in combination with carboplatin and paclitaxel in ovarian cancer
- Highly anticipated results from the phase III OUTBACK trial of CRT ± adjuvant CT in women with locally advanced cervical cancer
- A post hoc, pooled analysis, from phase I and phase II data of bintrafusp alfa, a first-in-class bifunctional fusion protein comprising a TGF-βRII (TGF-β trap) fused to a human monoclonal antibody targeting PD-L1
- Results from a prospective multicenter phase II trial evaluating anlotinib plus sutimlimab in recurrent/advanced cervical cancers
Presenters:
David Scott Miller, MD, FACOG, FACS
Amy and Vernon E. Faulconer Distinguished Chair in Medical Science
Director and Dallas Foundation Chair in Gynecologic Oncology
Professor of Obstetrics & Gynecology
University of Texas Southwestern Medical Center
Medical Director of Gynecologic Oncology
Chair, Cancer Committee
Parkland Health & Hospital System
Dallas, Texas
Melissa M. Hardesty, MD, MPH
Affiliate Associate Professor
OB/GYN/GYN Oncology
University of Alaska Anchorage
Gynecologic Oncologist and Managing Partner
Alaska Women’s Cancer Care
Anchorage, Alaska
Content supported by an educational grant from GlaxoSmithKline.
Link to full program, including a downloadable highlights slideset, and ClinicalThought commentaries:
https://bit.ly/3dAttwi
In this podcast episode, Suzanne Lentzsch, MD, PhD, and Saad Z. Usmani, MD, MBA, FACP, discuss how they select optimal treatment for relapsed/refractory (R/R) multiple myeloma (MM) and answer audience questions from a live webinar. Topics include:
- Selecting optimal triplet regimen after first relapse
- Sequencing treatment options after multiple relapses
- Managing patient expectations when selecting treatments
- Emerging treatment options for R/R MM
Presenters:
Suzanne Lentzsch, MD, PhD
Director, Multiple Myeloma and Amyloidosis Program
Professor of Medicine
Division of Hematology/Oncology
Columbia University Medical Center
New York, New York
Saad Z. Usmani, MD, MBA, FACP
Clinical Professor of Medicine
Department of Hematologic Oncology & Blood Disorders
Division Chief
Plasma Cell Disorders Division
Levine Cancer Institute/Atrium Health
Charlotte, North Carolina
Supported by educational grants from Amgen; Bristol-Myers Squibb; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Oncopeptides.
Link to full program, including an downloadable slidesets and an on-demand webcast:
https://bit.ly/3gjr62p
In this episode, Nathan Pennell, MD, PhD; Jamie E. Chaft, MD; and Stephen V. Liu, MD, answer questions asked by an audience of healthcare professionals during a live CCO webinar on biomarker-driven therapies for NSCLC. Topics include:
- Choosing between immune checkpoint inhibitor monotherapy and combination therapy with an immune checkpoint inhibitor plus chemotherapy for newly diagnosed NSCLC
- Incorporating newly approved immunotherapies into practice
- Evolving guidelines and recommendations for biomarker testing
- RNA- vs DNA-based next-generation sequencing
- Interpretation of NGS results
- Use of frontline TKI therapy for patients with CNS metastases
- Future role of KRAS inhibitors in the treatment of advanced NSCLC
- Improving rates of biomarker testing in lung cancer
Presenters:
Nathan Pennell, MD, PhD
Professor
Director, Cleveland Clinic Lung Cancer Medical Oncology Program
Department of Hematology and Medical Oncology
Cleveland Clinic Taussig Cancer Institute
Cleveland, Ohio
Jamie E. Chaft, MD
Associate Attending Physician
Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York
Stephen V. Liu, MD
Associate Professor of Medicine
Department of Medical Oncology
Lombardi Comprehensive Cancer Center
Georgetown University
Washington, DC
Supported by educational grants from Amgen; Lilly; Regeneron Pharmaceuticals, Inc.; and Sanofi Genzyme. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.
Link to full program, including an downloadable slidesets and an on-demand webcast:
https://bit.ly/3npjyyb
In this episode,Egbert F. Smit, MD, PhD; David Planchard, MD, PhD; and Helena A. Yu, MD, answer audience questions from a live webinar regarding clinical data on antibody–drug conjugates in NSCLC including:
- Biopsies and biomarker testing considerations
- Tumor heterogeneity and targeting of brain metastases
- Liquid biopsies
- Sequencing of ADCs following previous therapy
- Toxicity management
Presenters:
Egbert F. Smit, MD, PhD
Professor
Department of Pulmonary Diseases
Leiden University Medical Center
Leiden, Netherlands
Department of Thoracic Oncology
Netherlands Cancer Institute
Amsterdam, Netherlands
David Planchard, MD, PhD
Head of Thoracic Group
Department of Medical Oncology
Institute Gustave Roussy
Villejuif, France
Helena A. Yu, MD
Assistant Attending
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York
Content based on an online CME program supported by an educational grant from Daiichi Sankyo, Inc.
Congress to Clinic: Post-ELCC Updates on Antibody–Drug Conjugates in NSCLC - Oncology - Clinical Care Options (clinicaloptions.com)
Link to full program:
https://bit.ly/3fr2G6G
In this episode, Amit G. Singal, MD, MS, and Lipika Goyal, MD, discuss key considerations key considerations for hepatologists, oncologists, and other healthcare professionals in the contemporary use of immune checkpoint inhibitors for treating specific case patients with advanced hepatocellular carcinoma, including:
- First-line systemic treatment for a patient with Child-Pugh A liver function and no elevated bleeding risk
- First-line systemic treatment for a patient with Child-Pugh A liver function and elevated bleeding risk
- First-line systemic treatment for a patient with Child-Pugh B liver function
- Second-line systemic treatment for a patient previously receiving atezolizumab plus bevacizumab
- Management of immune-mediated hepatitis in a patient with HBV receiving an immune checkpoint inhibitor
Presenters:
Amit G. Singal, MD, MS
Chief of Hepatology
Medical Director, Liver Tumor Program
Professor, Department of Internal Medicine
UT Southwestern Medical Center
Dallas, Texas
Lipika Goyal, MD
Lead of the Liver Cancer Research Program
Assistant Professor of Medicine
Harvard Medical School
Massachusetts General Hospital Cancer Center
Boston, Massachusetts
Content based on an online CME program supported by an educational grant from Genentech, a member of the Roche Group.
Link to full program:
https://bit.ly/39V6s72
In this episode, Georgios Gakis, MD, and Mario Wolfgang Kramer, MD, PhD, discuss key data on immune checkpoint inhibitors for urothelial carcinoma informing their clinical practice in Germany. Topics include:
- Guideline changes for first-line UC based on data from JAVELIN Bladder 100 trial on avelumab maintenance after chemotherapy
- Results from IMvigor130 and KEYNOTE-361 trials on concurrent immune checkpoint inhibition plus chemotherapy
- When to consider first-line treatment with immune checkpoint inhibitor monotherapy
- Utility of PD-L1 as biomarker for immune checkpoint inhibitor–based therapy
Presenters:
Georgios Gakis, MD
Professor of Urology, Staff Urologist
University Hospital of Würzburg
Würzburg, Germany
Mario Wolfgang Kramer, MD, PhD
Consultant Urologist
Vice Director, Urology
University Hospital Schlewig-Holstein Campus Lübeck
Lübeck, Germany
Content based on an online IME program supported by an educational grant from Pfizer and EMD Serono, Inc.
Link to full program, including associated downloadable slidesets and on-demand webcast:
https://bit.ly/3kJC5SL
In this episode, Ignacio Durán, MD, PhD, and Alison Birtle, MD, FRCP, FRCR, discuss toxicities associated with FGFR inhibitors used in the treatment of urothelial cancer and other malignancies
Presenters:
Ignacio Durán, MD, PhD
Associate Professor
GU Oncology Program Leader
Department of Medical Oncology
Hospital Universitario Marques de Valdecilla-Idival
Santander, Spain
Alison Birtle, MD, FRCP, FRCR
Honorary Senior Lecturer
Faculty of Health and Medicine
University of Manchester
Manchester, United Kingdom
Consultant Oncologist
Rosemere Cancer Centre
Lancashire Teaching Hospitals
Preston, Lancashire, United Kingdom
Content based on an online IME program supported by educational grants from Janssen Pharmaceutica NV.
Link to full program:
http://bit.ly/3cf28jH
In this episode, Joleen Hubbard, MD, and John L. Marshall, MD, discuss use of the later-line treatment options regorafenib and TAS-102 for patients with mCRC, with topics including:
- Key data supporting the clinical use of these agents
- Optimal sequencing and timing of use
- Dosing considerations
- Key adverse events
Presenters:
Joleen Hubbard, MD
Associate Professor
Gastrointestinal Oncologist
Medical Oncology
Mayo Clinic
Rochester, Minnesota
John L. Marshall, MD
Chief, Division of Hematology/Oncology
Department of Medicine
Georgetown University Hospital
Washington, DC
Content based on an online CME program supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.
Link to full program: BITLY NEEDED
In this episode, Shaji K. Kumar, MD; Thomas G. Martin, MD; Philippe Moreau, MD; S. Vincent Rajkumar, MD, and Jesús F. San-Miguel, MD, PhD, answer audience questions from a recent Clinical Care Options live webinar on managing multiple myeloma. Topics include:
- Approaches for managing smoldering multiple myeloma
- Insights on new strategies for managing newly diagnosed multiple myeloma
- Incorporating newly approved agents in the frontline and early relapse setting
- Choosing and sequencing BCMA-targeted therapies
- Managing patients with refractory multiple myeloma
Presenters:
Shaji K. Kumar, MD
Mark and Judy Mullins Professor of Hematological Malignancies
Chair, Myeloma Amyloidosis Dysproteinemia Group
Consultant, Division of Hematology
Mayo Clinic
Rochester, Minnesota
Thomas G. Martin, MD
Clinical Professor of Medicine
Associate Director, Myeloma Program
University of California, San Francisco Medical Center
San Francisco, California
Philippe Moreau, MD
Professor of Clinical Hematology
Head, Hematology Department
University Hospital Hôtel-Dieu
Nantes, France
S. Vincent Rajkumar, MD
Edward W. and Betty Knight Scripps Professor of Medicine
Mayo Clinic
Rochester, Minnesota
Jesús F. San-Miguel, MD, PhD
Director of Clinical and Translational Medicine
Universidad de Navarra
Pamplona, Spain
Supported by educational grants from Amgen, Bristol-Myers Squibb, GlaxoSmithKline, Karyopharm and Oncopeptides.
Link to full program, including downloadable slidesets and expert commentaries:
https://bit.ly/39MWNid
In this episode, Karim Fizazi, MD, PhD, and Joaquin Mateo, MD, PhD, consider the potential implications of ongoing and planned clinical trials using PARP inhibitors in combination with other therapies to treat men with prostate cancer including:
- PARP inhibitors combined with androgen receptors
- Phase III trials of PARP inhibitors with androgen receptor–directed therapy
- PARP inhibitors combined with immunotherapy
- PARP inhibitors and DNA damaging agents
Presenters:
Karim Fizazi, MD, PhD
Full Professor
Cancer Medicine
Institut Gustave Roussey
Villejuif, France
Joaquin Mateo, MD, PhD
Attending Physician
Medical Oncology
Vall d’Hebron University Hospital,
Barcelona, Spain
Content is part of an online program supported by an educational grant from Pfizer Inc.
Link to full program, including associated downloadable Podcast Pearls slidesets, expert analysis, and expert commentary:
https://bit.ly/3spLzqa
In this episode, Karim Fizazi, MD, PhD, and Joaquin Mateo, MD, PhD, discuss the underlying rationale for using PARP inhibitors in combination with other therapies to treat men with prostate cancer including:
- Possible synergy between PARP inhibitors and androgen receptor–directed therapy
- Rationale for PARP inhibitors and immunotherapy combinations
- Benefits and challenges of combining DNA damaging agents and PARP inhibitor
Presenters:
Karim Fizazi, MD, PhD
Full Professor
Cancer Medicine
Institut Gustave Roussey
Villejuif, France
Joaquin Mateo, MD, PhD
Attending Physician
Medical Oncology
Vall d’Hebron University Hospital,
Barcelona, Spain
Content is part of an online program supported by an educational grant from Pfizer Inc.
Link to full program, including associated downloadable Podcast Pearls slidesets, expert analysis, and expert commentary:
https://bit.ly/3spLzqa
In this episode, Jubilee Brown, MD, and Ursula Matulonis, MD, provide expert perspectives on new data from SGO 2021 presented for endometrial and ovarian cancer including:
- Results from KEYNOTE-775, a phase III trial of lenvatinib plus pembrolizumab in advanced endometrial cancer
- Results from the confirmatory phase III ARIEL4 evaluating rucaparib vs chemotherapy in BRCA-mutated relapsed ovarian cancer
- 5-year follow-up from SOLO-1 trial of olaparib vs placebo in BRCA-mutated, newly diagnosed ovarian cancer
- Long-term follow-up results from the phase III ENGOT-OV16/NOVA trial of niraparib in patients with recurrent ovarian cancer
- OPAL: a phase II study evaluating dostarlimab, bevacizumab, and niraparib in platinum-resistant ovarian cancer
Presenters:
Jubilee Brown, MD
Professor and Director of Gynecologic Oncology
Levine Cancer Institute
Atrium Health
Charlotte, North Carolina
Ursula Matulonis, MD
Chief, Division of Gynecologic Oncology
Brock Wilson Family Chair
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Content supported by an educational grant from GlaxoSmithKline.
Link to full program, including a downloadable highlights slideset, and ClinicalThought commentaries:
https://bit.ly/3dAttwi
In this episode, Charles J. Ryan, MD, and Neal D. Shore, MD, FACS, answer questions from a healthcare professional audience on topics related to prostate cancer and PARP inhibition including:
- Germline and somatic mutation testing
- Managing adverse events with PARP inhibitors
- Resistance to PARP inhibitors
- Implications of monoallelic vs biallelic BRCA mutations
- ATM mutations and PARP inhibitor sensitivity
Presenters:
Charles J. Ryan, MD
Professor of Medicine
B.J. Kennedy Chair in Clinical Medical Oncology
Director, Division of Hematology, Oncology and Transplantation
Department of Medicine
University of Minnesota
Oncologist
Division of Hematology, Oncology and Transplantation
University of Minnesota Health Clinics and Surgery Center
Minneapolis, Minnesota
Neal D. Shore, MD, FACS
Director
Carolina Urologic Research Center
Atlantic Urology Clinics
Myrtle Beach, South Carolina
Link to full program, including downloadable slidesets, expert commentaries, and on-demand webcast:
https://bit.ly/2P31ZqF
In this episode, Jeremy S. Abramson, MD, MMSc, discusses highlights of the key data from ASH 2020 on the treatment of patients with lymphomas/CLL, with topics including:
- Approved and Investigational Targeted Therapeutics for CLL
- Investigational CAR T-Cell Therapy for Indolent Lymphomas, CLL, and Mantle Cell Lymphoma
- Bispecific Antibodies and Other Investigational Targeted Agents for Lymphomas
- Treatment for Older Patients With Hodgkin Lymphoma
Presenters:
Jeremy S. Abramson, MD, MMSc
Associate Professor
Department of Medicine
Harvard Medical School
Director, Center for Lymphoma
Massachusetts General Hospital
Boston, Massachusetts
Content based on an online CME program supported by educational grants from Amgen; AstraZeneca; Bristol-Myers Squibb; Epizyme, Inc.; GlaxoSmithKline; Incyte Corporation; Janssen Biotech; Karyopharm Therapeutics Inc.; Novartis; PharmaEssentia Corp.; Seattle Genetics; and Takeda Oncology.
Link to full program:
https://bit.ly/3tyQ9nG
In this episode, Enriqueta Felip, MD, PhD, and Matthew Gubens, MD, MS, discuss evolving practice standards for EGFR-mutated non-small-cell lung cancer with topics including:
- Biomarker testing and strategies
- Optimal first-line therapy in patients with NSCLC
- Management of patients with CNS disease
- Selecting therapy for patients with noncanonical mutations
- Management strategies after progression on first-line EGFR TKI therapy
- Selecting therapy for patients with early stage disease
Presenters:
Enriqueta Felip, MD, PhD
Head, Thoracic Oncology Unit
Oncology Service
Vall d'Hebron University Hospital
Barcelona, Spain
Matthew Gubens, MD, MS
Associate Professor
Thoracic Oncology
University of California, San Francisco
San Francisco, California
Content based on an online CME program supported by an educational grant from AstraZeneca.
Link to full program, including associated downloadable slidesets:
https://bit.ly/2PpFFHM
In this episode, Ignacio Durán, MD, PhD, and Alison Birtle, MD, FRCP, FRCR, interpret the latest clinical data on targeting FGFR in urothelial cancer
Presenters:
Ignacio Durán, MD, PhD
Associate Professor
GU Oncology Program Leader
Department of Medical Oncology
Hospital Universitario Marques de Valdecilla-Idival
Santander, Spain
Alison Birtle, MD, FRCP, FRCR
Honorary Senior Lecturer
Faculty of Health and Medicine
University of Manchester
Manchester, United Kingdom
Consultant Oncologist
Rosemere Cancer Centre
Lancashire Teaching Hospitals
Preston, Lancashire, United Kingdom
Content based on an online IME program supported by educational grants from Janssen Pharmaceutica NV.
Link to full program:
http://bit.ly/3cf28jH
In this episode, Michael J. Pishvaian, MD, PhD, and Rachna Shroff, MD, answer audience questions from a live CCO webinar focused on current best practices and emerging strategies in pancreatic cancer treatment, with questions including:
- What is your preferred regimen for neoadjuvant therapy in patients with resectable disease?
- How do you sequence therapy for patients with metastatic pancreatic cancer?
- How can you manage a patient who develops significant diarrhea with FOLFIRINOX?
- Are cisplatin and oxaliplatin equally efficacious for patients with BRCA-mutant disease?
- How should maintenance olaparib be used?
Presenters:
Michael J. Pishvaian, MD, PhD
Associate Professor of Oncology
Director, Gastrointestinal, Developmental Therapeutics, and Clinical Research Programs
NCR Kimmel Cancer Center at Sibley Memorial Hospital
John Hopkins University School of Medicine
Washington, DC
Rachna Shroff, MD
Associate Professor of Medicine
Chief, Section of GI Medical Oncology
Director, UACC Clinical Trials Office
The University of Arizona Cancer Center
Tucson, Arizona
Content based on an online CME program supported by educational grants from Bristol-Myers Squibb and Ipsen Group.
Link to full program:
http://bit.ly/314BALT
In this episode, Frederick L. Locke, MD, answers audience questions from a live CCO Webinar focused on emerging strategies in the use of CAR T-cell therapy for patients with lymphomas, with questions including:
- How does the recent approval of lisocabtagene maraleucel and the expanded indication for axicabtagene ciloleucel add to the treatment landscape for DLBCL?
- Do you see CAR T-cell therapy ever being used in the first-line setting for DLBCL?
- How should physicians select patients for CAR T-cell therapy vs ASCT in DLBCL?
- How should physicians sequence CAR T-cell therapy vs BTK inhibitors in MCL?
Presenter:
Frederick L. Locke, MD
Co-Leader
Moffitt Immuno-Oncology Program
Vice Chair and Associate Member
Department of Blood and Marrow Transplant and Cellular Immunotherapy
Research Director and Medical Director
Immune Cell Therapy Program
Moffitt Cancer Center
Tampa, Florida
Content based on an online CME program supported by educational grants from Bristol-Myers Squibb and Kite Pharma.
Link to full program:
https://bit.ly/3rDeFCV
In this episode, D. Ross Camidge, MD, PhD, and Joel W. Neal, MD, PhD, answer questions on investigational antibody-drug conjugates for advanced NSCLC
Presenters:
Ross Camidge, MD, PhD
Professor of Medicine/Oncology
University of Colorado Cancer Center
Aurora, Colorado
Joel W. Neal, MD, PhD
Associate Professor of Medicine
Division of Oncology
Department of Medicine
Stanford University
Attending Physician
Stanford Cancer Institute
Palo Alto, California
Content based on an online IME program supported by educational grants from Daiichi Sankyo, Inc .
Link to full program:
http://bit.ly/3twpIyl
In this episode, Noopur Raje, MD, answers audience questions from a live CCO Webinar focused on emerging strategies in the use of CAR T-cell therapy for patients with multiple myeloma and key toxicities associated with CAR T-cell therapy, with questions including:
- Now that belantamab mafodotin is approved for relapsed/refractory multiple myeloma, what are your thoughts on how BCMA-directed CAR T-cell therapy might be sequenced? Is there reason to think CAR T-cell therapy would still be efficacious following belantamab mafodotin?
- Could BCMA-directed CAR T-cell therapy replace transplant in the first-line setting for multiple myeloma?
- What are key considerations surrounding the use of tocilizumab for managing cytokine-release syndrome?
- What are some of the longer-term toxicities associated with CAR T-cell therapy? When do they emerge and how long do they typically last?
Presenter:
Noopur Raje, MD
Professor of Medicine
Harvard Medical School
Director
Center for Multiple Myeloma
Massachusetts General Hospital Cancer Center
Boston, Massachusetts
Content based on an online CME program supported by educational grants from Bristol-Myers Squibb and Kite Pharma.
Link to full program:
http://bit.ly/3rDeFCV
In this episode, Dr. Shaji Kumar from the Mayo Clinic and Dr. Sagar Lonial from Emory University discuss highlights of the key data from ASH 2020 on the treatment of patients with multiple myeloma. Topics include:
- Newly diagnosed multiple myeloma
- Relapsed/refractory multiple myeloma
- Anti-BCMA therapy: CAR T-cells
- Anti-BCMA therapy: bispecific antibodies
- Anti-BCMA therapy: antibody–drug conjugates
- Novel targeted agents for relapsed/refractory multiple myeloma
Presenters:
Shaji K. Kumar, MD
Mark and Judy Mullins Professor of Hematological Malignancies
Chair, Myeloma Amyloidosis Dysproteinemia Group
Consultant, Division of Hematology
Mayo Clinic
Rochester, Minnesota
Sagar Lonial, MD
Professor and Chair
Department of Hematology and Medical Oncology
Chief Medical Officer
Winship Cancer Institute of Emory University
Atlanta, Georgia
Link to the CCO website:
http://bit.ly/30EqUn0
In this episode, Jorge Cortes, MD, and Eunice S. Wang, MD, discuss the clinical implications of 3 key studies in acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) presented at the virtual ASH 2020 annual conference. Topics include:
- The macrophage immune checkpoint inhibitor magrolimab in AML
- The STAMP inhibitor asciminib in CML (the ASCEMBL trial)
- Optimal dosing for the TKI ponatinib in CML
Presenters:
Jorge Cortes, MD
Director, Georgia Cancer Center
Eminent Scholar, Georgia Research Academy
Augusta, Georgia
Eunice S. Wang, MD
Professor, Oncology
Chief, Leukemia Service
Department of Medicine
Roswell Park Comprehensive Cancer Center
Buffalo, New York
Content supported by educational grants from Amgen; AstraZeneca; Bristol-Myers Squibb; Epizyme, Inc; GlaxoSmithKline; Incyte Corporation; Janssen Biotech; Karyopharm Therapeutics Inc; Novartis; PharmaEssentia Corp; Seattle Genetics; and Takeda Oncology.
Link to full program and Capsule Summary downloadable slidesets:
https://bit.ly/3tyQ9nG
In this episode, Jamie E. Chaft, MD, provides her expert perspective on new data from WCLC 2020 in early-stage NSCLC, with topics including:
- Updated results from ADAURA on HRQoL and DFS outcomes with or without postoperative chemotherapy after adjuvant osimertinib
- An analysis of the ongoing ITACA study of personalizing chemotherapy based on biomarkers of drug resistance
- FDG PET/CT adaptive radiotherapy in RTOG 1106
- The TALENT study in Taiwan screening nonsmokers for lung cancer
Presenter:
Jamie E. Chaft, MD
Associate Attending Physician
Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York
Content supported by educational grants from Amgen; Bristol-Myers Squibb; Ipsen Biopharmaceuticals; Janssen Pharmaceutica NV; Jazz Pharmaceuticals; Regeneron Pharmaceuticals, Inc. & Sanofi Genzyme; and Takeda Oncology.
Link to full program, including a downloadable highlights slideset, and ClinicalThought commentaries:
http://bit.ly/2NzE6X6
In this episode, José Ignacio Nolazco, MD, and Alejandro Nolazco, MD, discuss in Spanish the latest immuno-oncology developments in the treatment of urothelial cancer from an Argentinian perspective.
Presenters:
José Ignacio Nolazco, MD
Urology Fellow
Hospital Universitario Austral
Buenos Aires, Argentina
Alejandro Nolazco, MD
Associate Professor
Department of Urology
Universidad Austral and Universidad Católica Argentina
Buenos Aires, Argentina
Content based on an online IME program supported by educational grants from EMD Serono, Inc and Pfizer.
Link to full program, including associated downloadable slidesets and on-demand Webcast:
https://bit.ly/3kJC5SL
In this episode, Hanny Al-Samkari, MD; Sujit Sheth, MD; and Mark A. Schroeder, MD, provide their clinical perspectives on new data from ASH 2020 on nonmalignant hematologic disorders, with topics including:
- Use of mycophenolate mofetil plus corticosteroids vs standard corticosteroid treatment in patients with ITP from the phase III FLIGHT study
- Analysis of an ongoing phase I/II trial of rilzabrutinib reporting safety and efficacy in the long-term extension for adult patients with relapsed/refractory ITP
- New data from the phase III HOPE-B study of etranacogene dezaparvovec gene therapy, using an AAV5-vector to deliver the Padua variant of the factor IX gene in patients with hemophilia B
- An update from the phase I/II CLIMB THAL-111/SCD-121 studies reporting safety and efficacy on the first 10 patients receiving CTX001 with at least 3 months of follow-up
- Primary analysis from the phase III REACH3 trial evaluating ruxolitinib, an oral JAK1/2 inhibitor, in combination with steroids and calcineurin inhibitors, as a treatment for steroid-refractory or steroid-dependent chronic GVHD
- Top-line results from the phase II ROCKstar study of belumosudil, a ROCK2 kinase inhibitor, in patients with heavily pretreated chronic GVHD
- Phase I data from the GRAVITAS-119 study of JAK1 inhibitor itacitinib plus calcineurin inhibitors as prophylaxis treatment for acute GVHD
Presenters:
Hanny Al-Samkari, MD
Instructor
Department of Medicine
Harvard Medical School
Attending Hematologist and Clinical Investigator
Division of Hematology Oncology
Massachusetts General Hospital
Boston, Massachusetts
Sujit Sheth, MD
Professor
Department of Pediatrics
Weill Cornell Medicine
New York, New York
Mark A. Schroeder, MD
Associate Professor of Medicine
Division of Oncology
Department of Medicine
Washington University School of Medicine in St Louis
St Louis, Missouri
Content supported by educational grants from Amgen; AstraZeneca; Bristol-Myers Squibb; Epizyme, Inc.; GlaxoSmithKline; Incyte Corporation; Janssen Biotech; Karyopharm Therapeutics Inc.; Novartis; PharmaEssentia Corp.; Seattle Genetics; and Takeda Oncology.
Link to full program, including downloadable slidesets, and on-demand Webcasts:
http://bit.ly/3tyQ9nG
In this episode, Amy E. DeZern, MD, MHS, and Srdan Verstovsek, MD, provide medical oncology and hematology perspectives on new data from ASH 2020 in MDS and MPNs, with topics including:
- 3-year OS results with RIC allogeneic transplantation in patients with higher-risk MDS in the BMT CTN 1102 study
- A post hoc analysis of phase II data on the addition of pevonedistat to azacitidine in higher-risk MDS patients
- 5-year results of ropeginterferon α-2b in polycythemia vera from the CONTINUATION-PV study
- Phase II results of luspatercept for anemia in patients with myelofibrosis who are transfusion dependent
- Analysis of clinical benefit in patients with myelofibrosis and OS benefit from imetelstat.
Presenters:
Amy E. DeZern, MD, MHS
Associate Professor
Oncology and Medicine
The Johns Hopkins University School of Medicine
Baltimore, Maryland
Srdan Verstovsek, MD, PhD
Professor
Division of Cancer Medicine
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas
Content supported by educational grants from Amgen; AstraZeneca; Bristol-Myers Squibb; Epizyme, Inc; GlaxoSmithKline; Incyte Corporation; Janssen Biotech; Karyopharm Therapeutics Inc; Novartis; PharmaEssentia Corp; Seattle Genetics; and Takeda Oncology.
Link to full program and Capsule Summary downloadable slidesets:
http://bit.ly/3tyQ9nG
In this episode, Guiseppe Procopio, MD, and Cora N. Sternberg, MD, FACP, discuss in Italian the latest immuno-oncology developments in the treatment of urothelial cancer.
Presenters:
Guiseppe Procopio, MD
Head of the Medical Oncology Genitourinary, Istituto Nazionale Tumori
Medical Oncology
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, Italy
Cora N. Sternberg, MD, FACP
Professor of Medicine
Department of Hematology/Oncology
Weill Cornell Medicine
New York, New York, USA
Content based on an online IME program supported by educational grants from EMD Serono, Inc and Pfizer.
Link to full program, including associated downloadable slidesets and on-demand Webcast: http://bit.ly/3kJC5SL
In this episode, Michael Callaghan, MD; Miguel A. Escobar, MD; and Rebecca Kruse-Jarres, MD, MPH, answer questions from a clinician audience on topics related to hemophilia management including:
- Maintaining long-term musculoskeletal health
- Identifying patients most likely to benefit from pharmacokinetics-guided prophylaxis
- Managing combination therapies in older patients with comorbidities
- Youngest age at which patients can be considered for emicizumab
- Development of resistance to emicizumab
- Switching recombinant factor therapies
- Using bypassing agents with emicizumab for breakthrough bleeds in patients with inhibitors
- Potential clinical role of extending FVIII half-life with BIVV001
- Considerations when dosing emicizumab monthly
Presenters:
Michael Callaghan, MD
Associate Professor
Department of Hematology
Wayne State University
Hematologist
Division of Hematology/Oncology
Children’s Hospital of Michigan
Detroit, Michigan
Miguel A. Escobar, MD
Professor of Medicine and Pediatrics
Department of Hematology
University of Texas Health Science Center
McGovern Medical School
Director
Gulf States Hemophilia and Thrombophilia Center
Houston, Texas
Rebecca Kruse-Jarres, MD, MPH
Professor
Department of Medicine
University of Washington
Executive/Medical Director
Washington Institute for Coagulation
Seattle, Washington
Content supported by educational grants from Genentech, a member of the Roche Group; Sanofi Genzyme Corporation; and Takeda Pharmaceutical Company Ltd.
Link to full program, including downloadable slidesets, expert commentaries, and on-demand Webcast: http://bit.ly/2MW5uhi
| In this episode, Petros Grivas, MD, PhD, and Jonathan E. Rosenberg, MD, discuss key data on immune checkpoint inhibitors for urothelial carcinoma informing their clinical practice in the United States. Topics include:* Guideline changes for first-line UC based on data from JAVELIN Bladder 100 trial on avelumab maintenance after chemotherapy * Results from IMvigor130 and KEYNOTE-361 trials on concurrent immune checkpoint inhibition plus chemotherapy * When to consider first-line treatment with immune checkpoint inhibitor monotherapy * Utility of PD-L1 as biomarker for immune checkpoint inhibitor–based therapy * Monitoring for and managing immune-related adverse events during the COVID-19 pandemic
Presenters:Petros Grivas, MD, PhDAssociate ProfessorClinical Director, Genitourinary Cancers ProgramDivision of Medical OncologyDepartment of MedicineUniversity of WashingtonSeattle Cancer Care AllianceSeattle, Washington, USAJonathan E. Rosenberg MDAttending PhysicianChief, Genitourinary Oncology ServiceDivision of Solid Tumor OncologyDepartment of MedicineMemorial Sloan Kettering Cancer CenterNew York, New York, USAContent based on an online IME program supported by educational grants from Pfizer and EMD Serono, Inc.Link to full program, including associated downloadable slidesets and on-demand Webcast:http://bit.ly/3kJC5SL |
Link to CME: Claim Credit
In this episode, Amit G. Singal, MD, MS, and Lipika Goyal, MD, discuss key considerations in the contemporary use of immune checkpoint inhibitors for treating patients with advanced hepatocellular carcinoma, with topics including:
- Optimal use of the newly approved immune checkpoint inhibitor/VEGF inhibitor combination of atezolizumab plus bevacizumab
- Use of nivolumab ± ipilimumab and pembrolizumab
- Emerging immunotherapy combinations currently being investigated in clinical trials
- Management of key adverse events with immune checkpoint inhibitors
Presenters:
Amit G. Singal, MD, MS
Chief of Hepatology
Medical Director, Liver Tumor Program
Professor, Department of Internal Medicine
UT Southwestern Medical Center
Dallas, Texas
Lipika Goyal, MD
Lead of the Liver Cancer Research Program
Assistant Professor of Medicine
Harvard Medical School
Massachusetts General Hospital Cancer Center
Boston, Massachusetts
Content based on an online CME program supported by an educational grant from Genentech, a member of the Roche Group.
Link to full program:
http://bit.ly/39V6s72
In this episode, Félix Guerrero Ramos, MD, PhD, FEBU, and Óscar Rodríguez-Faba, MD, discuss in Spanish the latest immuno-oncology developments in the treatment of urothelial cancer.
Presenters:
Félix Guerrero Ramos, MD, PhD, FEBU
Teaching Collaborator
Department of Surgery
Medicine School
Universidad Complutense de Madrid
Attending Urologist
Department of Urology
UroOncology Unit
Madrid, Spain
Óscar Rodríguez-Faba, MD
Urologist
Uro-Oncology
Fundació Puigvert
Barcelona, Catalonia, Spain
Content based on an online IME program supported by educational grants from EMD Serono, Inc and Pfizer.
Link to full program, including associated downloadable slidesets and on-demand Webcast:
http://bit.ly/3kJC5SL
In this episode, Nathan Pennell, MD, PhD, and Laura J. Tafe, MD, provide medical oncology and pathology perspectives, respectively, when answering questions from a clinician audience on topics including:
- Next steps in patient care after identifying a biomarker: selecting treatment, getting insurance approval, arranging for financial assistance
- Performing biomarker testing on cytology vs surgical or anatomic pathology specimens
- Factors affecting turnaround time when testing liquid biopsy vs tissue specimens
- Choice of a targeted agent vs chemotherapy plus immunotherapy for first-line treatment of patients with RET fusions, BRAF mutations, or MET exon 14 skipping
- Concordance between IHC and FISH or NGS for ALK rearrangements
- Use of fluid cytology specimens when testing for fusions in RET or NTRK and MET amplification
- Cost considerations with performing multiple single-gene assays vs upfront NGS
- Testing for driver mutations in early-stage NSCLC
- Developing institutional workflows to enable pathologists to order reflex molecular testing panels
Presenters:
Nathan Pennell, MD, PhD
Professor
Director, Cleveland Clinic Lung Cancer Medical Oncology Program
Department of Hematology and Medical Oncology
Cleveland Clinic Taussig Cancer Institute
Cleveland, Ohio
Laura J. Tafe, MD
Associate Professor of Pathology and Laboratory Medicine
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire
The Geisel School of Medicine at Dartmouth
Hanover, New Hampshire
Content supported by an educational grant from Lilly.
Link to full program, including an associated Podcast Pearls PDF, downloadable slidesets, and on-demand Webcasts:
http://bit.ly/3a3e1Xs
In this episode,William G. Wierda, MD, PhD, Jeremy S. Abramson, MD, MMSc, and Brian Hill, MD, PhD, answer questions focused on personalizing therapy for patients with CLL considering patient characteristics and currently available clinical evidence.
Presenters:
William G. Wierda, MD, PhD, Program Director
Professor of Medicine
Chief, Section of CLL
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas
Jeremy S. Abramson, MD, MMSc
Associate Professor
Department of Medicine
Harvard Medical School
Director, Center for Lymphoma
Massachusetts General Hospital
Boston, Massachusetts
Brian Hill, MD, PhD
Director, Lymphoid Malignancies Program
Taussig Cancer Institute
Cleveland Clinic
Cleveland, Ohio
Content based on an online CME program supported by educational grants from AstraZeneca; Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Lilly.
Link to full program, including associated downloadable slidesets:
http://bit.ly/3mLjeIb
In this episode, Helena A. Yu, MD, and Maria E. Arcila, MD, provide medical oncology and pathology perspectives, respectively, on new data from ESMO 2020 informing precision medicine in NSCLC, with topics including:
- Updated efficacy data from the phase III ADAURA study of adjuvant osimertinib for resected EGFR-mutated NSCLC with a focus on CNS disease recurrence
- Biomarker testing in early-stage lung cancer
- New data for sotorasib, a small molecule inhibitor of KRAS G12C, in heavily pretreated NSCLC
- Interim results from the phase I portion of the CHRYSALIS trial evaluating amivantamab, a bispecific antibody that targets EGFR and MET, in combination with lazertinib, a third-generation EGFR TKI, for the treatment of EGFR-mutated NSCLC
- Phase I data on the HER3-directed antibody–drug conjugate patritumab deruxtecan for NSCLC with progression on an EGFR TKI
Presenters:
Helena A. Yu, MD
Assistant Attending
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York
Maria E. Arcila, MD
Pathologist
Director, Diagnostic Molecular Pathology Laboratory
Memorial Sloan Kettering Cancer Center
New York, New York
Content supported by an educational grant from Lilly.
Link to full program, including an associated Podcast Pearls PDF, downloadable slidesets, and on-demand Webcasts:
http://bit.ly/3a3e1Xs
Link to CME: Claim Credit
In this episode, Amit G. Singal, MD, MS, and Lipika Goyal, MD, answer clinician questions on current best practices and emerging applications with immune checkpoint inhibitors in patients with advanced hepatocellular carcinoma, with topics including:
- Optimal use of the newly approved immune checkpoint inhibitor/VEGF inhibitor combination of atezolizumab plus bevacizumab
- Use of immune checkpoint inhibitor therapy in patients with Child-Pugh B liver function
- Use of biomarkers to inform treatment for patients with advanced HCC
Presenters:
Amit G. Singal, MD, MS
Chief of Hepatology
Medical Director, Liver Tumor Program
Professor, Department of Internal Medicine
UT Southwestern Medical Center
Dallas, Texas
Lipika Goyal, MD
Lead of the Liver Cancer Research Program
Assistant Professor of Medicine
Harvard Medical School
Massachusetts General Hospital Cancer Center
Boston, Massachusetts
Content based on an online CME program supported by an educational grant from Genentech, a member of the Roche Group.
Link to full program:
https://bit.ly/39V6s72
In this episode, Thomas Powles, MBBS, MRCP, MD, and Michiel van der Heijden, MD, PhD, discuss key data on immune checkpoint inhibitors for urothelial carcinoma informing their clinical practice in the United Kingdom and the Netherlands. Topics include:
- Data from registrational trials in the European Union for pembrolizumab and atezolizumab in the first-line/second-line settings
- Utility of PD-L1 and tumor mutational burden as biomarkers for immune checkpoint inhibitor–based therapy
- Results from the JAVELIN trial on avelumab maintenance after chemotherapy
- When to consider first-line treatment with immune checkpoint inhibitor–based therapy vs chemotherapy
Presenters:
Thomas Powles, MBBS, MRCP, MD
Deputy Centre Lead
Centre for Experimental Cancer Medicine
Barts Cancer Institute
Queen Mary University of London
Professor of Urology Cancer
Director of Barts Cancer Centre
Department of Cancer
St Bartholomew's Hospital (Barts Health NHS Trust)
London, United Kingdom
Michiel van der Heijden, MD, PhD
Medical Oncologist and Research Group Leader
Department of Medical Oncology and Molecular Carcinogenesis
Stichting Het Nederlands Kanker Instituut – Antoni van Leeuwenhoek Ziekenhuis
Medical Oncologist
Antoni van Leeuwenhoek Ziekenhuis/Netherlands Cancer Institute
Amsterdam, the Netherlands
Content based on an online IME program supported by educational grants from Pfizer and EMD Serono, Inc.
Link to full program, including associated downloadable slidesets and on-demand Webcast:
https://bit.ly/3kJC5SL
In this episode, Alain Ravaud, MD, PhD, and Marine Gross-Goupil, MD, PhD, discuss in French the latest immuno-oncology developments in the treatment of urothelial cancer.
Presenters:
Alain Ravaud, MD, PhD
Professor of Medical Oncology
Head of Department of Medical Oncology
Bordeaux University Hospital
Bordeaux, France
Marine Gross-Goupil, MD, PhD
Medical Oncologist
Saint-André Hospital
Bordeaux University Hospital
Bordeaux, France
Content based on an online IME program supported by educational grants from EMD Serono, Inc and Pfizer.
Link to full program:
https://bit.ly/3kJC5SL
In this episode, Mansoor Raza Mirza, MD, and Ana Oaknin, MD, PhD, discuss the implications of recent advances in the use of molecular testing and classification to guide the use of immunotherapy for the treatment of patients with endometrial cancer.
Presenters:
Ana Oaknin, MD, PhD
Head of Gynecologic Tumors Unit
Medical Oncology Department
Vall d´Hebron University Hospital
Barcelona, Spain
Mansoor Raza Mirza, MD
Chief Oncologist
Department of Oncology,
Rigshopitalet – Copenhagen University Hospital
Copenhagen, Denmark
Content based on an online CME program supported by an educational grant from GlaxoSmithKline.
Link to full program:
https://bit.ly/3kpJeaG
| In this episode, Mansoor Raza Mirza, MD, and Ana Oaknin, MD, PhD, discuss the implications of recent advances in the use of immunotherapy for the treatment of patients with endometrial cancer.Presenters:Ana Oaknin, MD, PhDHead of Gynecologic Tumors UnitMedical Oncology DepartmentVall d´Hebron University HospitalBarcelona, Spain Mansoor Raza Mirza, MDChief OncologistDepartment of Oncology,Rigshopitalet – Copenhagen University HospitalCopenhagen, Denmark Content based on an online CME program supported by an educational grant from GlaxoSmithKline. |
Link to full program:
https://bit.ly/3kpJeaG
In this episode, David Marks, MD, PhD, and Stéphane de Botton, MD, answer questions from clinicians on management pearls for patients with acute leukemias. Topics include:
- MRD in the management of ALL
- Therapy choice for older patients with AML
- Optimal use of inotuzumab ozogamicin and blinatumomab for ALL
- Use of CAR T-cell therapy for acute leukemias
Content based on an online CME program supported by an educational grant from Pfizer Inc.
Link to full program:
https://bit.ly/3jiCBaD
In this episode, Isabelle Ray Coquard, MD, PhD and Bradley J. Monk, MD, FACS, FACOG, discuss current first-line maintenance therapy options for patients with advanced ovarian cancer.
Presenters:
Prof Isabelle Ray Coquard
Professor of Department of Medical Oncology
Clinical Science Institute of the Léon Bérard Center
Lyon, France
Bradley J. Monk MD, FACS, FACOG
Professor
Division of Gynecologic Oncology
Arizona Oncology (US Oncology Network)
University of Arizona College of Medicine--Phoenix
Creighton University School of Medicine at St Joseph's Hospital
Phoenix, Arizona
Content based on an online CME program supported by an educational grant from GlaxoSmithKline.
Link to full program:
https://bit.ly/2Scnp2N
Listen to Prof Nicoletta Colombo and Bradley J. Monk, MD, FACS, FACOG, discuss current best practices for biomarker testing for your patients with advanced ovarian cancer.
In this episode, Prof Nicoletta Colombo and Bradley J. Monk, MD, FACS, FACOG, discuss current best practices for biomarker testing in the management of patients with advanced ovarian cancer. Topics include:
- Subtypes of ovarian cancer
- BRCA mutation testing
- Homologous recombination deficiency testing
Presenters:
Professor Nicoletta Colombo
Professor of Obstetrics and Gynecology
University of Milan-Bicocca
European Institute of Oncology
Milan, Italy
Bradley J. Monk MD, FACS, FACOG
Professor
Division of Gynecologic Oncology
Arizona Oncology (US Oncology Network)
University of Arizona College of Medicine--Phoenix
Creighton University School of Medicine at St Joseph's Hospital
Phoenix, Arizona
Content based on an online CME program supported by an educational grant from GlaxoSmithKline.
Link to full program:
https://bit.ly/2Scnp2N
In this podcast episode, listen to breast cancer experts Thomas Bachelot, MD, PhD; Adam M. Brufsky, MD, PhD; and Cristina Saura, MD, PhD, discuss clinical considerations for patients with HER2-positive MBC, with topics including:
- Local therapy in the context of MBC
- Choice of therapy after progression on available standards of care
- Choice of trastuzumab deruxtecan and tucatinib based on patient presentation
- Managing patients with CNS metastases
- Managing interstitial lung disease
Presenters:
Thomas Bachelot, MD, PhD
Chair, Unicancer Breast Group - UCBG
Breast Cancer Unit
Medical Oncology
Centre Léon Bérard
Lyon, France
Adam M. Brufsky, MD, PhD
Professor of Medicine
Hematology/Oncology
University of Pittsburgh School of Medicine
Associate Chief, Hematology-Oncology
University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania
Cristina Saura, MD, PhD
Medicine and Surgery/Medical Oncology
Universidad Universitat Autònoma Barcelona and Vall d’Hebron Institute of Oncology (VHIO)
Head, Breast Cancer Program
Medical Oncology
Vall d’Hebron University Hospital
Barcelona, Spain
Content based on an online CME program supported by an educational grant from Daiichi Sankyo, Inc.
Link to full program, including associated downloadable slidesets:
https://bit.ly/32A1HMb
In this episode, an expert medical oncology panel led by Elizabeth R. Plimack, MD, MS, with Brian A. Costello, MD, and Martin H. Voss, MD, discusses clinical pearls for the management of patients with metastatic renal cell carcinoma (RCC). Topics include:
- Treating beyond progression with immunotherapy
- Management of patients with less common histologic subtypes of RCC
- Potential biomarkers for RCC
- Adverse event management
Presenters:
Elizabeth R. Plimack, MD, MS
Chief, Division of Genitourinary Medical Oncology
Director, Genitourinary Clinical Research
Professor, Department of Hematology/
Oncology
Fox Chase Cancer Center
Temple Health
Philadelphia, Pennsylvania
Brian A. Costello, MD
Associate Professor of Oncology and Urology
Division of Medical Oncology
Mayo Clinic
Rochester, Minnesota
Martin H. Voss, MD
Clinical Director, Genitourinary Medical Oncology Service
Memorial Sloan Kettering Cancer Center
Assistant Professor
Weill Cornell Medical College
New York, New York
Content based on an online CME program supported by educational grants from Eisai, Exelixis, and Pfizer and EMD Serono.
Link to full program:
https://bit.ly/32IS9gx
In this episode, Jeff P. Sharman, MD, Danielle M. Brander, MD, and Nicole Lamanna, MD, answer questions focused on the optimizing BTK inhibitor therapy for previously untreated patients with CLL considering presentation characteristics and drug pharmacology.
Presenters:
Jeff P. Sharman, MD, Program Director
Medical Director
Hematology Research
US Oncology Research
Eugene, Oregon
Danielle M. Brander, MD
Assistant Professor of Medicine
Division of Hematologic Malignancies
& Cellular Therapy
Department of Medicine
Duke University
Attending Physician, Hematologic Malignancies
Duke University Health System
Durham, North Carolina
Nicole Lamanna, MD
Associate Attending
Leukemia Service
Director of CLL Program
Hematologic Malignancies Section
Department of Medicine
New York-Presbyterian/Columbia University Medical Center
New York, New York
Content based on an online CME program supported by an educational grant from AstraZeneca.
Link to full program, including associated downloadable slidesets:
https://bit.ly/3hATX0L
In this episode, Jeff P. Sharman, MD, Danielle M. Brander, MD, and Nicole Lamanna, MD, answer audience questions from a live Webinar focused on optimal use of BTK inhibitor therapy in patients with CLL, with topics including:
• The impact of COVID-19 on CLL treatment decisions
• The use of anti-CD20 antibodies in combination with BTK inhibitors
• Considerations when recommending BTK inhibitors
• MRD testing in patients with CLL
• The potential impact of targeted therapies on when to start treatment
Presenters:
Jeff P. Sharman, MD, Program Director
Medical Director
Hematology Research
US Oncology Research
Eugene, Oregon
Danielle M. Brander, MD
Assistant Professor of Medicine
Division of Hematologic Malignancies & Cellular Therapy
Department of Medicine
Duke University
Attending Physician, Hematologic Malignancies
Duke University Health System
Durham, North Carolina
Nicole Lamanna, MD
Associate Attending
Leukemia Service
Director of CLL Program
Hematologic Malignancies Section
Department of Medicine
New York-Presbyterian/Columbia University Medical Center
New York, New York
Content based on an online CME program supported by an educational grant from AstraZeneca.
Link to full program, including associated downloadable slidesets:
https://bit.ly/3hATX0L
In this podcast episode, listen to lung cancer experts Joshua Bauml, MD, a medical oncologist, and Dara L. Aisner, MD, PhD, a molecular pathologist, discuss clinical considerations for patients with RET fusion–positive NSCLC, with topics including:
- Optimal testing for RET fusions
- DNA NGS vs RNA NGS
- Molecular testing workflows
- Using new selective RET inhibitors to treat patients with RET fusion–positive NSCLC
- Common toxicities with new selective RET inhibitors
- Interdisciplinary communication between medical oncologists and pathologists
Presenters:
Dara L. Aisner, MD, PhD
Associate Professor
Department of Pathology
Director, Molecular Pathology
University of Colorado
Aurora, Colorado
Joshua Bauml, MD
Assistant Professor of Medicine
Division of Hematology/Oncology
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, Pennsylvania
Link to full program, including associated downloadable slidesets:
https://bit.ly/2Fsq9Wv
In this episode, Jeff P. Sharman, MD, Danielle M. Brander, MD, and Nicole Lamanna, MD, answer audience questions from a live Webinar focused on optimal use of BTK inhibitor therapy in patients with CLL, with topics including:
- Rechallenging patients with venetoclax and BTK inhibitors
- Mechanism by which BTK inhibitors may reduce infusion reactions
- Risk of secondary malignancies with BTK inhibition
- Different cytogenetic findings and adverse event risk
Presenters:
Jeff P. Sharman, MD, Program Director
Medical Director
Hematology Research
US Oncology Research
Eugene, Oregon
Danielle M. Brander, MD
Assistant Professor of Medicine
Division of Hematologic Malignancies
& Cellular Therapy
Department of Medicine
Duke University
Attending Physician, Hematologic Malignancies
Duke University Health System
Durham, North Carolina
Nicole Lamanna, MD
Associate Attending
Leukemia Service
Director of CLL Program
Hematologic Malignancies Section
Department of Medicine
New York-Presbyterian/Columbia University Medical Center
New York, New York
Content based on an online CME program supported by an educational grant from AstraZeneca.
Link to full program, including associated downloadable slidesets:
https://bit.ly/3hATX0L
In this episode, Michael R. Bishop, MD; Daniel J. DeAngelo, MD, PhD; and Noopur Raje, MD, answer clinician questions on current best practices and emerging applications with CAR T-cell therapy, with topics including:
- Optimal use of approved CAR T-cell therapies for lymphoma and ALL
- Investigational CAR T-cell therapies for multiple myeloma
- Managing CAR T-cell therapy–related toxicities
Presenters:
Michael R. Bishop, MD
Professor of Medicine
Section of Hematology/Oncology
Director, Cellular Therapy Program
University of Chicago
Chicago, Illinois
Daniel J. DeAngelo, MD, PhD
Professor of Medicine
Department of Medicine
Harvard Medical School
Chief, Division of Leukemia
Department of Medical Oncology
Division of Hematologic Malignancies
Dana‐Farber Cancer Institute
Boston, Massachusetts
Noopur Raje, MD
Professor of Medicine
Harvard Medical School
Director
Center for Multiple Myeloma
Massachusetts General Hospital Cancer Center
Boston, Massachusetts
Content based on an online CME program supported by educational grants from Celgene Corporation and Legend Biotech USA Inc.
Link to full program:
https://bit.ly/3iyt5zQ
In this episode, an expert medical oncology panel, led by Elizabeth R. Plimack, MD, with Brian A. Costello, MD, and Martin H. Voss, MD, discusses current best practices for the second-line treatment and beyond of patients with metastatic renal cell carcinoma (RCC). Topics include:
• Treatment sequencing with IO and TKI therapies
• Optimizing dose for patients with preexisting toxicities
• Considerations for local control of metastatic sites
• Ongoing clinical trials
Presenters:
Elizabeth R. Plimack, MD, MS
Chief, Division of Genitourinary Medical Oncology
Director, Genitourinary Clinical Research
Professor, Department of Hematology/Oncology
Fox Chase Cancer Center
Temple Health
Philadelphia, Pennsylvania
Brian A. Costello, MD
Associate Professor of Oncology and Urology
Division of Medical Oncology
Mayo Clinic
Rochester, Minnesota
Martin H. Voss, MD
Clinical Director, Genitourinary Medical Oncology Service
Memorial Sloan Kettering Cancer Center
Assistant Professor
Weill Cornell Medical College
New York, New York
Content based on an online CME program supported by an educational grant from Eisai, Exelixis, and Pfizer and EMD Serono.
Link to full program:
https://bit.ly/32IS9gx
In this episode, Jesús F. San-Miguel, MD, PhD; Paula Rodriguez-Otero, MD, PhD; and Prof. Dr. med. Katja Weisel answer questions focused on current and emerging therapies for early and late relapsed, refractory multiple myeloma, with topics including:
• Responses across different subgroups treated with idecabtagene vicleucel in the KarMMa trial
• Selecting therapy for a patient with lenalidomide-refractory disease at first relapse
• How CAR T-cell therapy, melflufen, and selinexor will fit into existing and future treatment algorithms
• Key findings from the DREAMM2 trial on belantamab mafodotin
• Monitoring and management strategies for ocular toxicity with belantamab mafodotin
Presenters:
Jesús F. San-Miguel, MD, PhD
Director of Clinical and Translational Medicine
Universidad de Navarra
Pamplona, Spain
Paula Rodriguez-Otero, MD, PhD
Associate Professor
Consultant in Hematology
Department of Hematology, Clínica Universidad de Navarra
University of Navarra
Pamplona, Spain
Prof. Dr. med. Katja Weisel
Deputy Director
II. Medical Clinic and Polyclinic
Department of Oncology and Hematology
Department of Pneumology and Bone Marrow Transplantation
University Medical Center
Hamburg-Eppendorf
Hamburg, Germany
Content based on an online CME program supported by an educational grant from GlaxoSmithKline.
Link to full program, including associated downloadable slidesets:
https://bit.ly/2QRqYuC
In this episode, Natalie S. Callander, MD, and Shaji Kumar, MD, answer audience questions from a live CCO Webinar on relapsed/refractory myeloma regarding challenges in treating patients in this setting, including optimizing treatment choices and sequencing of treatments, MRD testing in myeloma, promising BCMA-targeted agents, the promise and value of CAR T-cell therapy in myeloma, and more.
Presenters:
Natalie S. Callander, MD
Professor of Medicine
Director, Myeloma Clinical Program
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin
Shaji Kumar, MD
Department of Hematology
Mayo Clinic
Rochester, Minnesota
Content based on an online CME program supported by educational grants from GlaxoSmithKline LLC and Sanofi Genzyme.
Link to full program, including associated downloadable slidesets:
https://bit.ly/3gT324y
| In this episode, Elizabeth R. Plimack, MD, MS; Brian A. Costello, MD; and Martin H. Voss, MD, discuss current best practices for the first-line treatment of patients with metastatic renal cell carcinoma (RCC). Topics include:* Choice of first-line therapy * Combinations of targeted agents and immunotherapy * Combinations of immune checkpoint inhibitors * Active surveillance and monitoring * Cytoreductive nephrectomy
Presenters:Elizabeth R. Plimack, MD, MSChief, Division of Genitourinary Medical Oncology Director, Genitourinary Clinical Research Professor, Department of Hematology/Oncology Fox Chase Cancer Center Temple Health Philadelphia, PennsylvaniaBrian A. Costello, MDAssociate Professor of Oncology and UrologyDivision of Medical OncologyMayo ClinicRochester, MinnesotaMartin H. Voss, MDClinical Director, Genitourinary Medical Oncology ServiceMemorial Sloan Kettering Cancer CenterAssistant Professor Weill Cornell Medical CollegeNew York, New YorkContent based on an online CME program supported by educational grants from Eisai, Exelixis, Pfizer and EMD Serono, and Merck Sharp & Dohme Corp.Link to full program: https://bit.ly/32IS9gx |
| In this episode, Jennifer R. Brown, MD, PhD, and John Allan, MD, discuss recent key clinical trial results in Waldenström macroglobulinemia, mantle cell lymphoma, Hodgkin lymphoma, and DLBCL presented at the 2020 annual meetings of the American Society of Clinical Oncology (ASCO) and the European Hematology Association (EHA). Studies include:* ASPEN: Zanubrutinib vs ibrutinib in WM * OASIS: Ibrutinib, venetoclax, and obinutuzumab in MCL * GHSG HD17: PET-guided therapy in HL * KEYNOTE-024: Pembrolizumab vs brentuximab in HL * ALEXANDER: AUTO3 in DLBCL
Presenters:Jennifer R. Brown, MD, PhDAssociate Professor of MedicineDepartment of Hematologic MalignanciesDana-Farber Cancer InstituteHarvard Medical SchoolDirector, CLL CenterDepartment of Medical OncologyDana-Farber Cancer InstituteBoston, MassachusettsJohn Allan, MDAssistant Professor of MedicineDivision of Hematology and Medical OncologyWeill Cornell MedicineNew York, New YorkContent based on an online CME program supported by an educational grant from AstraZeneca.Link to full program: https://bit.ly/3aSfekM |
In this episode, Luis Paz-Ares, MD, PhD; D. Ross Camidge, MD, PhD; and Karen L. Reckamp, MD, MS, address questions on MET exon 14 testing and selecting MET-targeted therapies for patients with advanced NSCLC with topics including:
- Incorporating MET exon 14 testing into standard of care
- Comparison of RNA-based and DNA-based NGS platforms
- Availability of RNA-based NGS testing around the world
- Using FISH to quantify MET copy gain/amplification
- Regulatory and clinical differences between new, selective MET inhibitors
- Safety profiles of type I vs type II MET inhibitors
- Counseling patients on management of peripheral edema, a class effect with MET inhibitor therapy
- Insights on combining MET inhibition with immune checkpoint inhibition therapy or chemotherapy
- Selecting second-line therapy for a patient with MET exon 14–altered NSCLC progressing on tepotinib or capmatinib
Presenters:
Luis Paz-Ares, MD, PhD
Medical Oncology
University Hospital Doce de Octubre
Madrid, Spain
D. Ross Camidge, MD, PhD
Professor of Medicine/Oncology
University of Colorado Cancer Center
Aurora, Colorado
Karen L. Reckamp, MD, MS
Professor of Medicine
Director, Division of Medical Oncology
Department of Medicine
Cedars Sinai
Los Angeles, California
Content based on an online CME program supported by an independent grant from the Healthcare business of Merck KGaA, Darmstadt, Germany.
Link to full program, including associated downloadable slidesets:
https://bit.ly/2ExadCf
In this episode, Luis Paz-Ares, MD, PhD; D. Ross Camidge, MD, PhD; and Karen L. Reckamp, MD, MS, address questions on biomarking testing and the use of immunotherapy in METex14 mutation–positive NSCLC with topics including:
- Whether testing for MET exon 14 status should be standard of care
- Parallel vs sequential testing by DNA-based vs RNA-based NGS
- Co-occurring driver mutations in patients with METex14 mutation–positive NSCLC
- Optimal use of immune checkpoint inhibitor–based therapy in the setting of METex14-positive disease, including sequencing with MET inhibitor–based therapy
- EMA regulatory considerations for the new, selective MET inhibitors tepotinib and capmatinib
Presenters:
Luis Paz-Ares, MD, PhD
Medical Oncology
University Hospital Doce de Octubre
Madrid, Spain
D. Ross Camidge, MD, PhD
Professor of Medicine/Oncology
University of Colorado Cancer Center
Aurora, Colorado
Karen L. Reckamp, MD, MS
Professor of Medicine
Director, Division of Medical Oncology
Department of Medicine
Cedars Sinai
Los Angeles, California
Link to full program, including associated downloadable slidesets: https://bit.ly/2ExadCf
In this episode, Anna F. Farago, MD, PhD, and Taofeek K. Owonikoko, MD, PhD, answer questions focused on the topic of current and evolving use of immunotherapy in patients with advanced small-cell lung cancer with topics including:
- Selecting between atezolizumab and durvalumab in the frontline setting
- Integration of lurbinectedin, a novel anticancer drug that was recently approved for the treatment of relapsed SCLC after platinum-based chemotherapy, into patient care
- Which patients should receive salvage therapy with an immune checkpoint inhibitor in the third-line setting
- Management of brain metastases in patients with advanced SCLC
Presenters:
Anna F. Farago, MD, PhD
Assistant Professor of Medicine
Department of Medicine
Harvard Medical School
Assistant in Medicine
Division of Hematology/Oncology
Department of Medicine
Massachusetts General Hospital
Boston, Massachusetts
Taofeek K. Owonikoko, MD, PhD
Professor
Department of Hematology and
Medical Oncology
Co-Leader, Thoracic Oncology
Emory University
Atlanta, Georgia
Content based on an online CME program supported by educational grants from Genentech, a member of the Roche Group, and Merck Sharp & Dohme Corp.
Link to full program, including associated downloadable slidesets: https://bit.ly/3aTzthZ
In this episode, Jennifer R. Brown, MD, PhD, and John Allan, MD, discuss recent key clinical trial results in CLL presented at the 2020 annual meetings of the American Society of Clinical Oncology (ASCO) and the European Hematology Association (EHA). Studies and topics include:
- ASCEND: acalabrutinib vs idelalisib plus rituximab or BR
- ACE-CL-001: acalabrutinib long-term efficacy
- CLL14: Venetoclax plus obinutuzumab
- CLARITY: Ibrutinib plus venetoclax
- Measurable residual disease (MRD)
- Complex karyotypes
- Zanubrutinib plus obinutuzumab and venetoclax
Presenters:
Jennifer R. Brown, MD, PhD
Associate Professor of Medicine
Department of Hematologic Malignancies
Dana-Farber Cancer Institute
Harvard Medical School
Director, CLL Center
Department of Medical Oncology
Dana-Farber Cancer Institute
Boston, Massachusetts
John Allan, MD
Assistant Professor of Medicine
Division of Hematology and Medical Oncology
Weill Cornell Medicine
New York, New York
Content based on an online CME program supported by an educational grant from AstraZeneca.
Link to full program: https://bit.ly/3aSfekM
In this episode, Naval G. Daver, MD, discusses promising investigational agents and treatment combinations in clinical trials for patients with newly diagnosed and relapsed/refractory AML, including:
- FLT3 inhibitors crenolanib and quizartinib
- Anti-CD47 antibody magrolimab
- IMGN632, a CD123 antibody–drug conjugate
- Anti-CD70 antibody cusatuzumab
- APR-246, targeting the TP53 mutation
Content is part of an online CME program supported by an educational grant from Daiichi-Sankyo.
Link to full program, including a ClinicalThought commentary: https://bit.ly/2Y2uCG2
In this episode, George D. Demetri, MD; Alexander Drilon, MD; and Pashtoon Kasi, MD, answer questions about NTRK fusion testing and TRK inhibitor therapy for patients with advanced solid tumors, with topics including:
- Best practices in testing for NTRK fusions in solid tumors
- Optimal use of approved TRK inhibitors
- Key adverse events with TRK inhibitors and management strategies
- Emerging next-generation TRK inhibitors and their potential use in managing resistance to first-generation agents
Presenters:
George D. Demetri, MD
Professor of Medicine
Harvard Medical School
Harvard University
Co-Director, Ludwig Center at Harvard
Senior Vice President for Experimental Therapeutics
Director, Sarcoma Center
Dana-Farber Cancer Institute
Boston, Massachusetts
Alexander Drilon, MD
Chief, Early Drug Development
Attending, Thoracic Oncology
Memorial Sloan Kettering Cancer Center
New York, New York
Pashtoon Kasi, MD
Assistant Professor
College of Medicine and Oncology
Holden Comprehensive Cancer Center
University of Iowa
Iowa City, Iowa
Content based on an online CME program supported by educational grants from Bayer Healthcare Pharmaceuticals, Inc. and Genentech.
Link to full program: https://bit.ly/2PN0BWh
In this episode, Prof. Dr. med Tim Henrik Brümmendorf; Jorge Cortes, MD; and Carlo Gambacorti-Passerini, MD, answer questions focused on the optimal selection and management of tyrosine kinase inhibitor (TKI) therapy in patients with CML, with topics including:
- Frontline Management of Chronic-Phase CML
- Selection of TKI Based on Goal of Treatment-Free Remission
- Changing TKIs due to Intolerance: Second-line Therapy and Toxicity Management
- Changing TKIs due to CML Progression: Second-line Therapy and Future Options
Presenters:
Prof. Dr. med Tim Henrik Brümmendorf
Head
Department of Hematology, Oncology, Hematostaseology, and Stem Cell Transplantation
University Hospital Aachen, RWTH Aachen
Aachen, Germany
Jorge Cortes, MD
Director, Georgia Cancer Center
Eminent Scholar, Georgia Research Academy
Augusta, Georgia, USA
Carlo Gambacorti-Passerini, MD
Professor, Hematology
University Milano Bicocca
Director, Hematology
San Gerardo Hospital
Monza, Italy
Content based on an online CME program supported by an educational grant from Pfizer Inc.
Link to full program, including associated downloadable slidesets:
https://bit.ly/30P8Uaf
In this episode, an expert medical oncology panel led by John L. Marshall, MD, with Jamie E. Chaft, MD, and Scot Niglio, MD, provides a brief overview on the revolutionary changes brought by immuno-oncology to the management of gastrointestinal, thoracic, and genitourinary cancers. Then, the panel answers clinician questions on important topics such as:
- Selecting immuno-oncology vs targeted therapy in MSI-high cancers with co-occurring alterations (eg, BRCA, HER2, BRAF, NTRK)
- Switching to a new immuno-oncology strategy at progression on first-line immune checkpoint inhibition
- Neoadjuvant treatment with immune checkpoint inhibitors
- Financial considerations when selecting chemotherapy vs immuno-oncology
Presenters:
John L. Marshall, MD
Chief, Division of Hematology/Oncology
Department of Medicine
Georgetown University Hospital
Washington, DC
Jamie E. Chaft, MD
Associate Attending Physician
Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York
Scot Niglio, MD
Medical Oncologist
Bethesda, Maryland
Content based on an online CME program supported by an educational grant from Merck Sharp & Dohme Corp.
Link to full program:
https://bit.ly/31vQtqb
In this episode, Edward S. Kim, MD, FACP, and Leora Horn, MD, MSc, FRCPC, answer questions focused on biomarker testing and selecting targeted therapy for patients with advanced non-small-cell lung cancer with topics including:
- How to approach discordant results with liquid vs tissue biopsies
- Repeating NGS testing at progression
- Selecting urgent treatment when molecular results are not yet available
- Point mutations in NTRK fusion–positive disease
- Selecting second-line therapy for EGFR-positive disease with high PD-L1 expression after first-line TKI
- Selecting first-line and second-line therapy for ROS1-positive disease
- Standard of care for MET-altered disease
- Selecting second-line therapy for RET fusion–positive disease after first-line TKI
Presenters:
Edward S. Kim, MD, FACP
Chair, Solid Tumor Oncology and Investigational Therapeutics
Donald S. Kim Distinguished Chair for Cancer Research
Levine Cancer Institute
Atrium Health
Charlotte, North Carolina
Leora Horn, MD, MSc, FRCPC
Ingram Associate Professor of Cancer Research
Director, Thoracic Oncology Research Program
Assistant Vice Chairman for Faculty Development
Vanderbilt Ingram Cancer Center
Nashville, Tennessee
Content based on an online CME program supported by an educational grant from Lilly.
Link to full program, including associated downloadable slidesets: https://bit.ly/3a3e1Xs
In this episode, Edward S. Kim, MD, FACP, and Leora Horn, MD, MSc, FRCPC, answer questions focused on current and evolving biomarkers for immune checkpoint inhibitor–based therapies in advanced non-small-cell lung cancer with topics including:
- Selecting therapy for advanced NSCLC without actionable mutations and with different levels of PD-L1 expression
- Choosing therapy for advanced NSCLC with an actionable mutation on NGS and high PD-L1 expression
- Leveraging key data from CheckMate 9LA to identify patients who may benefit from chemotherapy plus nivolumab/ipilimumab
- STK11/KEAP1 as potential predictors for a lack of response to immune checkpoint inhibitor–based therapy
- Treatment for NSCLC after progression on chemotherapy plus an immune checkpoint inhibitor
- Rechallenging after stopping immune checkpoint inhibitor due to immune-related adverse events
Presenters:
Edward S. Kim, MD, FACP
Chair, Solid Tumor Oncology and Investigational Therapeutics
Donald S. Kim Distinguished Chair for Cancer Research
Levine Cancer Institute
Atrium Health
Charlotte, North Carolina
Leora Horn, MD, MSc, FRCPC
Ingram Associate Professor of Cancer Research
Director, Thoracic Oncology Research Program
Assistant Vice Chairman for Faculty Development
Vanderbilt Ingram Cancer Center
Nashville, Tennessee
Content based on an online CME program supported by an educational grant from Lilly.
Link to full program, including associated downloadable slidesets: https://bit.ly/3a3e1Xs